FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Andrade, MM
   Luiz, WB
   Souza, RDO
   Amorim, JH
AF Andrade, Mariana Moreira
   Luiz, Wilson Barros
   da Silva Oliveira Souza, Rayane
   Amorim, Jaime Henrique
TI The History of Methicillin-Resistant Staphylococcus aureus in Brazil
SO CANADIAN JOURNAL OF INFECTIOUS DISEASES & MEDICAL MICROBIOLOGY
LA English
DT Review
ID RIO-DE-JANEIRO; CYSTIC-FIBROSIS PATIENTS; SCCMEC TYPE-IV; BLOOD-STREAM
   INFECTION; GRAM-POSITIVE BACTERIA; HEALTH-CARE WORKERS; RISK-FACTORS;
   MOLECULAR CHARACTERIZATION; MULTIDRUG-RESISTANT; EPIDEMIC CLONE
AB Since the emergence of MRSA in the 1960s, a gradual increase in infections by resistant bacteria has been observed. Clinical manifestations may vary from brand to critical condition due to host risk factors, as well as pathogen virulence and resistance. The high adaptability and pathogenic profile of MRSA clones contributed to its spread in hospital and community settings. In Brazil, the first MRSA isolates were reported in the late 1980s, and since then different genetic profiles, such as the Brazilian epidemic clone (BEC) and other clones considered a pandemic, became endemic in the Brazilian population. Additionally, Brazil's MRSA clones were shown to be able to transfer genes involved in multidrug resistance and enhanced pathogenic properties. These events contributed to the rise of highly resistant and pathogenic MRSA. In this review, we present the main events which compose the history of MRSA in Brazil, including numbers and locations of isolation, as well as types of staphylococcal cassette chromosome mec (SCCmec) found in the Brazilian territory.
C1 [Andrade, Mariana Moreira; da Silva Oliveira Souza, Rayane; Amorim, Jaime Henrique] Univ Fed Oeste Bahia, Lab Agentes Infecciosos & Vetores, Ctr Ciencias Biol & Saude, Barreiras, BA, Brazil.
   [Andrade, Mariana Moreira; Luiz, Wilson Barros; Amorim, Jaime Henrique] Univ Estadual Santa Cruz, Programa Pograd Biol & Biotecnol Microrganismos, Ilheus, BA, Brazil.
RP Amorim, JH (corresponding author), Univ Fed Oeste Bahia, Lab Agentes Infecciosos & Vetores, Ctr Ciencias Biol & Saude, Barreiras, BA, Brazil.; Amorim, JH (corresponding author), Univ Estadual Santa Cruz, Programa Pograd Biol & Biotecnol Microrganismos, Ilheus, BA, Brazil.
EM marianaandrade94@outlook.com; wbluiz@uesc.br; ray.zeppelin@gmail.com;
   jaime.amorim@ufob.edu.br
RI Luiz, Wilson/L-7575-2015
OI Luiz, Wilson/0000-0003-3265-8547
FU CoordenacAo de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)CAPES
FX The authors are thankful to CoordenacAo de Aperfeicoamento de Pessoal de
   Nivel Superior (CAPES) for the mastering fellowship of Mariana Moreira
   Andrade.
CR Abad ED, 2020, J MICROBIOL IMMUNOL, V53, P724, DOI 10.1016/j.jmii.2018.12.014
   Amaral MM, 2005, J INFECT DIS, V192, P801, DOI 10.1086/432515
   Neto EDA, 2017, MEM I OSWALDO CRUZ, V112, P647, DOI 10.1590/0074-02760170040
   [Anonymous], 2018, PLAN AC PREV CONTR R
   Anvisa an de V. S., 2016, PROGRAMA NACL PREVEN
   Armand-Lefevre L, 2005, EMERG INFECT DIS, V11, P711, DOI 10.3201/eid1105.040866
   Assis DCM, 2014, BIOMED RES INT, V2014, P1, DOI DOI 10.1155/2014/909601
   Barreto HM, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/305610
   BARRETT FF, 1968, NEW ENGL J MED, V279, P441, DOI 10.1056/NEJM196808292790901
   Bastos LR, 2019, ANTON LEEUW INT J G, V112, P961, DOI 10.1007/s10482-019-01229-z
   Bastos MCF, 1999, EUR J CLIN MICROBIOL, V18, P393, DOI 10.1007/s100960050306
   Becker AP, 2012, EPIDEMIOL INFECT, V140, P1372, DOI 10.1017/S095026881100210X
   Beltrame CO, 2012, EUR J CLIN MICROBIOL, V31, P2011, DOI 10.1007/s10096-011-1534-1
   Beretta ALRZ, 2004, BRAZ J MED BIOL RES, V37, P1345, DOI 10.1590/S0100-879X2004000900009
   Bes TM, 2018, REV INST MED TROP SP, V60, DOI [10.1590/S1678-9946201860058, 10.1590/s1678-9946201860058]
   Bonesso MF, 2014, BRAZ J MICROBIOL, V45, P1401, DOI 10.1590/S1517-83822014000400034
   Bottega A, 2014, REV SOC BRAS MED TRO, V47, P589, DOI 10.1590/0037-8682-0140-2014
   BRANCHINI MLM, 1993, DIAGN MICR INFEC DIS, V17, P275, DOI 10.1016/0732-8893(93)90036-7
   da Silva ECBF, 2008, BRAZ J INFECT DIS, V12, P504, DOI 10.1590/S1413-86702008000600012
   Bride LD, 2019, REV SOC BRAS MED TRO, V52, DOI 10.1590/0037-8682-0095-2019
   Brites Carlos, 2006, Braz J Infect Dis, V10, P235, DOI 10.1590/S1413-86702006000400003
   Brust T, 2013, BRAZ J MICROBIOL, V44, P865, DOI 10.1590/S1517-83822013000300031
   BULGER RJ, 1967, ANN INTERN MED, V67, P81, DOI 10.7326/0003-4819-67-1-81
   Busato César Roberto, 2006, Braz J Infect Dis, V10, P185, DOI 10.1590/S1413-86702006000300006
   Caiaffa HH, 2013, DIAGN MICR INFEC DIS, V76, P518, DOI 10.1016/j.diagmicrobio.2013.04.024
   Camargo CH, 2013, DIAGN MICR INFEC DIS, V76, P372, DOI 10.1016/j.diagmicrobio.2013.03.013
   Campos GB, 2012, NEW MICROBIOL, V35, P183
   Caraciolo FB, 2012, AN BRAS DERMATOL, V87, P857, DOI 10.1590/S0365-05962012000600006
   Carmo MS, 2011, BRAZ J MED BIOL RES, V44, P1013, DOI 10.1590/S0100-879X2011007500114
   Cataneo C, 2011, REV LAT-AM ENFERM, V19, P1072, DOI 10.1590/S0104-11692011000500003
   Cavalcante FS, 2015, BRAZ J MED BIOL RES, V48, P588, DOI 10.1590/1414-431X20154221
   Cavalcante FS, 2014, J HOSP INFECT, V86, P151, DOI 10.1016/j.jhin.2013.12.004
   Cavalcante Fernanda S, 2014, BMC Res Notes, V7, P759, DOI 10.1186/1756-0500-7-759
   Cavalcante FS, 2017, AM J INFECT CONTROL, V45, P1190, DOI 10.1016/j.ajic.2017.06.003
   Cavalcante FS, 2016, J INFECT DEV COUNTR, V10, P195, DOI 10.3855/jidc.7414
   Cavalcanti Silvana M.M., 2005, Braz J Infect Dis, V9, P56, DOI 10.1590/S1413-86702005000100010
   Cechinel A, 2016, CAN J INFECT DIS MED, V2016, DOI 10.1155/2016/8163456
   Chambers HF, 2009, NAT REV MICROBIOL, V7, P629, DOI 10.1038/nrmicro2200
   Chamon RC, 2017, BRAZ J INFECT DIS, V21, P185, DOI 10.1016/j.bjid.2016.09.015
   Coimbra MVD, 2000, J MED MICROBIOL, V49, P187, DOI 10.1099/0022-1317-49-2-187
   Corso A, 1998, MICROB DRUG RESIST, V4, P277, DOI 10.1089/mdr.1998.4.277
   Cursino MA, 2012, DIAGN MICR INFEC DIS, V74, P343, DOI 10.1016/j.diagmicrobio.2012.08.006
   Cury GG, 2009, BRAZ J INFECT DIS, V13, P165, DOI 10.1590/S1413-86702009000300002
   da Costa TM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0160506
   Pereira JND, 2016, BRAZ J INFECT DIS, V20, P276, DOI 10.1016/j.bjid.2016.03.003
   da Silveira M, 2018, ANN CLIN MICROB ANTI, V17, DOI 10.1186/s12941-018-0271-z
   Dabul ANG, 2014, EPIDEMIOL INFECT, V142, P479, DOI 10.1017/S0950268813001325
   Damasco AP, 2019, BRAZ J INFECT DIS, V23, P139, DOI 10.1016/j.bjid.2019.03.003
   Damasco PV, 2013, INFECTION, V41, P851, DOI 10.1007/s15010-013-0430-2
   David MZ, 2010, CLIN MICROBIOL REV, V23, P616, DOI 10.1128/CMR.00081-09
   Cruz EDD, 2011, REV LAT-AM ENFERM, V19, P90, DOI 10.1590/S0104-11692011000100013
   Silva Helisângela de Almeida, 2003, Braz J Infect Dis, V7, P381, DOI 10.1590/S1413-86702003000600005
   de Araujo Bruno Espirito Santo, 2010, Am J Emerg Med, V28, DOI 10.1016/j.ajem.2009.08.010
   de Brito CS, 2015, REV SOC BRAS MED TRO, V48, P614, DOI 10.1590/0037-8682-0030-2015
   de Carvalho MJ, 2009, CLINICS, V64, P295, DOI 10.1590/S1807-59322009000400005
   de Carvalho SP, 2019, BRAZ J INFECT DIS, V23, P134, DOI 10.1016/j.bjid.2019.04.005
   de Carvalho SP, 2017, BRAZ J INFECT DIS, V21, P464, DOI 10.1016/j.bjid.2017.04.001
   de Matos PDM, 2010, MEM I OSWALDO CRUZ, V105, P931, DOI 10.1590/S0074-02762010000700017
   de Melo EC, 2009, BRAZ J INFECT DIS, V13, P398, DOI 10.1590/S1413-86702009000600002
   de Miranda OP, 2007, CLIN MICROBIOL INFEC, V13, P1165, DOI 10.1111/j.1469-0691.2007.01830.x
   de Moura JP, 2011, REV LAT-AM ENFERM, V19, P325, DOI 10.1590/S0104-11692011000200014
   de Oliveira BGRB, 2019, INT WOUND J, V16, P1408, DOI 10.1111/iwj.13205
   de Oliveira CF, 2015, J INFECT DEV COUNTR, V9, P743, DOI 10.3855/jidc.5868
   de Oliveira LM, 2015, BMC MICROBIOL, V15, DOI 10.1186/s12866-015-0598-y
   de Sousa FC, 2010, BRAZ J MICROBIOL, V41, P316, DOI 10.1590/S1517-83822010000200009
   de Sousa FC, 2009, REV SOC BRAS MED TRO, V42, P179, DOI 10.1590/S0037-86822009000200017
   De Sousa MA, 2001, J CLIN MICROBIOL, V39, P2197, DOI 10.1128/JCM.39.6.2197-2205.2001
   de Sousa MA, 1998, J CLIN MICROBIOL, V36, P2590, DOI 10.1128/JCM.36.9.2590-2596.1998
   Oliveira DMD, 2018, INTENS CRIT CARE NUR, V49, P51, DOI 10.1016/j.iccn.2018.08.003
   de Sousa FC, 2009, BRAZ J MED BIOL RES, V42, P877, DOI 10.1590/S0100-879X2009005000018
   de Vasconcellos AG, 2012, JPN J INFECT DIS, V65, P7
   Del'Alamo L, 2007, J HOSP INFECT, V65, P226, DOI 10.1016/j.jhin.2006.12.005
   Deurenberg RH, 2008, INFECT GENET EVOL, V8, P747, DOI 10.1016/j.meegid.2008.07.007
   DEVRIESE LA, 1972, ZENTRALB VET RIEHE B, V19, P598
   Diekema DJ, 2019, OPEN FORUM INFECT DI, V6, pS47, DOI 10.1093/ofid/ofy270
   dosSantos KRN, 1996, INFECT CONT HOSP EP, V17, P813
   Dowzicky M, 2000, DIAGN MICR INFEC DIS, V37, P57, DOI 10.1016/S0732-8893(99)00154-6
   DUARTE FC, 2018, REV INST MED TROP SP, V60, P5
   Duarte FC, 2019, J INFECT CHEMOTHER, V25, P293, DOI 10.1016/j.jiac.2018.09.010
   Egido Jesus M., 2003, Rev. Soc. Bras. Med. Trop., V36, P707, DOI 10.1590/S0037-86822003000600011
   Falcao MHL, 1999, J MED MICROBIOL, V48, P515, DOI 10.1099/00222615-48-6-515
   Pires BMFB, 2018, ADV SKIN WOUND CARE, V31, P399, DOI 10.1097/01.ASW.0000540069.99416.a6
   Caboclo RMF, 2013, AM J INFECT CONTROL, V41, pE21, DOI 10.1016/j.ajic.2012.08.008
   Ferreira FA, 2013, BMC MICROBIOL, V13, DOI 10.1186/1471-2180-13-93
   Ferreira FA, 2012, J MICROBIOL METH, V88, P393, DOI 10.1016/j.mimet.2012.01.007
   Cohen RWF, 2017, SAO PAULO MED J, V135, P420, DOI 10.1590/1516-3180.2016.0350240317
   Fortaleza CR, 2009, REV LAT-AM ENFERM, V17, P677, DOI 10.1590/S0104-11692009000500013
   Fortes CQ, 2008, BRAZ J INFECT DIS, V12, P541, DOI 10.1590/S1413-86702008000600020
   Freitas FIS, 1999, LETT APPL MICROBIOL, V29, P197, DOI 10.1046/j.1365-2672.1999.00617.x
   Gales AC, 2006, INT J ANTIMICROB AG, V27, P300, DOI 10.1016/j.ijantimicag.2005.11.008
   Gales AC, 2009, BRAZ J INFECT DIS, V13, P90, DOI 10.1590/S1413-86702009000200004
   Garcia CP, 2014, PEDIATR INFECT DIS J, V33, pE252, DOI 10.1097/INF.0000000000000435
   Gauna TT, 2013, REV SOC BRAS MED TRO, V46, P426, DOI 10.1590/0037-8682-0060-2013
   Gelatti LC, 2014, AN BRAS DERMATOL, V89, P404, DOI 10.1590/abd1806-4841.20142688
   Gelatti LC, 2013, REV SOC BRAS MED TRO, V46, P34, DOI 10.1590/0037-868213022013
   Gelatti LC, 2009, REV SOC BRAS MED TRO, V42, P458, DOI 10.1590/S0037-86822009000400019
   Gomes IM, 2014, AM J INFECT CONTROL, V42, P918, DOI 10.1016/j.ajic.2014.05.009
   Gomes RT, 2013, BRAZ J INFECT DIS, V17, P573, DOI 10.1016/j.bjid.2013.02.010
   Neves FPG, 2019, BMC INFECT DIS, V19, DOI 10.1186/s12879-019-4104-2
   Grothe Cibele, 2009, Nephrol Nurs J, V36, P613
   Grothe C, 2010, REV LAT-AM ENFERM, V18, P73, DOI 10.1590/S0104-11692010000100012
   Guilarde AO, 2007, REV ASSOC MED BRAS, V53, P34, DOI 10.1590/S0104-42302007000100016
   Guilarde AO, 2006, J HOSP INFECT, V63, P330, DOI 10.1016/j.jhin.2006.02.011
   Guimares MA, 2015, EUR J CLIN MICROBIOL, V34, P497, DOI 10.1007/s10096-014-2253-1
   Helito CP, 2015, CLINICS, V70, P30, DOI 10.6061/clinics/2015(01)06
   Huijsdens Xander W, 2006, Ann Clin Microbiol Antimicrob, V5, P26, DOI 10.1186/1476-0711-5-26
   Ito T, 2001, ANTIMICROB AGENTS CH, V45, P1323, DOI 10.1128/AAC.45.5.1323-1336.2001
   Ito T, 1999, ANTIMICROB AGENTS CH, V43, P1449, DOI 10.1128/AAC.43.6.1449
   Ito T, 2009, ANTIMICROB AGENTS CH, V53, P4961, DOI 10.1128/AAC.00579-09
   Jacoby TS, 2010, J HOSP INFECT, V75, P23, DOI 10.1016/j.jhin.2009.11.021
   JEVONS MP, 1961, BRIT MED J, V1, P124, DOI 10.1136/bmj.1.5219.124-a
   Johnson AP, 2005, J ANTIMICROB CHEMOTH, V56, P455, DOI 10.1093/jac/dki266
   Korn G P, 2001, Braz J Infect Dis, V5, P1
   Lakhundi S, 2018, CLIN MICROBIOL REV, V31, DOI [10.1128/CMR.00020-18, 10.1128/cmr.00020-18]
   Lamaro-Cardosa J, 2007, DIAGN MICR INFEC DIS, V57, P467, DOI 10.1016/j.diagmicrobio.2006.10.008
   Lamaro-Cardoso J, 2009, J CLIN MICROBIOL, V47, P3991, DOI 10.1128/JCM.01322-09
   Leite GC, 2011, REV PANAM SALUD PUBL, V30, P535
   Lima DF, 2017, MEM I OSWALDO CRUZ, V112, P79, DOI 10.1590/0074-02760160342
   Lima DF, 2014, DIAGN MICR INFEC DIS, V78, P59, DOI 10.1016/j.diagmicrobio.2013.10.004
   Pereira-Franchi EPL, 2017, REV SOC BRAS MED TRO, V50, P833, DOI 10.1590/0037-8682-0205-2017
   Liu JY, 2016, MICROB PATHOGENESIS, V101, P56, DOI 10.1016/j.micpath.2016.10.028
   Loureiro MM, 2000, MEM I OSWALDO CRUZ, V95, P777, DOI 10.1590/S0074-02762000000600005
   Luh KT, 2000, ANTIMICROB AGENTS CH, V44, P3374, DOI 10.1128/AAC.44.12.3374-3380.2000
   Lupinacci Felipe S, 2017, J Lab Physicians, V9, P314, DOI 10.4103/JLP.JLP_161_16
   Machado DP, 2013, CAN J INFECT DIS MED, V24, pE75, DOI 10.1155/2013/585834
   Almeida GCM, 2014, BMC INFECT DIS, V14, DOI 10.1186/1471-2334-14-328
   MAPLE PAC, 1989, LANCET, V1, P537
   Martins A, 2014, BRAZ J INFECT DIS, V18, P331, DOI 10.1016/j.bjid.2013.11.003
   dos Santos DCM, 2015, BRAZ J MICROBIOL, V46, P531, DOI 10.1590/S1517-838246220140179
   Marty FM, 2006, J CLIN MICROBIOL, V44, P595, DOI 10.1128/JCM.44.2.595-597.2006
   McCulloch JA, 2015, MICROBIOL RESOUR ANN, V3, DOI 10.1128/genomeA.00893-15
   Mebinda I., 2013, BMC RES NOTES, V27, P336, DOI [10.1186/1756-0500-6-336, DOI 10.1186/1756-0500-6-336]
   Meka VG, 2004, J INFECT DIS, V190, P311, DOI 10.1086/421471
   Melo MCN, 2004, J HOSP INFECT, V58, P276, DOI 10.1016/j.jhin.2004.04.023
   Mimica MJ, 2012, REV INST MED TROP SP, V54, P305, DOI 10.1590/S0036-46652012000600002
   Mimica MJ, 2011, CURR MICROBIOL, V62, P388, DOI 10.1007/s00284-010-9718-y
   Moraes B A, 2000, Rev Inst Med Trop Sao Paulo, V42, P201
   Moreira M, 1998, Rev Assoc Med Bras (1992), V44, P263
   de Matos PDM, 2016, MICROB DRUG RESIST, V22, P700, DOI 10.1089/mdr.2015.0255
   Nascimento-Carvalho CM, 2008, MICROB DRUG RESIST, V14, P129, DOI 10.1089/mdr.2008.0790
   Pirett CCNS, 2012, WOUNDS, V24, P67
   Nimmo GR, 2008, INT J ANTIMICROB AG, V31, P401, DOI 10.1016/j.ijantimicag.2007.08.011
   Nogueras Monica, 2001, Revista do Instituto de Medicina Tropical de Sao Paulo, V43, P149, DOI 10.1590/S0036-46652001000300006
   Novak FR, 2000, MEM I OSWALDO CRUZ, V95, P29, DOI 10.1590/S0074-02762000000100003
   Novak FR, 2000, J MED MICROBIOL, V49, P1109, DOI 10.1099/0022-1317-49-12-1109
   de Oliveira PMN, 2019, REV SOC BRAS MED TRO, V52, DOI 10.1590/0037-8682-0205-2019
   Okado JB, 2016, REV SOC BRAS MED TRO, V49, P51, DOI 10.1590/0037-8682-0284-2015
   Oliveira D., 1998, Clin Microbiol Infect, V4, P373, DOI 10.1111/j.1469-0691.1998.tb00081.x
   Oliveira DC, 2002, LANCET INFECT DIS, V2, P180, DOI 10.1016/S1473-3099(02)00227-X
   Oliveira DC, 2001, MICROB DRUG RESIST, V7, P349, DOI 10.1089/10766290152773365
   Oliveira G A, 2001, Braz J Infect Dis, V5, P163, DOI 10.1590/S1413-86702001000400001
   Oliveira Priscila Rosalba, 2016, Rev. bras. ortop., V51, P396, DOI 10.1016/j.rboe.2015.09.012
   Pacheco RL, 2011, CLINICS, V66, P2071, DOI 10.1590/S1807-59322011001200012
   Padoveze MC, 2001, INFECT CONT HOSP EP, V22, P783, DOI 10.1086/501864
   Paixao VA, 2010, BRAZ J INFECT DIS, V14, P406, DOI 10.1590/S1413-86702010000400016
   Zuma AVP, 2017, BRAZ J MICROBIOL, V48, P237, DOI 10.1016/j.bjm.2016.09.016
   Pereira Franchi E. P. L., 2018, TROP MED INT HEALTH, V24, P339, DOI [10.1111/tmi.13192, DOI 10.1111/TMI.13192]
   Pereira VC, 2014, ANN CLIN MICROB ANTI, V13, DOI 10.1186/s12941-014-0050-4
   Pereira VC, 2009, CLIN MED INSIGHTS-PE, V3, P23
   Perim MC, 2015, REV SOC BRAS MED TRO, V48, P546, DOI 10.1590/0037-8682-0146-2015
   Rodrigues MVP, 2013, BURNS, V39, P1242, DOI 10.1016/j.burns.2013.02.006
   Pires FV, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092537
   Falci SPP, 2015, ACTA CIR BRAS, V30, P491, DOI [10.1590/S0102-865020150070000007, 10.1590/S0102-865020150060000005]
   Porto JP, 2013, REV SOC BRAS MED TRO, V46, P713, DOI 10.1590/0037-8682-0199-2013
   Rossatto FCP, 2014, REV INST MED TROP SP, V56, P469, DOI 10.1590/S0036-46652014000600002
   Prates KA, 2010, BRAZ J INFECT DIS, V14, P316, DOI 10.1590/S1413-86702010000300021
   Rabelo MA, 2014, REV SOC BRAS MED TRO, V47, P437, DOI [10.1590/0037-8682-, 10.1590/0037-8682-0071-2014]
   Ramos RLB, 1999, J MED MICROBIOL, V48, P303, DOI 10.1099/00222615-48-3-303
   Razera F, 2009, AN BRAS DERMATOL, V84, P515, DOI 10.1590/S0365-05962009000500011
   Regina Pedrosa Soares Cynthia, 2018, BMC Res Notes, V11, P794, DOI 10.1186/s13104-018-3899-z
   Reinato Lílian Andreia Fleck, 2015, Rev. Bras. Enferm., V68, P320, DOI 10.1590/0034-7167.2015680119i
   Reinert C, 2008, EMERG INFECT DIS, V12, P1995, DOI DOI 10.1590/s1413-86702008000300010
   Vendemiato AVR, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-0798-y
   Reiter KC, 2010, REV SOC BRAS MED TRO, V43, P377, DOI 10.1590/S0037-86822010000400008
   Ribas RM, 2007, BRAZ J INFECT DIS, V11, P351, DOI 10.1590/S1413-86702007000300010
   Ribeiro A, 2005, J CLIN MICROBIOL, V43, P1985, DOI 10.1128/JCM.43.4.1985-1988.2005
   Ribeiro A, 2007, DIAGN MICR INFEC DIS, V59, P339, DOI 10.1016/j.diagmicrobio.2007.05.007
   Ribeiro Julival, 2005, Braz J Infect Dis, V9, P52, DOI 10.1590/S1413-86702005000100009
   Rocha LA, 2013, AM J INFECT CONTROL, V41, P1236, DOI 10.1016/j.ajic.2013.04.009
   Rodrigues Mauricio M., 2012, Journal of Parasitology Research, P507874, DOI 10.1155/2012/507874
   Perez LRR, 2008, REV I MED TROP, V50, P135, DOI 10.1590/S0036-46652008000300001
   Perez LRR, 2012, J CLIN MICROBIOL, V50, P2506, DOI 10.1128/JCM.00549-12
   Rodriguez-Noriega E, 2010, BRAZ J INFECT DIS, V14, pS87, DOI 10.1590/S1413-86702010000800004
   Rodriguez-Noriega E, 2010, INT J INFECT DIS, V14, pE560, DOI 10.1016/j.ijid.2009.08.018
   Rose WE, 2006, PHARMACOTHERAPY, V26, P1099, DOI 10.1592/phco.26.8.1099
   Rossi F, 2014, NEW ENGL J MED, V370, P1524, DOI 10.1056/NEJMoa1303359
   Rozenbaum R, 2006, INFECT CONT HOSP EP, V27, P1041, DOI 10.1086/507921
   Rozenbaum R, 2009, BRAZ J MED BIOL RES, V42, P756, DOI 10.1590/S0100-879X2009005000007
   SADER, 1994, INFECT CONT HOSP EP, V15, P508
   SADER HS, 1993, INFECT CONT HOSP EP, V14, P260
   Sadoyama G, 2000, Braz J Infect Dis, V4, P135
   Sadoyama G, 2008, APMIS, V116, P953, DOI 10.1111/j.1600-0463.2008.01053.x
   Salgueiro VC, 2019, J INFECT DEV COUNTR, V13, P810, DOI 10.3855/jidc.11241
   Salomao R, 2008, REV PANAM SALUD PUBL, V24, P195, DOI 10.1590/S1020-49892008000900006
   Sandri AM, 2006, INFECT CONT HOSP EP, V27, P185, DOI 10.1086/500625
   Santoro-Lopes G, 2005, LIVER TRANSPLANT, V11, P203, DOI 10.1002/lt.20338
   Santos HB, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-328
   Santos KRN, 1999, J MED MICROBIOL, V48, P17, DOI 10.1099/00222615-48-1-17
   Santos L, 1996, MEM I OSWALDO CRUZ, V91, P101, DOI 10.1590/S0074-02761996000100018
   Schuenck RP, 2012, FEMS IMMUNOL MED MIC, V65, P501, DOI 10.1111/j.1574-695X.2012.00958.x
   Schuenck RP, 2009, DIAGN MICR INFEC DIS, V64, P434, DOI 10.1016/j.diagmicrobio.2009.04.007
   Scribel LV, 2009, DIAGN MICR INFEC DIS, V65, P457, DOI 10.1016/j.diagmicrobio.2009.08.012
   Seligman R, 2013, J BRAS PNEUMOL, V39, P339, DOI 10.1590/S1806-37132013000300011
   Senna JPM, 2003, J HOSP INFECT, V54, P167, DOI 10.1016/S0195-6701(02)00386-9
   Senna JPM, 2003, J HOSP INFECT, V53, P156, DOI 10.1053/jhin.2002.1346
   Silva-Carvalho MC, 2009, DIAGN MICR INFEC DIS, V65, P300, DOI 10.1016/j.diagmicrobio.2009.07.023
   Silveira ACO, 2015, BRAZ J INFECT DIS, V19, P384, DOI 10.1016/j.bjid.2015.04.009
   Soares JMD, 2000, J HOSP INFECT, V44, P301
   Soares MJD, 2001, J MED MICROBIOL, V50, P732, DOI 10.1099/0022-1317-50-8-732
   Soares MJS, 1997, J MED MICROBIOL, V46, P214, DOI 10.1099/00222615-46-3-214
   Souza RR, 2009, CLIN MICROBIOL INFEC, V15, P204, DOI 10.1111/j.1469-0691.2008.02118.x
   Spinardi Julia R, 2017, Germs, V7, P61, DOI 10.18683/germs.2017.1110
   Stephens C, 2015, MICROBIOL RESOUR ANN, V3, DOI 10.1128/genomeA.00907-15
   Teixeira LA, 1996, MICROB DRUG RESIST, V2, P393, DOI 10.1089/mdr.1996.2.393
   TEIXEIRA LA, 1995, J CLIN MICROBIOL, V33, P2400, DOI 10.1128/JCM.33.9.2400-2404.1995
   Teixeira MM, 2012, BRAZ J MED BIOL RES, V45, P637, DOI 10.1590/S0100-879X2012007500065
   Teodoro CRS, 2012, MICROBIOL IMMUNOL, V56, P647, DOI 10.1111/j.1348-0421.2012.00481.x
   Timerman A, 2013, BRAZ J INFECT DIS, V17, P647, DOI 10.1016/j.bjid.2013.03.005
   Tortora Joao Carlos De Olivieira, 1996, Revista Latinoamericana de Microbiologia, V38, P1
   Olivo TET, 2009, BURNS, V35, P1104, DOI 10.1016/j.burns.2009.02.008
   Tresoldi Antonia Teresinha, 1997, Revista do Instituto de Medicina Tropical de Sao Paulo, V39, P333, DOI 10.1590/S0036-46651997000600005
   Trindade PD, 2005, J CLIN MICROBIOL, V43, P3435, DOI 10.1128/JCM.43.7.3435-3437.2005
   Urushibara N, 2020, J ANTIMICROB CHEMOTH, V75, P46, DOI 10.1093/jac/dkz406
   van der Heijden IM, 2016, J MED MICROBIOL, V65, P1060, DOI 10.1099/jmm.0.000324
   van Rijen MML, 2008, CLIN INFECT DIS, V46, P261, DOI 10.1086/524672
   Veloso JO, 2019, APMIS, V127, P717, DOI 10.1111/apm.12989
   Braga EDV, 2014, BMC INFECT DIS, V14, DOI 10.1186/1471-2334-14-538
   Vidal PM, 2009, INFECT CONT HOSP EP, V30, P139, DOI 10.1086/593954
   Vieira MA, 2014, BRAZ J INFECT DIS, V18, P42, DOI 10.1016/j.bjid.2013.04.012
   Vieira MTC, 2016, PEDIATR INFECT DIS J, V35, P1126, DOI 10.1097/INF.0000000000001246
   Vivoni AM, 2006, J CLIN MICROBIOL, V44, P1686, DOI 10.1128/JCM.44.5.1686-1691.2006
   Vola ME, 2013, ARQ BRAS OFTALMOL, V76, P350, DOI 10.1590/S0004-27492013000600006
   Witzel CD, 2014, ANN CLIN MICROB ANTI, V13, DOI 10.1186/1476-0711-13-25
   Yamada Ogatta E. E., 1993, J HOSP INFECT, V25, P97, DOI [10.1016/0195-6701(93)90100-e, DOI 10.1016/0195-6701(93)90100-E]
   Zanella RC, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0221525
NR 235
TC 0
Z9 0
U1 0
U2 0
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1712-9532
EI 1918-1493
J9 CAN J INFECT DIS MED
JI Can. J. Infect. Dis. Med. Microbiol.
PD OCT 7
PY 2020
VL 2020
AR 1721936
DI 10.1155/2020/1721936
PG 18
WC Infectious Diseases; Microbiology
SC Infectious Diseases; Microbiology
GA OG9GL
UT WOS:000582183200001
PM 33082892
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Bernardes, SS
   Pinto, MCX
   Amorim, JH
   Azevedo, VAD
   Resende, RR
   Mintz, A
   Birbrair, A
AF Bernardes, Sara Santos
   Pinto, Mauro Cunha Xavier
   Amorim, Jaime Henrique
   Azevedo, Vasco Ariston de Carvalho
   Resende, Rodrigo Ribeiro
   Mintz, Akiva
   Birbrair, Alexander
TI Glioma Pericytes Promote Angiogenesis by Producing Periostin
SO CELLULAR AND MOLECULAR NEUROBIOLOGY
LA English
DT Review; Early Access
DE Pericytes; Glioma; Tumor microenvironment; Periostin
ID HUMAN BRAIN PERICYTES; STEM-CELLS; MICROVASCULAR PERICYTES;
   ENDOTHELIAL-CELLS; TUMOR-GROWTH; MACROPHAGES; CANCER; NICHE; LUNG;
   REGENERATION
AB Glioma is the prevalent aggressive primary brain tumor, with a very poor prognosis. The absence of advanced understanding of the roles played by the cells within the glioma microenvironment limits the development of effective drugs. A recent study indicates that periostin expressed by pericytes is crucial for glioma angiogenesis. Here, we describe succinctly the results and implications of this discovery in what we know about pericytes within the glioma microenvironment. The emerging knowledge from this work will benefit the development of therapies for gliomas.
C1 [Bernardes, Sara Santos; Birbrair, Alexander] Univ Fed Minas Gerais, Dept Pathol, Tissue Microenvironm Lab, Belo Horizonte, MG, Brazil.
   [Pinto, Mauro Cunha Xavier] Univ Fed Goias, Inst Biol Sci, Lab Neuropharmacol & Neurochem, Goiania, Go, Brazil.
   [Amorim, Jaime Henrique] Fed Univ West Bahia, Ctr Biol Sci & Hlth, Barreiras, BA, Brazil.
   [Azevedo, Vasco Ariston de Carvalho] Univ Fed Minas Gerais, Dept Genet Ecol & Evolut, Cellular & Mol Genet Lab, Belo Horizonte, MG, Brazil.
   [Resende, Rodrigo Ribeiro] Univ Fed Minas Gerais, Dept Biochem & Immunol, Belo Horizonte, MG, Brazil.
   [Mintz, Akiva; Birbrair, Alexander] Columbia Univ, Med Ctr, Dept Radiol, New York, NY 10027 USA.
RP Birbrair, A (corresponding author), Univ Fed Minas Gerais, Dept Pathol, Tissue Microenvironm Lab, Belo Horizonte, MG, Brazil.; Birbrair, A (corresponding author), Columbia Univ, Med Ctr, Dept Radiol, New York, NY 10027 USA.
EM birbrair@icb.ufmg.br
RI Bernardes, Sara Santos/AAP-2640-2020; Azevedo, Vasco A/B-1556-2019;
   Cunha Xavier Pinto, Mauro/G-1052-2010
OI Bernardes, Sara Santos/0000-0001-6700-2447; Azevedo, Vasco
   A/0000-0002-4775-2280; Resende, Rodrigo/0000-0002-2003-0739; Cunha
   Xavier Pinto, Mauro/0000-0002-1680-8130
FU Instituto Serrapilheira [Serra-1708-15285]; Pro-reitoria de
   Pesquisa/Universidade Federal de Minas Gerais (PRPq/UFMG) [Edital
   05/2016]; CNPQNational Council for Scientific and Technological
   Development (CNPq) [405977/2018-2]; National Institute of Science and
   Technology in Theranostics and Nanobiotechnology (CNPq/CAPES/FAPEMIG)
   [465669/2014-0]; FAPEMIG [Rede Mineira de Engenharia de Tecidos e
   Terapia Celular (REMETTEC)] [RED-00570-16]; FAPEMIG [Rede De Pesquisa Em
   Doencas Infecciosas Humanas E Animais Do Estado De Minas Gerais)]
   [RED-00313-16]; National Council for Scientific and Technological
   Development (CNPq)National Council for Scientific and Technological
   Development (CNPq); National Institute of HealthUnited States Department
   of Health & Human ServicesNational Institutes of Health (NIH) - USA
   [1R01CA179072-01A1]; American Cancer Society Mentored Research Scholar
   grantAmerican Cancer Society [124443-MRSG-13-121-01-CDD]
FX Alexander Birbrair is supported by a grant from Instituto
   Serrapilheira/Serra-1708-15285, a grant from Pro-reitoria de
   Pesquisa/Universidade Federal de Minas Gerais (PRPq/UFMG) (Edital
   05/2016), a grant from CNPQ (Universal, Process No. 405977/2018-2), a
   grant from National Institute of Science and Technology in Theranostics
   and Nanobiotechnology (CNPq/CAPES/FAPEMIG, Process No. 465669/2014-0), a
   grant from FAPEMIG [Rede Mineira de Engenharia de Tecidos e Terapia
   Celular (REMETTEC, RED-00570-16)], a grant from FAPEMIG [Rede De
   Pesquisa Em Doencas Infecciosas Humanas E Animais Do Estado De Minas
   Gerais (RED-00313-16)], and a productivity fellowship from the National
   Council for Scientific and Technological Development (CNPq); Akiva Mintz
   is supported by the National Institute of Health (1R01CA179072-01A1) and
   by the American Cancer Society Mentored Research Scholar grant
   (124443-MRSG-13-121-01-CDD).
CR ALLSOPP G, 1979, J ANAT, V128, P155
   Almeida VM, 2018, NEUROSCIENTIST, V24, P440, DOI 10.1177/1073858417731522
   Andreotti JP, 2019, SEMIN CELL DEV BIOL, V95, P42, DOI 10.1016/j.semcdb.2019.01.005
   Andreotti JP, 2018, CELL MOL IMMUNOL, V15, P941, DOI 10.1038/s41423-018-0023-1
   Andreotti JP, 2018, INT J DEV NEUROSCI, V67, P33, DOI 10.1016/j.ijdevneu.2018.03.002
   Andreotti JP, 2017, CELL STEM CELL, V21, P293, DOI 10.1016/j.stem.2017.08.005
   Armulik A, 2011, DEV CELL, V21, P193, DOI 10.1016/j.devcel.2011.07.001
   Asada N, 2017, NAT CELL BIOL, V19, P214, DOI 10.1038/ncb3475
   Azevedo PO, 2018, CANCER METAST REV, V37, P779, DOI 10.1007/s10555-018-9759-4
   Azevedo PO, 2018, J CELL PHYSIOL, V233, P5523, DOI 10.1002/jcp.26348
   Azevedo PO, 2017, NEUROSCIENCE, V363, P62, DOI 10.1016/j.neuroscience.2017.08.059
   Balabanov R, 1999, J NEUROSCI RES, V55, P578, DOI 10.1002/(SICI)1097-4547(19990301)55:5<578::AID-JNR5>3.0.CO;2-E
   Balabanov R, 1996, MICROVASC RES, V52, P127, DOI 10.1006/mvre.1996.0049
   Bechmann I, 2001, EUR J NEUROSCI, V14, P1651, DOI 10.1046/j.0953-816x.2001.01793.x
   Bell RD, 2010, NEURON, V68, P409, DOI 10.1016/j.neuron.2010.09.043
   Birbrair A, 2017, ADV EXP MED BIOL, V1041, P1, DOI 10.1007/978-3-319-69194-7_1
   Birbrair A, 2017, STEM CELLS DEV, V26, P1013, DOI 10.1089/scd.2017.0044
   Birbrair A, 2017, STEM CELL TRANSL MED, V6, P471, DOI 10.5966/sctm.2016-0007
   Birbrair A, 2016, ANN NY ACAD SCI, V1370, P82, DOI 10.1111/nyas.13016
   Birbrair A, 2015, STEM CELL REV REP, V11, P547, DOI 10.1007/s12015-015-9588-6
   Birbrair A, 2014, STEM CELL RES THER, V5, DOI 10.1186/scrt512
   Birbrair A, 2014, FRONT AGING NEUROSCI, V6, DOI 10.3389/fnagi.2014.00245
   Birbrair A, 2015, CLIN SCI, V128, P81, DOI 10.1042/CS20140278
   Birbrair A, 2014, AM J PHYSIOL-CELL PH, V307, pC25, DOI 10.1152/ajpcell.00084.2014
   Birbrair A, 2013, AM J PHYSIOL-CELL PH, V305, pC1098, DOI 10.1152/ajpcell.00171.2013
   Birbrair A, 2013, STEM CELLS DEV, V22, P2298, DOI 10.1089/scd.2012.0647
   Birbrair A, 2013, STEM CELL RES, V10, P67, DOI 10.1016/j.scr.2012.09.003
   Birbrair A, 2013, EXP CELL RES, V319, P45, DOI 10.1016/j.yexcr.2012.09.008
   Birbrair A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016816
   Borges I, 2017, STEM CELL REV REP, V13, P567, DOI 10.1007/s12015-017-9747-z
   Bouchard BA, 1997, ARTERIOSCL THROM VAS, V17, P1, DOI 10.1161/01.ATV.17.1.1
   Buckingham ME, 2011, DEV CELL, V21, P394, DOI 10.1016/j.devcel.2011.07.019
   Caspani EM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101402
   Castejon OJ, 2011, FOLIA NEUROPATHOL, V49, P162
   Cheng L, 2013, CELL, V153, P139, DOI 10.1016/j.cell.2013.02.021
   Coatti GC, 2017, STEM CELL REV REP, V13, P686, DOI 10.1007/s12015-017-9752-2
   Costa MA, 2018, J MOL CELL CARDIOL, V116, P1, DOI 10.1016/j.yjmcc.2018.01.014
   Crisan M, 2012, J CELL MOL MED, V16, P2851, DOI 10.1111/j.1582-4934.2012.01617.x
   de Alvarenga EC, 2018, ANN HEMATOL, V97, P1749, DOI 10.1007/s00277-018-3463-x
   De Vleeschouwer S, 2017, GLIOBLASTOMA, P315, DOI 10.15586/codon.glioblastoma.2017.ch16
   Prazeres PHDM, 2017, DEV BIOL, V427, P6, DOI 10.1016/j.ydbio.2017.05.001
   Enge M, 2002, EMBO J, V21, P4307, DOI 10.1093/emboj/cdf418
   FABRY Z, 1993, J NEUROIMMUNOL, V47, P23, DOI 10.1016/0165-5728(93)90281-3
   Fisher M, 2009, STROKE, V40, pS13, DOI 10.1161/STROKEAHA.108.533117
   Gerl K, 2015, KIDNEY INT, V88, P1345, DOI 10.1038/ki.2015.274
   Goncalves WA, 2020, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.03120
   Goritz C, 2011, SCIENCE, V333, P238, DOI 10.1126/science.1203165
   Guerra DAP, 2018, ANGIOGENESIS, V21, P667, DOI 10.1007/s10456-018-9621-x
   Guerra DAP, 2018, CYTOM PART A, V93A, P167, DOI 10.1002/cyto.a.23301
   Guillemin GJ, 2004, J LEUKOCYTE BIOL, V75, P388, DOI 10.1189/jlb.0303114
   HASAN M, 1990, J HIRNFORSCH, V31, P237
   Hellstrom M, 2001, J CELL BIOL, V153, P543, DOI 10.1083/jcb.153.3.543
   Henriques F, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-36626-3
   Hong LZ, 2013, ONCOL LETT, V6, P1595, DOI 10.3892/ol.2013.1590
   Huizer Karin, 2020, J Neuropathol Exp Neurol, V79, P863, DOI 10.1093/jnen/nlaa067
   Isasi E, 2020, CURR TISSUE MICROENV, V1, P131, DOI [10.1007/s43152-020-00012-x, DOI 10.1007/S43152-020-00012-X]
   JEYNES B, 1985, STROKE, V16, P121, DOI 10.1161/01.STR.16.1.121
   Kamouchi M, 2011, CELL MOL NEUROBIOL, V31, P175, DOI 10.1007/s10571-010-9605-x
   Kanashiro A, 2020, PHARMACOL RES, V151, DOI 10.1016/j.phrs.2019.104580
   Khan JA, 2016, SCIENCE, V351, P176, DOI 10.1126/science.aad0084
   Kikuchi Y, 2014, AM J PATHOL, V184, P859, DOI 10.1016/j.ajpath.2013.11.012
   Kim JA, 2006, J CEREBR BLOOD F MET, V26, P209, DOI 10.1038/sj.jcbfm.9600181
   Krex D, 2007, BRAIN, V130, P2596, DOI 10.1093/brain/awm204
   Kudo Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044488
   Leonel C, 2019, J CELL MOL MED, V23, P5949, DOI 10.1111/jcmm.14415
   LEVEEN P, 1994, GENE DEV, V8, P1875, DOI 10.1101/gad.8.16.1875
   Lindahl P, 1997, SCIENCE, V277, P242, DOI 10.1126/science.277.5323.242
   Lousado L, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.456
   Manini I, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19010147
   Ostrom QT, 2014, NEURO-ONCOLOGY, V16, P1, DOI 10.1093/neuonc/nou223
   Paiva AE, 2018, CANCER RES, V78, P2779, DOI 10.1158/0008-5472.CAN-17-3883
   Paiva AE, 2017, NEOPLASIA, V19, P928, DOI 10.1016/j.neo.2017.08.007
   Pallone TL, 2003, AM J PHYSIOL-RENAL, V284, pF253, DOI 10.1152/ajprenal.00304.2002
   Payne LB, 2020, CURR TISSUE MICROENV, V1, P143, DOI [10.1007/s43152-020-00014-9, DOI 10.1007/S43152-020-00014-9]
   Picoli CC, 2019, AM J PATHOL, V189, P1327, DOI 10.1016/j.ajpath.2019.03.008
   Picoli CC, 2020, STEM CELLS TRANSL ME
   Prazeres PHDM, 2020, J CELL MOL MED, V24, P9574, DOI 10.1111/jcmm.15381
   Prazeres PHDM, 2018, INT J BIOCHEM CELL B, V99, P109, DOI 10.1016/j.biocel.2018.04.002
   Prazeres PHDM, 2018, CELL MOL NEUROBIOL, V38, P777, DOI 10.1007/s10571-017-0549-2
   Quail DF, 2013, NAT MED, V19, P1423, DOI 10.1038/nm.3394
   Roberts LaDeidra Monet, 2020, Curr Tissue Microenviron Rep, V1, P99, DOI 10.1007/s43152-020-00010-z
   Rouget C., 1873, ARCH PHYSL NORM PATH, V5, P603
   Santos GSP, 2018, EYE, V32, P483, DOI 10.1038/eye.2017.220
   Santos GSP, 2019, NEUROSCI BULL, V35, P551, DOI 10.1007/s12264-018-0296-5
   Sena IFG, 2018, CANCER MED-US, V7, P1232, DOI 10.1002/cam4.1375
   Sena IFG, 2017, CELL CYCLE, V16, P2018, DOI 10.1080/15384101.2017.1367072
   Sena IFG, 2017, EXP HEMATOL, V54, P12, DOI 10.1016/j.exphem.2017.06.349
   Silva WN, 2018, WOUND REPAIR REGEN, V26, P392, DOI 10.1111/wrr.12647
   Silva WN, 2018, EXP DERMATOL, V27, P630, DOI 10.1111/exd.13524
   Miranda VHS, 2020, PLOS NEGLECT TROP D, V14, DOI 10.1371/journal.pntd.0008635
   Sims DE, 2000, CLIN EXP PHARMACOL P, V27, P842, DOI 10.1046/j.1440-1681.2000.03343.x
   SIMS DE, 1991, CAN J CARDIOL, V7, P431
   Snippert HJ, 2011, EMBO REP, V12, P113, DOI 10.1038/embor.2010.216
   Soderblom C, 2013, J NEUROSCI, V33, P13882, DOI 10.1523/JNEUROSCI.2524-13.2013
   SORIANO P, 1994, GENE DEV, V8, P1888, DOI 10.1101/gad.8.16.1888
   Spitzer TLB, 2012, BIOL REPROD, V86, DOI 10.1095/biolreprod.111.095885
   Stark K, 2013, NAT IMMUNOL, V14, P41, DOI 10.1038/ni.2477
   Tanaka S, 2013, NAT REV CLIN ONCOL, V10, P14, DOI 10.1038/nrclinonc.2012.204
   Thanabalasundaram G, 2011, INT J BIOCHEM CELL B, V43, P1284, DOI 10.1016/j.biocel.2011.05.002
   Thomas WE, 1999, BRAIN RES REV, V31, P42, DOI 10.1016/S0165-0173(99)00024-7
   Tu ZD, 2011, INVEST OPHTH VIS SCI, V52, P9005, DOI 10.1167/iovs.11-8008
   Utispan K, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-13
   Valdor R, 2017, ONCOTARGET, V8, P68614, DOI 10.18632/oncotarget.19804
   Valle IB, 2020, HEAD NECK PATHOL, DOI 10.1007/s12105-020-01188-2
   Vannucci L, 2015, CANCER MICROENVIRON, V8, P159, DOI 10.1007/s12307-014-0150-x
   VERBEEK MM, 1995, J IMMUNOL, V154, P5876
   Magno LAV, 2019, J NEUROSCI, V39, P3234, DOI 10.1523/JNEUROSCI.2277-18.2019
   Weller M, 2015, NAT REV DIS PRIMERS, V1, DOI 10.1038/nrdp.2015.17
   Winkler EA, 2014, BRAIN PATHOL, V24, P371, DOI 10.1111/bpa.12152
   Zhou WC, 2017, CELL STEM CELL, V21, P591, DOI 10.1016/j.stem.2017.10.002
   Zhou WC, 2015, NAT CELL BIOL, V17, P170, DOI 10.1038/ncb3090
   Zhu M, 2011, MOL CANCER THER, V10, P1500, DOI 10.1158/1535-7163.MCT-11-0046
   Zimmermann KW, 1923, Z ANAT ENTWICKLUNGS, V68, P29, DOI [10.1007/BF02593544, DOI 10.1007/BF02593544]
NR 113
TC 1
Z9 1
U1 0
U2 0
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0272-4340
EI 1573-6830
J9 CELL MOL NEUROBIOL
JI Cell. Mol. Neurobiol.
DI 10.1007/s10571-020-00975-3
EA OCT 2020
PG 8
WC Cell Biology; Neurosciences
SC Cell Biology; Neurosciences & Neurology
GA NW1OB
UT WOS:000574780300001
PM 33010018
DA 2020-12-01
ER

PT J
AU Pinheiro-Michelsen, JR
   Souza, RDO
   Santana, IVR
   da Silva, PD
   Mendez, EC
   Luiz, WB
   Amorim, JH
AF Pinheiro-Michelsen, Josilene Ramos
   Oliveira Souza, Rayane da Silva
   Rocha Santana, Itana Vivian
   da Silva, Patricia de Souza
   Mendez, Erick Carvalho
   Luiz, Wilson Barros
   Amorim, Jaime Henrique
TI Anti-dengue Vaccines: From Development to Clinical Trials
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Review
DE dengue; vaccine development; pre-clinical tests; clinical trials;
   countries
ID FLAVIVIRUS-NAIVE ADULTS; DOG KIDNEY-CELLS; PHASE-I TRIAL; YELLOW-FEVER;
   VIRUS-VACCINE; PROTECTIVE EFFICACY; HEALTHY-CHILDREN; DNA VACCINE;
   STRAIN 16681; CYD-TDV
AB Dengue Virus(DENV) is an arbovirus (arthropod-borne virus). Four serotypes of DENV are responsible for the infectious disease called dengue that annually affects nearly 400 million people worldwide. Although there is only one vaccine formulation licensed for use in humans, there are other vaccine formulations under development that apply different strategies. In this review, we present information about anti-dengue vaccine formulations regarding development, pre-clinical tests, and clinical trials. The improvement in vaccine development against dengue is much needed, but it should be considered that the correlate of protection is still uncertain. Neutralizing antibodies have been proposed as a correlate of protection, but this ignores the key role of T-cell mediated immunity in controlling DENV infection. It is important to confirm the accurate correlate of protection against DENV infection, and also to have other anti-dengue vaccine formulations licensed for use.
C1 [Pinheiro-Michelsen, Josilene Ramos; Oliveira Souza, Rayane da Silva; Rocha Santana, Itana Vivian; da Silva, Patricia de Souza; Amorim, Jaime Henrique] Univ Fed Oeste Bahia, Lab Agentes Infecciosos & Vetores, Ctr Ciencias Biol & Saude, Barreiras, Brazil.
   [Pinheiro-Michelsen, Josilene Ramos; da Silva, Patricia de Souza; Mendez, Erick Carvalho; Luiz, Wilson Barros; Amorim, Jaime Henrique] Univ Estadual Santa Cruz, Programa Posgrad Biol & Biotecnol Microrganismos, Barreiras, Brazil.
RP Amorim, JH (corresponding author), Univ Fed Oeste Bahia, Lab Agentes Infecciosos & Vetores, Ctr Ciencias Biol & Saude, Barreiras, Brazil.; Amorim, JH (corresponding author), Univ Estadual Santa Cruz, Programa Posgrad Biol & Biotecnol Microrganismos, Barreiras, Brazil.
EM jaime.amorim@ufob.edu.br
RI Luiz, Wilson/L-7575-2015
OI Luiz, Wilson/0000-0003-3265-8547; Mendez, Erick
   Carvalho/0000-0002-8546-4204
FU Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
   (CNPq)National Council for Scientific and Technological Development
   (CNPq); Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior
   (CAPES)CAPES
FX We are thankful to Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico (CNPq) for providing undergraduate research fellowship to
   IS. We are also grateful to Coordenacao de Aperfeicoamento de Pessoal de
   Nivel Superior (CAPES) for providing graduate fellowship to JP-M.
CR Arredondo-Garcia JL, 2018, CLIN MICROBIOL INFEC, V24, P755, DOI 10.1016/j.cmi.2018.01.018
   Bauer K, 2015, AM J TROP MED HYG, V93, P441, DOI 10.4269/ajtmh.14-0625
   Beltramello M, 2010, CELL HOST MICROBE, V8, P271, DOI 10.1016/j.chom.2010.08.007
   BHAMARAPRAVATI N, 1987, B WORLD HEALTH ORGAN, V65, P189
   Bhamarapravati N, 2000, VACCINE, V18, P44, DOI 10.1016/S0264-410X(00)00040-2
   Bhatt S, 2013, NATURE, V496, P504, DOI 10.1038/nature12060
   Biswal S, 2019, NEW ENGL J MED, V381, P2009, DOI 10.1056/NEJMoa1903869
   Blair PJ, 2006, VACCINE, V24, P1427, DOI 10.1016/j.vaccine.2005.09.032
   Blaney JE, 2006, VIRAL IMMUNOL, V19, P10, DOI 10.1089/vim.2006.19.10
   Blaney JE, 2004, AM J TROP MED HYG, V71, P811, DOI 10.4269/ajtmh.2004.71.811
   Blaney JE, 2004, BMC INFECT DIS, V4, DOI 10.1186/1471-2334-4-39
   Blaney JE, 2008, VACCINE, V26, P817, DOI 10.1016/j.vaccine.2007.11.082
   Borges MB, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1007721
   Brandler S, 2005, AM J TROP MED HYG, V72, P74, DOI 10.4269/ajtmh.2005.72.74
   BRAY M, 1991, P NATL ACAD SCI USA, V88, P10342, DOI 10.1073/pnas.88.22.10342
   Brewoo JN, 2012, VACCINE, V30, P1513, DOI 10.1016/j.vaccine.2011.11.072
   Butrapet S, 2000, J VIROL, V74, P3011, DOI 10.1128/JVI.74.7.3011-3019.2000
   Butrapet S, 2000, VECTOR-BORNE ZOONOT, V11, P683, DOI [10.1089/vbz.2010.0150, DOI 10.1089/VBZ.2010.0150]
   Byers Anthony M, 2015, Open Forum Infect Dis, V2, pofv172, DOI 10.1093/ofid/ofv172
   Capeding MR, 2014, LANCET, V384, P1358, DOI 10.1016/S0140-6736(14)61060-6
   Capeding RZ, 2011, VACCINE, V29, P3863, DOI 10.1016/j.vaccine.2011.03.057
   Chambers TJ, 1999, J VIROL, V73, P3095, DOI 10.1128/JVI.73.4.3095-3101.1999
   Clements DE, 2010, VACCINE, V28, P2705, DOI 10.1016/j.vaccine.2010.01.022
   Coudeville L, 2016, VACCINE, V34, P6426, DOI 10.1016/j.vaccine.2016.08.050
   Coudeville L, 2016, VACCINE, V34, P6417, DOI 10.1016/j.vaccine.2015.11.023
   Crill WD, 2001, J VIROL, V75, P7769, DOI 10.1128/JVI.75.16.7769-7773.2001
   Danko JR, 2018, AM J TROP MED HYG, V98, P849, DOI 10.4269/ajtmh.17-0416
   Dayan GH, 2014, HUM VACC IMMUNOTHER, V10, P2853, DOI 10.4161/21645515.2014.972131
   Dayan GH, 2013, AM J TROP MED HYG, V89, P1058, DOI 10.4269/ajtmh.13-0304
   Diaz C, 2018, AM J TROP MED HYG, V98, P1435, DOI 10.4269/ajtmh.17-0627
   Didierlaurent AM, 2017, EXPERT REV VACCINES, V16, P55, DOI 10.1080/14760584.2016.1213632
   Dubey AP, 2016, HUM VACC IMMUNOTHER, V12, P512, DOI 10.1080/21645515.2015.1076598
   Durbin AP, 2006, HUM VACCINES, V2, P167, DOI 10.4161/hv.2.4.2944
   Durbin AP, 2006, HUM VACCINES, V2, P255, DOI 10.4161/hv.2.6.3494
   Durbin Anna P, 2016, J Infect Dis, V214, P832, DOI 10.1093/infdis/jiw067
   Durbin AP, 2013, J INFECT DIS, V207, P957, DOI 10.1093/infdis/jis936
   Durbin AP, 2011, VACCINE, V29, P7242, DOI 10.1016/j.vaccine.2011.07.023
   Durbin AP, 2011, J INFECT DIS, V203, P327, DOI 10.1093/infdis/jiq059
   Durbin AP, 2005, J INFECT DIS, V191, P710, DOI 10.1086/427780
   Durbin AP, 2001, AM J TROP MED HYG, V65, P405, DOI 10.4269/ajtmh.2001.65.405
   ECKELS KH, 1976, INFECT IMMUN, V14, P1221, DOI 10.1128/IAI.14.5.1221-1227.1976
   Eckels KH, 2003, AM J TROP MED HYG, V69, P12, DOI 10.4269/ajtmh.2003.69.12
   Edelman R, 2003, AM J TROP MED HYG, V69, P48, DOI 10.4269/ajtmh.2003.69.48
   Fernandez S, 2015, AM J TROP MED HYG, V92, P698, DOI 10.4269/ajtmh.14-0268
   Franco LD, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02260
   Gailhardou S, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004821
   Garcon N, 2011, EXPERT REV VACCINES, V10, P471, DOI [10.1586/erv.11.29, 10.1586/ERV.11.29]
   George SL, 2015, J INFECT DIS, V212, P1032, DOI 10.1093/infdis/jiv179
   Godoi IP, 2017, J COMP EFFECT RES, V6, P165, DOI 10.2217/cer-2016-0045
   Govindarajan D, 2015, VACCINE, V33, P4105, DOI 10.1016/j.vaccine.2015.06.067
   GRUENBERG A, 1988, J GEN VIROL, V69, P1391, DOI 10.1099/0022-1317-69-6-1391
   Gubler DJ, 2004, COMP IMMUNOL MICROB, V27, P319, DOI 10.1016/j.cimid.2004.03.013
   Guirakhoo F, 2000, J VIROL, V74, P5477, DOI 10.1128/JVI.74.12.5477-5485.2000
   Guirakhoo F, 2004, J VIROL, V78, P4761, DOI 10.1128/JVI.78.9.4761-4775.2004
   Guirakhoo F, 2001, J VIROL, V75, P7290, DOI 10.1128/JVI.75.16.7290-7304.2001
   Guirakhoo F, 2006, HUM VACCINES, V2, P60, DOI 10.4161/hv.2.2.2555
   Guy B, 2008, VACCINE, V26, P5712, DOI 10.1016/j.vaccine.2008.08.019
   Guy B, 2017, EXPERT REV VACCINES, V16, P671, DOI 10.1080/14760584.2017.1335201
   Guy B, 2016, NAT REV MICROBIOL, V14, P45, DOI 10.1038/nrmicro.2015.2
   Guzman MG, 2015, LANCET, V385, P453, DOI 10.1016/S0140-6736(14)60572-9
   Hadinegoro SR, 2015, NEW ENGL J MED, V373, P1195, DOI 10.1056/NEJMoa1506223
   HAHN YS, 1988, VIROLOGY, V162, P167, DOI 10.1016/0042-6822(88)90406-0
   Halstead SB, 2003, AM J TROP MED HYG, V69, P5
   HALSTEAD SB, 1979, J INFECT DIS, V140, P527, DOI 10.1093/infdis/140.4.527
   Halstead SB, 2017, LANCET INFECT DIS, V17, pE378, DOI 10.1016/S1473-3099(17)30362-6
   Harenberg A, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004830
   Harenberg A, 2013, HUM VACC IMMUNOTHER, V9, P2317, DOI 10.4161/hv.25562
   Henein S, 2017, J INFECT DIS, V215, P351, DOI 10.1093/infdis/jiw576
   Higgs S, 2006, AM J TROP MED HYG, V75, P986, DOI 10.4269/ajtmh.2006.75.986
   Hss AS, 2013, VACCINE, V31, P5814, DOI 10.1016/j.vaccine.2013.10.013
   Huang CYH, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002243
   Huang CYH, 2003, J VIROL, V77, P11436, DOI 10.1128/JVI.77.21.11436-11447.2003
   Huang CYH, 2000, J VIROL, V74, P3020, DOI 10.1128/JVI.74.7.3020-3028.2000
   Jackson LA, 2018, VACCINE, V36, P3976, DOI 10.1016/j.vaccine.2018.05.028
   Katzelnick LC, 2016, J IMMIGR MINOR HEALT, V349, P1338, DOI [10.1126/science.aac5017, DOI 10.1126/SCIENCE.AAC5017]
   Kinney RM, 1997, VIROLOGY, V230, P300, DOI 10.1006/viro.1997.8500
   Kirkpatrick BD, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf1517
   Kirkpatrick BD, 2015, J INFECT DIS, V212, P702, DOI 10.1093/infdis/jiv082
   Kirstein J, 2018, BMC INFECT DIS, V18, DOI 10.1186/s12879-018-3389-x
   Kitchener S, 2006, VACCINE, V24, P1238, DOI 10.1016/j.vaccine.2005.09.029
   Kochel T, 1997, VACCINE, V15, P547, DOI 10.1016/S0264-410X(97)00215-6
   L'Azou M, 2016, NEW ENGL J MED, V374, P1155, DOI 10.1056/NEJMoa1503877
   Lai CY, 2008, J VIROL, V82, P6631, DOI 10.1128/JVI.00316-08
   Lanata CF, 2012, VACCINE, V30, P5935, DOI 10.1016/j.vaccine.2012.07.043
   Larsen CP, 2015, VACCINE, V33, P7075, DOI 10.1016/j.vaccine.2015.09.052
   Leo YS, 2012, HUM VACC IMMUNOTHER, V8, P1259, DOI 10.4161/hv.21224
   Lindenbach BD, 2007, FIELDS VIROLOGY, P1101, DOI DOI 10.1016/0038-092X(88)90131-4
   Lindow JC, 2013, VACCINE, V31, P3347, DOI 10.1016/j.vaccine.2013.05.075
   Lok SM, 2008, NAT STRUCT MOL BIOL, V15, P312, DOI 10.1038/nsmb.1382
   Lopez P, 2016, PEDIATR INFECT DIS J, V35, P1140, DOI 10.1097/INF.0000000000001250
   Lu Y, 2003, VACCINE, V21, P2178, DOI 10.1016/S0264-410X(03)00009-4
   Manoff SB, 2019, HUM VACC IMMUNOTHER, V15, P2195, DOI 10.1080/21645515.2018.1546523
   Manoff SB, 2015, VACCINE, V33, P7126, DOI 10.1016/j.vaccine.2015.09.101
   Martinez LJ, 2015, AM J TROP MED HYG, V93, P454, DOI 10.4269/ajtmh.14-0819
   Men RH, 1996, J VIROL, V70, P3930, DOI 10.1128/JVI.70.6.3930-3937.1996
   Mendoza-Montero J, 1998, CLIN INFECT DIS, V27, P434, DOI 10.1086/514684
   Morrison D, 2010, J INFECT DIS, V201, P370, DOI 10.1086/649916
   Nealon J, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004918
   Oliphant T, 2006, J VIROL, V80, P12149, DOI 10.1128/JVI.01732-06
   Olivera-Botello G, 2016, J INFECT DIS, V214, P994, DOI 10.1093/infdis/jiw297
   Osatomi K, 1988, Virus Genes, V2, P99, DOI 10.1007/BF00569739
   Osorio JE, 2016, EXPERT REV VACCINES, V15, P497, DOI 10.1586/14760584.2016.1128328
   Osorio JE, 2014, LANCET INFECT DIS, V14, P830, DOI 10.1016/S1473-3099(14)70811-4
   Osorio JE, 2011, AM J TROP MED HYG, V84, P978, DOI 10.4269/ajtmh.2011.10-0592
   Plennevaux E, 2018, CLIN INFECT DIS, V66, P1164, DOI 10.1093/cid/cix966
   Plennevaux E, 2016, VACCINE, V34, P2707, DOI 10.1016/j.vaccine.2016.04.028
   Poo J, 2011, PEDIATR INFECT DIS J, V30, pE9, DOI 10.1097/INF.0b013e3181fe05af
   Popper SJ, 2018, J INFECT DIS, V218, P1911, DOI 10.1093/infdis/jiy434
   Porter KR, 2012, VACCINE, V30, P336, DOI 10.1016/j.vaccine.2011.10.085
   Porter KR, 1998, ARCH VIROL, V143, P997, DOI 10.1007/s007050050348
   Putnak JR, 2005, VACCINE, V23, P4442, DOI 10.1016/j.vaccine.2005.03.042
   Putnak R, 1996, J INFECT DIS, V174, P1176, DOI 10.1093/infdis/174.6.1176
   Qiao M, 2011, AM J TROP MED HYG, V85, P724, DOI 10.4269/ajtmh.2011.10-0436
   Rabaa MA, 2017, ELIFE, V6, DOI [10.7554/eLife.24196, 10.7554/elife.24196]
   Raviprakash K, 2000, VACCINE, V18, P2426, DOI 10.1016/S0264-410X(99)00570-8
   Raviprakash K, 2006, VIROLOGY, V353, P166, DOI 10.1016/j.virol.2006.05.005
   Raviprakash K, 2012, HUM VACC IMMUNOTHER, V8, P1764, DOI 10.4161/hv.21806
   Melo FIR, 2017, PEDIATR INFECT DIS J, V36, P602, DOI 10.1097/INF.0000000000001542
   Rupp R, 2015, VACCINE, V33, P6351, DOI 10.1016/j.vaccine.2015.09.008
   Sabchareon A, 2012, LANCET, V380, P1559, DOI 10.1016/S0140-6736(12)61428-7
   Saez-Llorens X, 2018, LANCET INFECT DIS, V18, P162, DOI 10.1016/S1473-3099(17)30632-1
   Saez-Llorens X, 2017, LANCET INFECT DIS, V17, P615, DOI 10.1016/S1473-3099(17)30166-4
   Schmidt AC, 2017, AM J TROP MED HYG, V96, P1325, DOI 10.4269/ajtmh.16-0634
   Simasathien S, 2008, AM J TROP MED HYG, V78, P426, DOI 10.4269/ajtmh.2008.78.426
   Simmons M, 2010, VIROLOGY, V396, P280, DOI 10.1016/j.virol.2009.10.023
   Sridhar S, 2018, NEW ENGL J MED, V379, P327, DOI 10.1056/NEJMoa1800820
   Sun W, 2003, AM J TROP MED HYG, V69, P24
   Sun W, 2009, HUM VACCINES, V5, P33, DOI 10.4161/hv.5.1.6348
   Swanstrom JA, 2018, J INFECT DIS, V217, P1932, DOI 10.1093/infdis/jiy063
   Thomas SJ, 2013, AM J TROP MED HYG, V88, P73, DOI 10.4269/ajtmh.2012.12-0361
   Torresi J, 2017, J INFECT DIS, V216, P834, DOI 10.1093/infdis/jix314
   Torresi J, 2015, VACCINE, V33, P5127, DOI 10.1016/j.vaccine.2015.08.008
   Tran NH, 2012, J VACCINES VACCIN, V3, P7, DOI [10.4172/2157-7560.1000162, DOI 10.4172/2157-7560.1000162]
   Troyer JM, 2001, AM J TROP MED HYG, V65, P414, DOI 10.4269/ajtmh.2001.65.414
   Vaughn DW, 1996, VACCINE, V14, P329, DOI 10.1016/0264-410X(95)00167-Y
   Vigne C, 2017, HUM VACC IMMUNOTHER, V13, P2004, DOI 10.1080/21645515.2017.1333211
   Villar L, 2015, NEW ENGL J MED, V372, P113, DOI 10.1056/NEJMoa1411037
   Villar LA, 2013, PEDIATR INFECT DIS J, V32, P1102, DOI 10.1097/INF.0b013e31829b8022
   Watanaveeradej V, 2014, AM J TROP MED HYG, V91, P119, DOI 10.4269/ajtmh.13-0452
   Watanaveeradej V, 2011, AM J TROP MED HYG, V85, P341, DOI 10.4269/ajtmh.2011.10-0501
   Weiskopf D, 2015, J VIROL, V89, P120, DOI 10.1128/JVI.02129-14
   Whitehead SS, 2003, VACCINE, V21, P4307, DOI 10.1016/S0264-410X(03)00488-2
   Whitehead SS, 2003, J VIROL, V77, P1653, DOI 10.1128/JVI.77.2.1653-1657.2003
   Whitehead SS, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005584
   Wilder-Smith A, 2019, LANCET INFECT DIS, V19, pE31, DOI 10.1016/S1473-3099(18)30494-8
   ZHAO B, 1986, VIROLOGY, V155, P77, DOI 10.1016/0042-6822(86)90169-8
NR 146
TC 1
Z9 1
U1 0
U2 0
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PD JUN 18
PY 2020
VL 11
AR 1252
DI 10.3389/fimmu.2020.01252
PG 18
WC Immunology
SC Immunology
GA MH7YV
UT WOS:000546940500001
PM 32655561
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Andreata-Santos, R
   Alves, RPD
   Pereira, SA
   Pereira, LR
   de Freitas, CL
   Pereira, SS
   Venceslau-Carvalho, AA
   Castro-Amarante, MF
   Favaro, MTP
   Mathias-Santos, C
   Amorim, JH
   Ferreira, LCD
AF Andreata-Santos, Robert
   dos Santos Alves, Rubens Prince
   Pereira, Sara Araujo
   Pereira, Lennon Ramos
   de Freitas, Carla Longo
   Pereira, Samuel Santos
   Venceslau-Carvalho, Alexia Adrianne
   Castro-Amarante, Maria Fernanda
   Pinho Favaro, Marianna Teixeira
   Mathias-Santos, Camila
   Amorim, Jaime Henrique
   de Souza Ferreira, Luis Carlos
TI Transcutaneous Administration of Dengue Vaccines
SO VIRUSES-BASEL
LA English
DT Article
DE transcutaneous immunization; dengue vaccines; heat-labile toxin;
   adjuvant; intradermic immunization
ID HEAT-LABILE TOXIN; HUMAN MONOCLONAL-ANTIBODIES; T-CELLS; MICRONEEDLE
   ARRAYS; PROTECTIVE ROLE; DENDRITIC CELL; VIRUS; IMMUNIZATION; DELIVERY;
   RESPONSES
AB In the present study, we evaluated the immunological responses induced by dengue vaccines under experimental conditions after delivery via a transcutaneous (TC) route. Vaccines against type 2 Dengue virus particles (DENV2 New Guinea C (NGC) strain) combined with enterotoxigenic Escherichia coli (ETEC) heat-labile toxin (LT) were administered to BALB/c mice in a three-dose immunization regimen via the TC route. As a control for the parenteral administration route, other mouse groups were immunized with the same vaccine formulation via the intradermic (ID) route. Our results showed that mice vaccinated either via the TC or ID routes developed similar protective immunity, as measured after lethal challenges with the DENV2 NGC strain. Notably, the vaccine delivered through the TC route induced lower serum antibody (IgG) responses with regard to ID-immunized mice, particularly after the third dose. The protective immunity elicited in TC-immunized mice was attributed to different antigen-specific antibody properties, such as epitope specificity and IgG subclass responses, and cellular immune responses, as determined by cytokine secretion profiles. Altogether, the results of the present study demonstrate the immunogenicity and protective properties of a dengue vaccine delivered through the TC route and offer perspectives for future clinical applications.
C1 [Andreata-Santos, Robert; dos Santos Alves, Rubens Prince; Pereira, Sara Araujo; Pereira, Lennon Ramos; de Freitas, Carla Longo; Pereira, Samuel Santos; Venceslau-Carvalho, Alexia Adrianne; Castro-Amarante, Maria Fernanda; Pinho Favaro, Marianna Teixeira; Mathias-Santos, Camila; de Souza Ferreira, Luis Carlos] Univ Sao Paulo, Inst Biomed Sci, Microbiol Dept, Vaccine Dev Lab, BR-05508000 Sao Paulo, Brazil.
   [Amorim, Jaime Henrique] Fed Univ Western Bahia, Ctr Biol & Hlth Sci, BR-47810047 Barreiras, BA, Brazil.
RP Ferreira, LCD (corresponding author), Univ Sao Paulo, Inst Biomed Sci, Microbiol Dept, Vaccine Dev Lab, BR-05508000 Sao Paulo, Brazil.
EM robert_andreata@hotmail.com; rubens.bmc@gmail.com;
   araujopereirasara@gmail.com; lennon_rp@hotmail.com;
   carla.longofreitas@gmail.com; samuelbiomedicina@usp.br;
   alexia_myt@hotmail.com; mfamarante@gmail.com; favaro.mtp@gmail.com;
   camilamathias@gmail.com; jaime.henrique.amorim@gmail.com; lcsf@usp.br
RI ; Ferreira, Luis/M-3954-2014
OI Andreata-Santos, Robert/0000-0002-4506-3756; Castro Amarante, Maria
   Fernanda/0000-0003-2162-9505; Ferreira, Luis/0000-0002-4883-1693
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo
   (FAPESP)/GlaxoSmithKline (GSK) [12/50362-3]; FAPESPFundacao de Amparo a
   Pesquisa do Estado de Sao Paulo (FAPESP) [2016/23560-0, 2014/17595-0,
   2015/02352-7, 2016/05570-8, 2016/20045-7]; Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico (CNPq)National Council for
   Scientific and Technological Development (CNPq) [440409/16-0
   88881.130787/2016-01 (88887.137920/2017-00)]; Coordenacao de
   Aperfeicoamento de Pessoal de Nivel Superior (CAPES)CAPES
   [8888130782/2016-00, 33002010026P9 (88887.473724/2020-00)]
FX This research was funded by Fundacao de Amparo a Pesquisa do Estado de
   Sao Paulo (FAPESP)/GlaxoSmithKline (GSK), grant number 12/50362-3;
   FAPESP, grant numbers 2016/23560-0 (R.A.-S.), 2014/17595-0, 2015/02352-7
   (R.P.S.A.), 2016/05570-8 (L.R.P.), 2016/20045-7; Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico (CNPq), grant numbers
   440409/16-0 88881.130787/2016-01 (88887.137920/2017-00) (R.A.-S.),
   Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES),
   grant number 8888130782/2016-00 (S.S.P.), 33002010026P9
   (88887.473724/2020-00) (A.A.V.-C).
CR Amorim JH, 2016, VIROLOGY, V487, P41, DOI 10.1016/j.virol.2015.10.006
   Amorim JH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044984
   Andreata-Santos R., 2020, NO OTHER ADVERSE REA
   Andreata-Santos R., 2020, FLOW CYTOMETRY ASSAY
   Bal SM, 2010, J CONTROL RELEASE, V148, P266, DOI 10.1016/j.jconrel.2010.09.018
   Basu A, 2008, FEMS IMMUNOL MED MIC, V53, P287, DOI 10.1111/j.1574-695X.2008.00420.x
   Belyakov IM, 2011, CURR MED CHEM, V18, P3953, DOI 10.2174/092986711796957293
   Bhatt S, 2013, NATURE, V496, P504, DOI 10.1038/nature12060
   Boaz MJ, 2002, J IMMUNOL, V169, P6376, DOI 10.4049/jimmunol.169.11.6376
   Cheng JY, 2009, J CONTROL RELEASE, V135, P242, DOI 10.1016/j.jconrel.2009.01.014
   Clark RA, 2010, J INVEST DERMATOL, V130, P362, DOI 10.1038/jid.2009.247
   Combadiere B, 2011, HUM VACCINES, V7, P811, DOI 10.4161/hv.7.8.16274
   Combadiere B, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010818
   Constenla D, 2015, PHARMACOECONOMICS, V33, P1107, DOI 10.1007/s40273-015-0294-7
   Costa SM, 2006, VACCINE, V24, P195, DOI 10.1016/j.vaccine.2005.07.059
   Costin JM, 2013, J VIROL, V87, P52, DOI 10.1128/JVI.02273-12
   Ding Z, 2009, J CONTROL RELEASE, V136, P71, DOI 10.1016/j.jconrel.2009.01.025
   Alves RPD, 2016, CLIN VACCINE IMMUNOL, V23, P460, DOI 10.1128/CVI.00081-16
   El-Ghorr AA, 2000, FEMS IMMUNOL MED MIC, V29, P255, DOI 10.1016/S0928-8244(00)00214-5
   Frolov VG, 2008, INFLUENZA OTHER RESP, V2, P53, DOI 10.1111/j.1750-2659.2008.00040.x
   Giudice EL, 2006, ADV DRUG DELIVER REV, V58, P68, DOI 10.1016/j.addr.2005.12.003
   Glenn GM, 1998, J IMMUNOL, V161, P3211
   Glenn GM, 2000, NAT MED, V6, P1403, DOI 10.1038/82225
   Guo L, 2013, BIOMED MICRODEVICES, V15, P1077, DOI 10.1007/s10544-013-9799-z
   Hatch S, 2011, J INFECT DIS, V203, P1282, DOI 10.1093/infdis/jir012
   Henriques HR, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002330
   Hirschberg H, 2012, EUR J PHARM SCI, V46, P1, DOI 10.1016/j.ejps.2012.01.013
   Johnson AJ, 1999, J VIROL, V73, P783, DOI 10.1128/JVI.73.1.783-786.1999
   Lasaro MA, 2008, J BACTERIOL, V190, P2400, DOI 10.1128/JB.00988-07
   Lasaro MA, 2009, FEMS IMMUNOL MED MIC, V55, P93, DOI 10.1111/j.1574-695X.2008.00506.x
   Lee MY, 2013, BMB REP, V46, P17, DOI 10.5483/BMBRep.2013.46.1.001
   Libraty DH, 2002, J INFECT DIS, V185, P1213, DOI 10.1086/340365
   Lindow JC, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001742
   Liu T, 2001, J VIROL, V75, P11178, DOI 10.1128/JVI.75.22.11178-11184.2001
   Martins MA, 2008, VACCINE, V26, P1173, DOI 10.1016/j.vaccine.2007.12.035
   Matsuo K, 2012, J CONTROL RELEASE, V161, P10, DOI 10.1016/j.jconrel.2012.01.033
   Mawas F, 2004, J INFECT DIS, V190, P1177, DOI 10.1086/423327
   Muller DA, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7040189
   Ngono AE, 2016, EBIOMEDICINE, V13, P284, DOI 10.1016/j.ebiom.2016.10.006
   Perez AB, 2004, J MED VIROL, V73, P230, DOI 10.1002/jmv.20080
   Putnak R, 1996, AM J TROP MED HYG, V55, P504
   Rancan F, 2014, J CONTROL RELEASE, V176, P115, DOI 10.1016/j.jconrel.2013.12.022
   Rodrigues JF, 2011, J BIOL CHEM, V286, P5222, DOI 10.1074/jbc.M110.173682
   Schaeffer E, 2015, J INVEST DERMATOL, V135, P1743, DOI 10.1038/jid.2014.525
   Scharton-Kersten T, 2000, INFECT IMMUN, V68, P5306, DOI 10.1128/IAI.68.9.5306-5313.2000
   Schexneider Katherine I, 2005, Curr Hematol Rep, V4, P145
   Shen BQ, 2001, J BIOL CHEM, V276, P5281, DOI 10.1074/jbc.M007969200
   Silva ML, 2011, VACCINE, V29, P583, DOI 10.1016/j.vaccine.2010.08.046
   Lasaro MAS, 2006, FEMS IMMUNOL MED MIC, V48, P123, DOI 10.1111/j.1574-695X.2006.00134.x
   Slifka MK, 2014, J ALLERGY CLIN IMMUN, V133, P439, DOI 10.1016/j.jaci.2013.10.037
   Stahl HC, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-1048
   Trandem K, 2011, J IMMUNOL, V186, P3642, DOI 10.4049/jimmunol.1003292
   Tsai WY, 2013, J VIROL, V87, P12562, DOI 10.1128/JVI.00871-13
   Turvey ME, 2019, BIOENG TRANSL MED, V4, DOI 10.1002/btm2.10127
   Vogt A, 2008, J IMMUNOL, V180, P1482, DOI 10.4049/jimmunol.180.3.1482
   Vrdoljak A, 2012, J CONTROL RELEASE, V159, P34, DOI 10.1016/j.jconrel.2011.12.026
   World Health Organization (WHO), DENG SEV DENG
   Yauch LE, 2010, J IMMUNOL, V185, P5405, DOI 10.4049/jimmunol.1001709
   Yauch LE, 2009, J IMMUNOL, V182, P4865, DOI 10.4049/jimmunol.0801974
   Zellweger RM, 2015, J VIROL, V89, P6494, DOI 10.1128/JVI.00036-15
   Zhang JF, 2006, INFECT IMMUN, V74, P3607, DOI 10.1128/IAI.01836-05
NR 61
TC 0
Z9 0
U1 0
U2 1
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1999-4915
J9 VIRUSES-BASEL
JI Viruses-Basel
PD MAY
PY 2020
VL 12
IS 5
AR 514
DI 10.3390/v12050514
PG 16
WC Virology
SC Virology
GA NJ2FF
UT WOS:000565860200031
PM 32384822
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Arcanjo, DBMC
   Vidal, PO
   dos Santos, JYG
   Venancio, LPR
   Suesdek, L
   Amorim, JH
AF Marques Campos Arcanjo, Danielle Beatriz
   Vidal, Paloma Oliveira
   Gomes dos Santos, Jose Yure
   Rodrigues Venancio, Larissa Paola
   Suesdek, Lincoln
   Amorim, Jaime Henrique
TI Geometric morphometrics of Aedes aegypti populations and study of
   transmission of arboviral diseases in Barreiras, Brazil
SO REVISTA BRASILEIRA DE ENTOMOLOGIA
LA English
DT Article
DE A.aegypti; geometric morphometrics; transmission; barriers; segregation
ID RAINFALL; DYNAMICS; STATE
AB Aedes (Stegontyia) aegypti (A. aegypti) transmits arboviral diseases of high public health importance, including those caused by Zika virus(ZIKV), Dengue virus(DENV), Chikungunya virus (CHIKV) and Yellow fever virus(YFV). Barreiras is a city with 157,638 inhabitants in the West of the State of Bahia, Northeast of Brazil. The climate is dry, with well-determined and concentrated seasons of rains. The city is crossed by a Federal Highway and by the Rio Grande river. In this study, we aimed to understand the dynamics of mosquito vectors and arboviral diseases in Barreiras. We used correlation statistics to investigate a possible relationship among rains, mosquito abundance and transmission of diseases. In addition, as a preliminary population genetics estimate, we used geometric morphometrics to compare mosquitoes from areas limited by a highway and a river. We found that i) infestation occurs in rain-dependent cycles and that ii) both, the river and the highway segregate populations of A. aegypti in different areas of the studied city. Our results indicate that it is necessary to treat anthropic containers with mosquito breading capacity during both, the dry and rain seasons in urban areas similar to Barreiras.
C1 [Marques Campos Arcanjo, Danielle Beatriz; Vidal, Paloma Oliveira; Rodrigues Venancio, Larissa Paola; Amorim, Jaime Henrique] Univ Fed Oeste Bahia, Ctr Ciencias Biol & Saude, Lab Agentes Infecciosos & Verores, Barreiros, BA, Brazil.
   [Gomes dos Santos, Jose Yure] Univ Fed Oeste Bahia, Ctr Humanidades, Lab Geoproc, Barreiros, BA, Brazil.
   [Suesdek, Lincoln] Inst Butantan, Lab Parasitol, Sao Paulo, SP, Brazil.
   [Suesdek, Lincoln] Univ Sao Paulo, Inst Med Trop, Sao Paulo, SP, Brazil.
RP Amorim, JH (corresponding author), Univ Fed Oeste Bahia, Ctr Ciencias Biol & Saude, Lab Agentes Infecciosos & Verores, Barreiros, BA, Brazil.
EM jaime.amorim@ufob.edu.br
RI Santos, Jose Yure Gomes dos/AAK-8651-2020
OI Santos, Jose Yure Gomes dos/0000-0001-9840-8132
FU International Society for Infectious Diseases; Fundacao de Amparo a
   Pesquisa do Estado da Bahia (FAPESB) [PET 0024/2016]; Conselho Nacional
   de Desenvolvimento Cientifico e Tecnologico (CNPq)National Council for
   Scientific and Technological Development (CNPq) [311805/2014-0]; FAPESB;
   Center of Control of Zoonotic and Endemic Diseases of Barreiras, Bahia,
   Brazil
FX We appreciate the financial support of the International Society for
   Infectious Diseases, Fundacao de Amparo a Pesquisa do Estado da Bahia
   (FAPESB) (PET 0024/2016) and Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico (CNPq), Grant #311805/2014-0. We are thankful
   to FAPESB by providing undergraduate research fellowship for Danielle
   Beatriz Marques Campos Arcanjo. We are also thankful to the support of
   Center of Control of Zoonotic and Endemic Diseases of Barreiras, Bahia,
   Brazil. We are thankful to Karina Zanatta and Fernanda Almeida Lopes for
   technical assistance.
CR Calvet G, 2016, LANCET INFECT DIS, V16, P653, DOI 10.1016/S1473-3099(16)00095-5
   CENTERS FOR DISEASE CONTROL AND PREVEN- TION, 2016, ZIK VIR
   Centers for Disease Control and Prevention, 2017, ZIK VIR TRANSM
   Demirci B, 2012, J VECTOR ECOL, V37, P197, DOI 10.1111/j.1948-7134.2012.00217.x
   Dibo MR, 2008, MEM I OSWALDO CRUZ, V103, P554, DOI 10.1590/S0074-02762008000600008
   Lagrotta MT, 2008, CAD SAUDE PUBLICA, V24, P70, DOI 10.1590/S0102-311X2008000100007
   Gomez MM, 2018, J GEN VIROL, V99, P536, DOI 10.1099/jgv.0.001033
   Guagliardo SA, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0003033
   Hemme RR, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000634
   Lorenz C, 2017, INFECT GENET EVOL, V54, P205, DOI 10.1016/j.meegid.2017.06.029
   Lorenz C, 2014, PARASITE VECTOR, V7, DOI 10.1186/s13071-014-0581-8
   Louise C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137851
   Lozano-Fuentes S, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000468
   Moreira-Soto A, 2018, CLIN MICROBIOL INFEC, V24, DOI 10.1016/j.cmi.2018.01.026
   Pongsumpun P, 2008, TROP MED INT HEALTH, V13, P1180, DOI 10.1111/j.1365-3156.2008.02124.x
   Silva FD, 2016, CIENC SAUDE COLETIVA, V21, P641, DOI 10.1590/1413-81232015212.09592015
   SOPER FL, 1967, B WORLD HEALTH ORGAN, V36, P536
   Vicente JL, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-5
   Vidal PO, 2012, MEM I OSWALDO CRUZ, V107, P1030, DOI 10.1590/S0074-02762012000800011
   Wee LK, 2013, SE ASIAN J TROP MED, V44, P157
   Wikan N, 2016, LANCET INFECT DIS, V16, pE119, DOI 10.1016/S1473-3099(16)30010-X
NR 21
TC 0
Z9 0
U1 0
U2 0
PU SOC BRASILEIRA ENTOMOLOGIA
PI CURITIBA
PA CAIXA POSTAL 19030, CURITIBA, PR 81531-980, BRAZIL
SN 0085-5626
EI 1806-9665
J9 REV BRAS ENTOMOL
JI Rev. Bras. Entomol.
PY 2020
VL 64
IS 1
AR e201960
DI 10.1590/1806-9665-RBENT-2019-60
PG 7
WC Entomology
SC Entomology
GA KT1MZ
UT WOS:000518777000001
OA DOAJ Gold
DA 2020-12-01
ER

PT J
AU Franco, LD
   Gushi, LT
   Luiz, WB
   Amorim, JH
AF Franco, Lorrany dos Santos
   Gushi, Leticia Tsieme
   Luiz, Wilson Barros
   Amorim, Jaime Henrique
TI Seeking Flavivirus Cross-Protective Immunity
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Article
DE epitopes; flavivirus; serocomplex; cross-protection; immune response
ID JAPANESE ENCEPHALITIS-VIRUS; T-CELL RESPONSES; WEST-NILE-VIRUS;
   ANTIBODY-DEPENDENT ENHANCEMENT; TETRAVALENT DENGUE VACCINE; ENVELOPE
   PROTEIN; MONOCLONAL-ANTIBODIES; DOMAIN-III; YELLOW-FEVER; INFECTION
AB The Flavivirus genus is composed by viral serocomplexes with relevant global epidemiological impact. Many areas of the world present both, vector fauna and geographical conditions compatible with co-circulation, importing, emergence, and epidemics of flaviviruses of different serocomplexes. In this study, we aimed to identify both, immunological determinants and patterns of immune response possibly involved in flavivirus serocomplex cross-protection. We searched B and T cells epitopes which were thoroughly shown to be involved in flavivirus immunological control. Such epitopes were analyzed regarding their conservation, population coverage, and location along flavivirus polyprotein. We found that epitopes capable of eliciting flavivirus cross-protective immunity to a wide range of human populations are concentrated in proteins E, NS3, and NS5. Such identification of both, immunological determinants and patterns of immune response involved in flavivirus cross-protective immunity should be considered in future vaccine development. Moreover, cross-reactive epitopes presented in this work may be involved in dynamics of diseases caused by flaviviruses worldwide.
C1 [Franco, Lorrany dos Santos; Gushi, Leticia Tsieme; Amorim, Jaime Henrique] Univ Fed Oeste Bahia, Ctr Ciencias Biol & Saude, Lab Agentes Infecciosos & Vetores, Programa Posgrad Patol Invest, Barreiras, BA, Brazil.
   [Luiz, Wilson Barros; Amorim, Jaime Henrique] Univ Estadual Santa Cruz, Programa Posgrad Biol & Biotecnol Microrganismos, Ilheus, BA, Brazil.
RP Amorim, JH (corresponding author), Univ Fed Oeste Bahia, Ctr Ciencias Biol & Saude, Lab Agentes Infecciosos & Vetores, Programa Posgrad Patol Invest, Barreiras, BA, Brazil.; Amorim, JH (corresponding author), Univ Estadual Santa Cruz, Programa Posgrad Biol & Biotecnol Microrganismos, Ilheus, BA, Brazil.
EM jaime.amorim@ufob.edu.br
RI Luiz, Wilson/L-7575-2015; Amorim, Jaime Henrique/O-9222-2017
OI Luiz, Wilson/0000-0003-3265-8547; Amorim, Jaime
   Henrique/0000-0002-0623-2879
FU FAPESB; CNPqNational Council for Scientific and Technological
   Development (CNPq)
FX We are grateful to FAPESB for providing undergraduation fellowship to
   LS. We are also grateful to CNPq for providing postdoc fellowship to LG.
CR Amarilla AA, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0199071
   Amorim JH, 2016, VIROLOGY, V487, P41, DOI 10.1016/j.virol.2015.10.006
   de Brito CAA, 2016, REV SOC BRAS MED TRO, V49, P537, DOI 10.1590/0037-8682-0328-2016
   Apte-Sengupta S, 2014, CURR OPIN VIROL, V9, P134, DOI 10.1016/j.coviro.2014.09.020
   Terzian ACB, 2017, CLIN INFECT DIS, V65, P1260, DOI 10.1093/cid/cix558
   Bhatt S, 2013, NATURE, V496, P504, DOI 10.1038/nature12060
   Brazil. Ministerio da Saude. Secretaria de Vigilancia em Saude. Departamento de Vigilancia Epidemiologica, 2009, DIRETRIZES NACIONAIS
   Bui HH, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-361
   Bui HH, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-153
   CALISHER CH, 1989, J GEN VIROL, V70, P37, DOI 10.1099/0022-1317-70-1-37
   Campbell GL, 2011, B WORLD HEALTH ORGAN, V89, P766, DOI 10.2471/BLT.10.085233
   Castanha PMS, 2017, J INFECT DIS, V215, P781, DOI 10.1093/infdis/jiw638
   Chancey C, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/376230
   Chowdhury P, 2016, INT J INFECT DIS, V45, P434, DOI 10.1016/j.ijid.2016.02.922
   Cockburn JJB, 2012, STRUCTURE, V20, P303, DOI 10.1016/j.str.2012.01.001
   Crill WD, 2001, J VIROL, V75, P7769, DOI 10.1128/JVI.75.16.7769-7773.2001
   Dai LP, 2016, IUBMB LIFE, V68, P783, DOI 10.1002/iub.1556
   de Melo AB, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0001938
   de Rezende IM, 2018, PLOS NEGLECT TROP D, V12, DOI 10.1371/journal.pntd.0006538
   Dejnirattisai W, 2016, NAT IMMUNOL, V17, P1102, DOI 10.1038/ni.3515
   Duan ZL, 2015, VIRUS RES, V196, P5, DOI 10.1016/j.virusres.2014.10.022
   Fibriansah G, 2016, ANTIVIR RES, V128, P7, DOI 10.1016/j.antiviral.2016.01.002
   Franco LD, 2017, J BIOMED SCI, V24, DOI 10.1186/s12929-017-0395-z
   Gubler DJ, 2014, REFERENCE MODULE BIO, DOI [10.1016/b978-0-12-801238-3.02556-3, DOI 10.1016/B978-0-12-801238-3.02556-3]
   Gubler Duane J, 2011, Trop Med Health, V39, P3, DOI 10.2149/tmh.2011-S05
   Hadinegoro SR, 2015, NEW ENGL J MED, V373, P1195, DOI 10.1056/NEJMoa1506223
   Jentes ES, 2011, LANCET INFECT DIS, V11, P622, DOI 10.1016/S1473-3099(11)70147-5
   Konishi E, 2010, VACCINE, V28, P2664, DOI 10.1016/j.vaccine.2010.01.008
   Li JQ, 2016, SCI REP-UK, V6, DOI 10.1038/srep19953
   Li SH, 2011, IMMUNOL LETT, V138, P156, DOI 10.1016/j.imlet.2011.04.003
   Lin HE, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001447
   Mansfield KL, 2011, J GEN VIROL, V92, P2821, DOI 10.1099/vir.0.031641-0
   Melo MN, 2009, J MOL BIOL, V392, P736, DOI 10.1016/j.jmb.2009.07.035
   Ministerio da Saude, 2017, FEBR AM GUIA PROF SA
   Modis Y, 2004, NATURE, V427, P313, DOI 10.1038/nature02165
   Ngono AE, 2016, EBIOMEDICINE, V13, P284, DOI 10.1016/j.ebiom.2016.10.006
   Nybakken GE, 2005, NATURE, V437, P764, DOI 10.1038/nature03956
   Paul LM, 2016, CLIN TRANSL IMMUNOL, V5, DOI 10.1038/cti.2016.72
   Priyamvada L, 2016, P NATL ACAD SCI USA, V113, P7852, DOI 10.1073/pnas.1607931113
   Raboni SM, 2017, TRANSPL INFECT DIS, V19, DOI 10.1111/tid.12700
   Regla-Nava JA, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05458-0
   Rey FA, 2018, EMBO REP, V19, P206, DOI 10.15252/embr.201745302
   Reynolds CJ, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-017-18781-1
   Rivino L, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa0526
   Rivino L, 2013, J IMMUNOL, V191, P4010, DOI 10.4049/jimmunol.1301507
   Rivino L, 2013, J VIROL, V87, P2693, DOI 10.1128/JVI.02675-12
   Rothman AL, 2011, NAT REV IMMUNOL, V11, P532, DOI 10.1038/nri3014
   Sabchareon A, 2012, LANCET, V380, P1559, DOI 10.1016/S0140-6736(12)61428-7
   Saron WAA, 2018, SCI ADV, V4, DOI 10.1126/sciadv.aar4297
   Shi X, 2016, MABS-AUSTIN, V8, P574, DOI 10.1080/19420862.2016.1148850
   Sironi M, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004978
   Smith DP, 2013, MBIO, V4, DOI 10.1128/mBio.00133-12
   Sukupolvi-Petty S, 2007, J VIROL, V81, P12816, DOI 10.1128/JVI.00432-07
   Tsai WY, 2013, J VIROL, V87, P12562, DOI 10.1128/JVI.00871-13
   Turtle L, 2016, J EXP MED, V213, P1331, DOI 10.1084/jem.20151517
   Veronesi F, 2015, TRATADO INFECTOLOGIA
   Villar L, 2015, NEW ENGL J MED, V372, P113, DOI 10.1056/NEJMoa1411037
   Weiskopf D, 2015, P NATL ACAD SCI USA, V112, pE4256, DOI 10.1073/pnas.1505956112
   Weiskopf D, 2015, J VIROL, V89, P120, DOI 10.1128/JVI.02129-14
   Weiskopf D, 2013, P NATL ACAD SCI USA, V110, pE2046, DOI 10.1073/pnas.1305227110
   Weiskopf D, 2011, J IMMUNOL, V187, P4268, DOI 10.4049/jimmunol.1101970
   Wen JS, 2017, NAT MICROBIOL, V2, DOI 10.1038/nmicrobiol.2017.36
   Whitehead SS, 2007, NAT REV MICROBIOL, V5, P518, DOI 10.1038/nrmicro1690
   Wikan N, 2016, LANCET INFECT DIS, V16, pE119, DOI 10.1016/S1473-3099(16)30010-X
NR 64
TC 5
Z9 5
U1 0
U2 2
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PD SEP 20
PY 2019
VL 10
AR 2260
DI 10.3389/fimmu.2019.02260
PG 12
WC Immunology
SC Immunology
GA IZ6KF
UT WOS:000487189600001
PM 31616432
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Rocha, LB
   Alves, RPD
   Caetano, BA
   Pereira, LR
   Mitsunari, T
   Amorim, JH
   Polatto, JM
   Botosso, VF
   Gallina, NMF
   Palacios, R
   Precioso, AR
   Granato, CFH
   Oliveira, DBL
   da Silveira, VB
   Luz, D
   Ferreira, LCD
   Piazza, RMF
AF Rocha, Leticia Barboza
   dos Santos Alves, Rubens Prince
   Caetano, Bruna Alves
   Pereira, Lennon Ramos
   Mitsunari, Thais
   Amorim, Jaime Henrique
   Polatto, Juliana Moutinho
   Botosso, Viviane Fongaro
   Frazatti Gallina, Neuza Maria
   Palacios, Ricardo
   Precioso, Alexander Roberto
   Hernandes Granato, Celso Francisco
   Leal Oliveira, Danielle Bruna
   da Silveira, Vanessa Barbosa
   Luz, Daniela
   de Souza Ferreira, Luis Carlos
   Fontes Piazza, Roxane Maria
TI Epitope Sequences in Dengue Virus NS1 Protein Identified by Monoclonal
   Antibodies
SO ANTIBODIES
LA English
DT Article
DE dengue virus; NS1; Zika virus; mAbs; antibody recognition; amino acid
   sequences
ID GLYCOPROTEIN; REPLICATION; REGION
AB Dengue nonstructural protein 1 (NS1) is a multi-functional glycoprotein with essential functions both in viral replication and modulation of host innate immune responses. NS1 has been established as a good surrogate marker for infection. In the present study, we generated four anti-NS1 monoclonal antibodies against recombinant NS1 protein from dengue virus serotype 2 (DENV2), which were used to map three NS1 epitopes. The sequence (193)AVHADMGYWIESALNDT(209) was recognized by monoclonal antibodies 2H5 and 4H1BC, which also cross-reacted with Zika virus (ZIKV) protein. On the other hand, the sequence (25)VHTWTEQYKFQPES(38) was recognized by mAb 4F6 that did not cross react with ZIKV. Lastly, a previously unidentified DENV2 NS1-specific epitope, represented by the sequence (127)ELHNQTFLIDGPETAEC(143), is described in the present study after reaction with mAb 4H2, which also did not cross react with ZIKV. The selection and characterization of the epitope, specificity of anti-NS1 mAbs, may contribute to the development of diagnostic tools able to differentiate DENV and ZIKV infections.
C1 [Rocha, Leticia Barboza; Caetano, Bruna Alves; Mitsunari, Thais; Polatto, Juliana Moutinho; Luz, Daniela; Fontes Piazza, Roxane Maria] Inst Butantan, Lab Bacteriol, BR-05503900 Sao Paulo, SP, Brazil.
   [dos Santos Alves, Rubens Prince; Pereira, Lennon Ramos; Amorim, Jaime Henrique; de Souza Ferreira, Luis Carlos] Univ Sao Paulo, Lab Dev Vacinas, Inst Ciencias Biomed, BR-05508000 Sao Paulo, SP, Brazil.
   [Botosso, Viviane Fongaro] Inst Butantan, Lab Virol, BR-05503900 Sao Paulo, SP, Brazil.
   [Frazatti Gallina, Neuza Maria] Div Dev Tecnol & Prod, BR-05503 Sao Paulo, SP, Brazil.
   [Frazatti Gallina, Neuza Maria] Inst Butantan, BR-05503 Sao Paulo, SP, Brazil.
   [Palacios, Ricardo; Precioso, Alexander Roberto] Inst Butantan, Div Ensaios Clin & Farmacovigilancia, BR-05503900 Sao Paulo, SP, Brazil.
   [Hernandes Granato, Celso Francisco] Univ Fed Sao Paulo, Dept Medicina, Disciplina Doencas Infecciosas & Parasitarias, BR-04023062 Sao Paulo, SP, Brazil.
   [Leal Oliveira, Danielle Bruna; da Silveira, Vanessa Barbosa] Univ Sao Paulo, Inst Ciencias Biomed, Dept Microbiol, Lab Virol Mol & Clin, BR-05508000 Sao Paulo, SP, Brazil.
   [Amorim, Jaime Henrique] Univ Fed Oeste Bahia, Ctr Ciencias Biol & Saude, Lab Microbiol, BR-47805100 Barreiras, Bahia, Brazil.
RP Piazza, RMF (corresponding author), Inst Butantan, Lab Bacteriol, BR-05503900 Sao Paulo, SP, Brazil.
EM leticia.rocha@butantan.gov.br; rubens.bmc@gmail.com;
   bruna.caetano@butantan.gov.br; lennon_rp@usp.br;
   thais.mitsunari@butantan.gov.br; jh.biomedico@gmail.com;
   juliana.yassuda@butantan.gov.br; viviane.botosso@butantan.gov.br;
   neuza.gallina@butantan.gov.br; ricardo.palacios@butantan.gov.br;
   alexander.precioso@butantan.gov.br; celso.granato@grupofleury.com.br;
   danibruna@gmail.com; vanessa.silveirabio@gmail.com;
   daniedaluz@yahoo.com.br; lcsf@usp.br; roxane@butantan.gov.br
RI Piazza, Roxane MF/A-9915-2018; Botosso, Viviane/I-5591-2014; Piazza,
   Roxane/ABD-9196-2020; Oliveira, Danielle BL/H-8030-2015; Precioso,
   Alexander Roberto/A-9712-2013; Palacios, Ricardo/AAN-7606-2020;
   Silveira, Vanessa/AAJ-9535-2020; Palacios, Ricardo/B-7248-2018; Amorim,
   Jaime Henrique/O-9222-2017
OI Piazza, Roxane MF/0000-0003-0068-8506; Botosso,
   Viviane/0000-0002-7876-3687; Piazza, Roxane/0000-0003-0068-8506;
   Oliveira, Danielle BL/0000-0002-3452-1336; Precioso, Alexander
   Roberto/0000-0001-8657-9292; Palacios, Ricardo/0000-0002-1410-8579;
   Palacios, Ricardo/0000-0002-1410-8579; Alves Caetano,
   Bruna/0000-0002-0484-2243; Amorim, Jaime Henrique/0000-0002-0623-2879;
   Barbosa da Silveira, Vanessa/0000-0002-9699-0875
FU Sao Paulo Research Foundation (FAPESP)Fundacao de Amparo a Pesquisa do
   Estado de Sao Paulo (FAPESP) [2009/53894-3, 2011/51761-6, 2014/17595-0,
   2013/06589-6, 2013/50955-7]; Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico (CNPq)National Council for Scientific and
   Technological Development (CNPq); FAPESP fellowshipFundacao de Amparo a
   Pesquisa do Estado de Sao Paulo (FAPESP) [2012/09096-8]
FX We would like to thank Pedro Vasconcelos, from Evandro Chagas Institute,
   Belem, PA, Brazil for providing a lyophilized ZIKVBR seed. This work was
   supported by grants from Sao Paulo Research Foundation (FAPESP):
   2009/53894-3; 2011/51761-6; 2014/17595-0 to L.C.S.F. 2013/06589-6;
   2013/50955-7 to R.M.F.P and from Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico (CNPq) awarded to R.M.F.P. LBR was a recipient
   of post-doctoral FAPESP fellowship (2012/09096-8).
CR Akey DL, 2014, SCIENCE, V343, P881, DOI 10.1126/science.1247749
   Amorim JH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044984
   Amorim JH, 2010, J VIROL METHODS, V167, P186, DOI 10.1016/j.jviromet.2010.04.003
   Bhatt S, 2013, NATURE, V496, P504, DOI 10.1038/nature12060
   Blaney JE, 2002, VIROLOGY, V300, P125, DOI 10.1006/viro.2002.1528
   Blaney JE, 2008, VACCINE, V26, P817, DOI 10.1016/j.vaccine.2007.11.082
   CHAMBERS TJ, 1990, ANNU REV MICROBIOL, V44, P649, DOI 10.1146/annurev.mi.44.100190.003245
   Chaudhury S, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005395
   Daep CA, 2014, J NEUROVIROL, V20, P539, DOI 10.1007/s13365-014-0285-z
   FALCONAR AKI, 1994, ARCH VIROL, V137, P315, DOI 10.1007/BF01309478
   FRIGUET B, 1985, J IMMUNOL METHODS, V77, P305, DOI 10.1016/0022-1759(85)90044-4
   Gelanew T, 2015, J VIROL METHODS, V222, P214, DOI 10.1016/j.jviromet.2015.06.003
   Guzman MG, 2010, NAT REV MICROBIOL, pS7, DOI 10.1038/nrmicro2460
   Gyawali N, 2016, INFECT DIS POVERTY, V5, DOI 10.1186/s40249-016-0132-y
   Jiang L, 2010, VIRUS RES, V150, P49, DOI 10.1016/j.virusres.2010.02.012
   Jiao Y., 2014, PLOS ONE, V2, DOI 10.1371/journal.pone.008819124516609
   Jones ML, 2017, MOLECULES, V22, DOI 10.3390/molecules22040607
   Kelley LA, 2015, NAT PROTOC, V10, P845, DOI 10.1038/nprot.2015.053
   Kochakarn T, 2016, ASIAN PAC J TROP MED, V9, P1026, DOI 10.1016/j.apjtm.2016.10.002
   Kohler G, 1975, BIOTECHNOLOGY, V24, P524
   Lebani K, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0180669
   Mackenzie JM, 1996, VIROLOGY, V220, P232, DOI 10.1006/viro.1996.0307
   Muller DA, 2013, ANTIVIR RES, V98, P192, DOI 10.1016/j.antiviral.2013.03.008
   Rocha LB, 2012, TOXINS, V4, P729, DOI 10.3390/toxins4090729
   Salvador FS, 2015, MICROBIOL RESOUR ANN, V3, DOI 10.1128/genomeA.00779-15
   Secretaria de Vigilancia em Saude Ministerio da Saude, 2017, B EPIDEMIOL, V48, P2358
   Silva EM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057514
   Vaughn DW, 1997, J INFECT DIS, V176, P322, DOI 10.1086/514048
   Whitehead SS, 2003, J VIROL, V77, P1653, DOI 10.1128/JVI.77.2.1653-1657.2003
   Zhang XZ, 2013, P NATL ACAD SCI USA, V110, P6795, DOI 10.1073/pnas.1304300110
NR 30
TC 7
Z9 8
U1 0
U2 2
PU MDPI AG
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 2073-4468
J9 ANTIBODIES
JI Antibodies
PD DEC
PY 2017
VL 6
IS 4
AR 14
DI 10.3390/antib6040014
PG 13
WC Immunology
SC Immunology
GA FR6KQ
UT WOS:000419175100001
PM 31548529
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Franco, LD
   Vidal, PO
   Amorim, JH
AF Franco, Lorrany dos Santos
   Vidal, Paloma Oliveira
   Amorim, Jaime Henrique
TI In silico design of a Zika virus non-structural protein 5 aiming vaccine
   protection against zika and dengue in different human populations
SO JOURNAL OF BIOMEDICAL SCIENCE
LA English
DT Article
DE Zika virus; Dengue virus; Vaccine; Epitopes; Bioinformatics
ID IMMUNE-RESPONSE; ANTIBODIES; INFECTION; SAFETY
AB Background: The arboviruses Zika virus (ZIKV) and Dengue virus (DENV) have important epidemiological impact in Brazil and other tropical regions of the world. Recently, it was shown that previous humoral immunity to DENV enhances ZIKV replication in vitro, which may lead to more severe forms of the disease. Thus, traditional approaches of vaccine development aiming to control viral infection through neutralizing antibodies may induce cross-reactive enhancing antibodies. In contrast, cellular immune response was shown to be capable of controlling DENV infection independently of antibodies. The aim of the present study was to design a flavivirus NS5 protein capable of inducing a cellular immune response against DENV and ZIKV.
   Methods: A consensus sequence of ZIKV NS5 protein was designed among isolates from various continents. Epitopes were predicted for the most prevalent alleles of class I and II HLA in the Brazilian population. Then, this epitopes were analyzed with regard to their conservation, population coverage and distribution along the whole antigen.
   Results: Nineteen epitopes predicted to be more reactive (percentile rank <1) and 100% conserved among ZIKV and DENV serotypes were selected. The distribution of such epitopes along the protein was shown on a three-dimensional model and population coverage was calculated for different regions of the world. The designed protein was predicted to be stable and the distribution of selected epitopes was shown to be homogeneous along domains. The population coverage of selected epitopes was higher than 50% for most of tropical areas of the world.
   Conclusion: Such results indicate that the proposed antigen has the potential to induce protective cellular immune response to ZIKV and DENV in different human populations of the world.
C1 [Franco, Lorrany dos Santos; Vidal, Paloma Oliveira; Amorim, Jaime Henrique] Univ Fed Oeste Bahia, Lab Microbiol, Ctr Ciencias Biol & Saude, Rua Bertioga 892,Morada Nobre 2, BR-47810059 Barreiras, BA, Brazil.
RP Amorim, JH (corresponding author), Univ Fed Oeste Bahia, Lab Microbiol, Ctr Ciencias Biol & Saude, Rua Bertioga 892,Morada Nobre 2, BR-47810059 Barreiras, BA, Brazil.
EM jaime.amorim@ufob.edu.br
RI Amorim, Jaime Henrique/O-9222-2017
OI Amorim, Jaime Henrique/0000-0002-0623-2879
FU International Society of Infectious Diseases
FX This research work was funded by International Society of Infectious
   Diseases.
CR Alves RPDS, 2016, CLIN VACCINE IMMUNOL
   Amorim JH, 2016, VIROLOGY, V487, P41, DOI 10.1016/j.virol.2015.10.006
   [Anonymous], AR ZIK VIR
   Basarab M, 2016, BMJ-BRIT MED J, V352, DOI 10.1136/bmj.i1049
   Bhatt S, 2013, NATURE, V496, P504, DOI 10.1038/nature12060
   Calvet G, 2016, LANCET INFECT DIS
   Castanha PM, 2016, J INFECT DIS
   Dejnirattisai W, 2016, NAT IMMUNOL, V17, P1102, DOI 10.1038/ni.3515
   Gil L, 2009, VIRAL IMMUNOL, V22, P23, DOI 10.1089/vim.2008.0063
   Guirakhoo F, 2000, J VIROL, V74, P5477, DOI 10.1128/JVI.74.12.5477-5485.2000
   Guirakhoo F, 2004, J VIROL, V78, P4761, DOI 10.1128/JVI.78.9.4761-4775.2004
   Guirakhoo F, 2001, J VIROL, V75, P7290, DOI 10.1128/JVI.75.16.7290-7304.2001
   Hadinegoro SR, 2015, NEW ENGL J MED, V373, P1195, DOI 10.1056/NEJMoa1506223
   Knipe D., 2007, FIELDS VIROLOGY
   Paul LM, 2016, CLIN TRANSL IMMUNOL, V5, DOI 10.1038/cti.2016.72
   Priyamvada L, 2016, P NATL ACAD SCI USA, V113, P7852, DOI 10.1073/pnas.1607931113
   Rivino L, 2013, J VIROL, V87, P2693, DOI 10.1128/JVI.02675-12
   Tamura K, 2013, MOL BIOL EVOL, V30, P2725, DOI [10.1093/molbev/mst197, 10.1093/molbev/msr121]
   Villar L, 2014, NEW ENGL J MED, V372
   Weiskopf D, 2014, J VIROL
   Wikan N, 2016, LANCET INFECT DIS, V16, pE119, DOI 10.1016/S1473-3099(16)30010-X
   Yoshida T, 2013, ARCH VIROL, V158, P1209, DOI 10.1007/s00705-013-1618-6
   Zhao BT, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14586
NR 23
TC 6
Z9 7
U1 0
U2 1
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1021-7770
EI 1423-0127
J9 J BIOMED SCI
JI J. Biomed. Sci.
PD NOV 23
PY 2017
VL 24
AR 88
DI 10.1186/s12929-017-0395-z
PG 10
WC Cell Biology; Medicine, Research & Experimental
SC Cell Biology; Research & Experimental Medicine
GA FN5QA
UT WOS:000416061500001
PM 29169357
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Maeda, DLNF
   Batista, MT
   Pereira, LR
   Cintra, MD
   Amorim, JH
   Mathias-Santos, C
   Pereira, SA
   Boscardin, SB
   Silva, SD
   Faquim-Mauro, EL
   Silveira, VB
   Oliveira, DBL
   Johnston, SA
   Ferreira, LCD
   Rodrigues, JF
AF Nascimento Fabris Maeda, Denicar Lina
   Batista, Milene Tavares
   Pereira, Lennon Ramos
   Cintra, Mariana de Jesus
   Amorim, Jaime Henrique
   Mathias-Santos, Camila
   Pereira, Sara Araujo
   Boscardin, Silvia Beatriz
   Silva, Sandriana dos Ramos
   Faquim-Mauro, Eliana L.
   Silveira, Vanessa Barbosa
   Leal Oliveira, Danielle Bruna
   Johnston, Stephen Albert
   de Souza Ferreira, Luis Carlos
   Rodrigues, Juliana Falcao
TI Adjuvant-Mediated Epitope Specificity and Enhanced Neutralizing Activity
   of Antibodies Targeting Dengue Virus Envelope Protein
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Article
DE heat-labile toxins; labile toxins; adjuvants; dengue virus; envelope
   protein; vaccines; antibodies; immunosignature
ID HEAT-LABILE TOXIN; ENTEROTOXIGENIC ESCHERICHIA-COLI; DOMAIN-III;
   PROTECTIVE IMMUNITY; MONOCLONAL-ANTIBODIES; ANTIVIRAL PEPTIDES;
   CHOLERA-TOXIN; VACCINATION; CELLS; IMMUNOGENICITY
AB The heat-labile toxins (LT) produced by enterotoxigenic Escherichia coil display adjuvant effects to coadministered antigens, leading to enhanced production of serum antibodies. Despite extensive knowledge of the adjuvant properties of LT derivatives, including in vitro generated non-toxic mutant forms, little is known about the capacity of these adjuvants to modulate the epitope specificity of antibodies directed against antigens. This study characterizes the role of LT and its non-toxic B subunit (LTB) in the modulation of antibody responses to a coadministered antigen, the dengue virus (DENV) envelope glycoprotein domain III (EDIII), which binds to surface receptors and mediates virus entry into host cells. In contrast to non-adjuvanted or alum-adjuvanted formulations, antibodies induced in mice immunized with LT or LTB showed enhanced virus-neutralization effects that were not ascribed to a subclass shift or antigen affinity. Nonetheless, immunosignature analyses revealed that purified LT-adjuvanted EDIII-specific antibodies display distinct epitope-binding patterns with regard to antibodies raised in mice immunized with EDIII or the alum-adjuvanted vaccine. Notably, the analyses led to the identification of a specific EDIII epitope located in the EF to FG loop, which is involved in the entry of DENV into eukaryotic cells. The present results demonstrate that LT and LTB modulate the epitope specificity of antibodies generated after immunization with coadministered antigens that, in the case of EDIII, was associated with the induction of neutralizing antibody responses. These results open perspectives for the more rational development of vaccines with enhanced protective effects against DENV infections.
C1 [Nascimento Fabris Maeda, Denicar Lina; Batista, Milene Tavares; Pereira, Lennon Ramos; Cintra, Mariana de Jesus; Mathias-Santos, Camila; Pereira, Sara Araujo; de Souza Ferreira, Luis Carlos; Rodrigues, Juliana Falcao] Univ Sao Paulo, Vaccine Dev Lab, Dept Microbiol, Inst Biomed Sci, Sao Paulo, Brazil.
   [Batista, Milene Tavares; Johnston, Stephen Albert] Arizona State Univ, Biodesign Inst, Ctr Innovat Med, Tempe, AZ USA.
   [Amorim, Jaime Henrique] Fed Univ Western Bahia, Ctr Biol & Hlth Sci, Salvador, Brazil.
   [Boscardin, Silvia Beatriz] Univ Sao Paulo, Inst Biomed Sci, Dept Parasitol, Sao Paulo, Brazil.
   [Silva, Sandriana dos Ramos] Pasteur Inst, Sao Paulo, Brazil.
   [Faquim-Mauro, Eliana L.] Butantan Inst, Lab Immunopathol, Sao Paulo, Brazil.
   [Silveira, Vanessa Barbosa; Leal Oliveira, Danielle Bruna] Univ Sao Paulo, Clin & Mol Virol Lab, Dept Microbiol, Inst Biomed Sci, Sao Paulo, Brazil.
RP Ferreira, LCD (corresponding author), Univ Sao Paulo, Vaccine Dev Lab, Dept Microbiol, Inst Biomed Sci, Sao Paulo, Brazil.
EM lcsf@usp.br
RI Oliveira, Danielle BL/H-8030-2015; Faquim-Mauro, Eliana/M-2489-2017;
   Silveira, Vanessa/AAJ-9535-2020; Boscardin, Silvia Beatriz/C-3397-2012;
   Rodrigues, Juliana/AAC-3512-2019; Amorim, Jaime Henrique/O-9222-2017
OI Oliveira, Danielle BL/0000-0002-3452-1336; Faquim-Mauro,
   Eliana/0000-0001-8083-4272; Boscardin, Silvia
   Beatriz/0000-0002-7845-7110; Amorim, Jaime Henrique/0000-0002-0623-2879;
   Oliveira, Danielle/0000-0002-0534-0886; Araujo Pereira,
   Sara/0000-0001-8218-9465; Barbosa da Silveira,
   Vanessa/0000-0002-9699-0875
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP grants)
   [2012/51204-2, 2014/17595-0]; Conselho Nacional do Desenvolvimento
   Cientifico e Tecnologico (CNPq grants) [485546/2012-4, 309392/2015-2];
   Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES
   grant) [88887.116618/2016-01-AUXPE 0448/2016]; Department of Homeland
   SecurityUnited States Department of Homeland Security (DHS); CIM Peptide
   Array Core
FX This study was supported by grants from the Fundacao de Amparo a
   Pesquisa do Estado de Sao Paulo (FAPESP grants to LCSF: 2012/51204-2,
   2014/17595-0), the Conselho Nacional do Desenvolvimento Cientifico e
   Tecnologico (CNPq grants to JR and EF-M, respectively: 485546/2012-4 and
   309392/2015-2), and the Coordenacao de Aperfeicoamento de Pessoal de
   Nivel Superior (CAPES grant: 88887.116618/2016-01-AUXPE 0448/2016). At
   ASU by a grant from the Department of Homeland Security to SJ and the
   CIM Peptide Array Core (HSHQDC-15-C-B0008). The authors thank Dr.
   Phillip Stafford for his invaluable assistance, and the authors
   acknowledge the helpful technical assistance of E. G. Martins, C.
   Bertelli, Pattie Madjidi, and Penny Gwynne.
CR Alhoot MA, 2013, INT J MED SCI, V10, P719, DOI 10.7150/ijms.5037
   Amorim JH, 2012, VACCINE, V30, P837, DOI 10.1016/j.vaccine.2011.12.034
   Azevedo AS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020528
   Batista MT, 2014, INFECT IMMUN, V82, P4978, DOI 10.1128/IAI.02074-14
   Beltramello M, 2010, CELL HOST MICROBE, V8, P271, DOI 10.1016/j.chom.2010.08.007
   Bernardo L, 2011, VACCINE, V29, P4256, DOI 10.1016/j.vaccine.2011.03.040
   Braga CJM, 2014, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00487
   Brereton CF, 2011, J IMMUNOL, V186, P5896, DOI 10.4049/jimmunol.1003789
   Chen LM, 2017, ANTIVIR RES, V141, P140, DOI 10.1016/j.antiviral.2017.02.009
   Chiang CY, 2014, VACCINE, V32, P1346, DOI 10.1016/j.vaccine.2014.01.041
   Chiang CY, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001645
   Clements JD, 2016, CLIN VACCINE IMMUNOL, V23, P438, DOI 10.1128/CVI.00214-16
   Cockburn JJB, 2012, STRUCTURE, V20, P303, DOI 10.1016/j.str.2012.01.001
   Coffman RL, 2010, IMMUNITY, V33, P492, DOI 10.1016/j.immuni.2010.10.002
   Costin JM, 2013, J VIROL, V87, P52, DOI 10.1128/JVI.02273-12
   Crill WD, 2001, J VIROL, V75, P7769, DOI 10.1128/JVI.75.16.7769-7773.2001
   da Hora VP, 2011, VACCINE, V29, P1538, DOI 10.1016/j.vaccine.2010.11.091
   de Haan L, 1998, IMMUNOL CELL BIOL, V76, P270, DOI 10.1046/j.1440-1711.1998.00745.x
   Di Pasquale A, 2015, VACCINES-BASEL, V3, P320, DOI 10.3390/vaccines3020320
   Diaz-Montero CM, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-62
   EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010
   Erb SM, 2010, VIROLOGY, V406, P328, DOI 10.1016/j.virol.2010.07.024
   Etemad B, 2008, AM J TROP MED HYG, V79, P353, DOI 10.4269/ajtmh.2008.79.353
   Giuliani MM, 1998, J EXP MED, V187, P1123, DOI 10.1084/jem.187.7.1123
   Hajishengallis G, 2005, J DENT RES, V84, P1104, DOI 10.1177/154405910508401205
   Halperin RF, 2012, BMC BIOINFORMATICS, V13, DOI 10.1186/1471-2105-13-1
   Heinz FX, 2012, J CLIN VIROL, V55, P289, DOI 10.1016/j.jcv.2012.08.024
   Hu JC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113978
   Hughes AK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040201
   Hung JJ, 2004, J VIROL, V78, P378, DOI 10.1128/JVI.78.1.378-388.2004
   Ji J, 2015, J CELL MOL MED, V19, P2019, DOI 10.1111/jcmm.12599
   Johnston SA, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-657
   Kaufmann B, 2011, MICROBES INFECT, V13, P1, DOI 10.1016/j.micinf.2010.09.005
   KOSTNER GM, 1979, CLIN CHEM, V25, P939
   Kuhn RJ, 2002, CELL, V108, P717, DOI 10.1016/S0092-8674(02)00660-8
   Lasaro MA, 2008, J BACTERIOL, V190, P2400, DOI 10.1128/JB.00988-07
   Lasaro MA, 2009, FEMS IMMUNOL MED MIC, V55, P93, DOI 10.1111/j.1574-695X.2008.00506.x
   Legutki JB, 2013, P NATL ACAD SCI USA, V110, P18614, DOI 10.1073/pnas.1309390110
   Legutki JB, 2010, VACCINE, V28, P4529, DOI 10.1016/j.vaccine.2010.04.061
   Lencer WI, 1999, BBA-MOL CELL RES, V1450, P177, DOI 10.1016/S0167-4889(99)00070-1
   Lewis DJM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006999
   Li XQ, 2013, J GEN VIROL, V94, P2191, DOI 10.1099/vir.0.055178-0
   Lok SM, 2008, NAT STRUCT MOL BIOL, V15, P312, DOI 10.1038/nsmb.1382
   Luiz WB, 2015, INFECT IMMUN, V83, P4555, DOI 10.1128/IAI.00858-15
   Luo QW, 2016, CLIN VACCINE IMMUNOL, V23, P628, DOI 10.1128/CVI.00248-16
   Malyala P, 2008, J PHARM SCI-US, V97, P2041, DOI 10.1002/jps.21152
   Mathias-Santos C, 2011, CLIN VACCINE IMMUNOL, V18, P1243, DOI 10.1128/CVI.00012-11
   Midgey CM, 2012, J IMMUNOL, V188, P4971, DOI 10.4049/jimmunol.1200227
   Mukhopadhyay S, 2005, NAT REV MICROBIOL, V3, P13, DOI 10.1038/nrmicro1067
   Nataro JP, 1998, CLIN MICROBIOL REV
   O'Donnell B, 2015, CANCER INFORM, V14, P219, DOI [10.4137/CIN.S17285, 10.4137/CIn.s17285]
   O'Hagan DT, 2009, DRUG DISCOV TODAY, V14, P541, DOI 10.1016/j.drudis.2009.02.009
   Olafsdottir TA, 2007, SCAND J IMMUNOL, V66, P426, DOI 10.1111/j.1365-3083.2007.01970.x
   Panya A, 2014, CHEM BIOL DRUG DES, V84, P148, DOI 10.1111/cbdd.12309
   Poggianella M, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003947
   Price JV, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064555
   Robbiani DF, 2017, CELL, V169, P597, DOI 10.1016/j.cell.2017.04.024
   Rodenhuis-Zybert IA, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003564
   Rodrigues JF, 2011, J BIOL CHEM, V286, P5222, DOI 10.1074/jbc.M110.173682
   Ryan EJ, 2000, J IMMUNOL, V165, P5750, DOI 10.4049/jimmunol.165.10.5750
   Savelkoul HFJ, 2015, VACCINES-BASEL, V3, P148, DOI 10.3390/vaccines3010148
   Schmidt AG, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000851
   Lasaro MAS, 2006, FEMS IMMUNOL MED MIC, V48, P123, DOI 10.1111/j.1574-695X.2006.00134.x
   Singh S, 2018, MOL NEUROBIOL, V55, P633, DOI 10.1007/s12035-016-0334-0
   Skalickova S, 2015, VIRUSES-BASEL, V7, P5428, DOI 10.3390/v7102883
   Stafford P, 2014, P NATL ACAD SCI USA, V111, pE3072, DOI 10.1073/pnas.1409432111
   Stanaway JD, 2016, LANCET INFECT DIS, V16, P712, DOI 10.1016/S1473-3099(16)00026-8
   Sukupolvi-Petty S, 2007, J VIROL, V81, P12816, DOI 10.1128/JVI.00432-07
   Summerton NA, 2010, VACCINE, V28, P1404, DOI 10.1016/j.vaccine.2009.10.147
   Sykes KF, 2013, TRENDS BIOTECHNOL, V31, P45, DOI 10.1016/j.tibtech.2012.10.012
   Tritto E, 2007, J IMMUNOL, V179, P5346, DOI 10.4049/jimmunol.179.8.5346
   Valentini D, 2017, INT J INFECT DIS, V56, P140, DOI 10.1016/j.ijid.2017.01.027
   Wagner D, 2004, EMERG INFECT DIS, V10, P1872, DOI 10.3201/eid1010.031037
   Wahala WMPB, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000821
   WHO, 2016, DENG VACC WHO POSS P
   Wumkes ML, 2017, VACCINE, V35, P1299, DOI 10.1016/j.vaccine.2017.01.039
NR 76
TC 6
Z9 6
U1 0
U2 2
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PD SEP 25
PY 2017
VL 8
AR 1175
DI 10.3389/fimmu.2017.01175
PG 13
WC Immunology
SC Immunology
GA FI0FH
UT WOS:000411598500001
PM 28993770
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Alves, RPD
   Pereira, LR
   Fabris, DLN
   Salvador, FS
   Santos, RA
   Zanotto, PMD
   Romano, CM
   Amorim, JH
   Ferreiraa, LCD
AF dos Santos Alves, Rbens Prince
   Pereira, Lennon Ramos
   Nascimento Fabris, Denicar Lina
   Salvador, Felipe Scassi
   Santos, Robert Andreata
   de Andrade Zanotto, Paolo Marinho
   Romano, Camila Malta
   Amorim, Jaime Henrique
   de Souza Ferreiraa, Luis Carlos
TI Production of a Recombinant Dengue Virus 2 NS5 Protein and Potential Use
   as a Vaccine Antigen
SO CLINICAL AND VACCINE IMMUNOLOGY
LA English
DT Article
ID CD8(+) T-LYMPHOCYTES; IMMUNE-RESPONSE; MONONUCLEAR PHAGOCYTES;
   PROTECTIVE IMMUNITY; DNA VACCINE; IMMUNOGENICITY; INFECTION; MOUSE;
   ENHANCEMENT; ANTIBODY
AB Dengue fever is caused by any of the four known dengue virus serotypes (DENV1 to DENV4) that affect millions of people worldwide, causing a significant number of deaths. There are vaccines based on chimeric viruses, but they still are not in clinical use. Anti-DENV vaccine strategies based on nonstructural proteins are promising alternatives to those based on whole virus or structural proteins. The DENV nonstructural protein 5 (NS5) is the main target of anti-DENV T cell-based immune responses in humans. In this study, we purified a soluble recombinant form of DENV2 NS5 expressed in Escherichia coli at large amounts and high purity after optimization of expression conditions and purification steps. The purified DENV2 NS5 was recognized by serum from DENV1-, DENV2-, DENV3-, or DENV4-infected patients in an epitope-conformation-dependent manner. In addition, immunization of BALB/c mice with NS5 induced high levels of NS5-specific antibodies and expansion of gamma interferon-and tumor necrosis factor alpha-producing T cells. Moreover, mice immunized with purified NS5 were partially protected from lethal challenges with the DENV2 NGC strain and with a clinical isolate (JHA1). These results indicate that the recombinant NS5 protein preserves immunological determinants of the native protein and is a promising vaccine antigen capable of inducing protective immune responses.
C1 [dos Santos Alves, Rbens Prince; Pereira, Lennon Ramos; Nascimento Fabris, Denicar Lina; Santos, Robert Andreata; Amorim, Jaime Henrique; de Souza Ferreiraa, Luis Carlos] Univ Sao Paulo, Dept Microbiol, Inst Ciencias Biomed, Lab Desenvolvimento Vacinas, Sao Paulo, Brazil.
   [Salvador, Felipe Scassi; Romano, Camila Malta] Univ Sao Paulo, Escola Med, Inst Trop Med, Sao Paulo, Brazil.
   [de Andrade Zanotto, Paolo Marinho] Univ Sao Paulo, Dept Microbiol, Inst Ciencias Biomed, Lab Evolucao & Mol Bioinformat, Sao Paulo, Brazil.
   [Amorim, Jaime Henrique] Univ Fed Oeste Bahia, Ctr Ciencias Biol & Saude, Barreiras, BA, Brazil.
RP Amorim, JH; Ferreiraa, LCD (corresponding author), Univ Sao Paulo, Dept Microbiol, Inst Ciencias Biomed, Lab Desenvolvimento Vacinas, Sao Paulo, Brazil.; Amorim, JH (corresponding author), Univ Fed Oeste Bahia, Ctr Ciencias Biol & Saude, Barreiras, BA, Brazil.
EM jaime.amorim@ufob.edu.br; lcsf@usp.br
RI de A. Zanotto, Paolo M./B-9286-2019; Amorim, Jaime Henrique/O-9222-2017;
   Romano, Camila M/C-8185-2013; Romano, Camila/ABC-2883-2020; Ferreira,
   Luis/M-3954-2014
OI de A. Zanotto, Paolo M./0000-0002-8167-0625; Amorim, Jaime
   Henrique/0000-0002-0623-2879; Romano, Camila/0000-0003-4550-1987;
   Ferreira, Luis/0000-0002-4883-1693
FU FAPESPFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
   [2011/51.761-6, 2012/2012/21077-9, 2014/17595-0, 2015/02352-7]
FX This work, including the efforts of Rubens Prince dos Santos Alves, was
   funded by FAPESP (2011/51.761-6, 2012/2012/21077-9, 2014/17595-0, and
   2015/02352-7).
CR Ackermann M, 2001, J BIOL CHEM, V276, P39926, DOI 10.1074/jbc.M104248200
   Amorim JH, 2016, VIROLOGY, V487, P41, DOI 10.1016/j.virol.2015.10.006
   Amorim JH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044984
   Amorim JH, 2012, VACCINE, V30, P837, DOI 10.1016/j.vaccine.2011.12.034
   Arora U, 2013, VACCINE, V31, P873, DOI 10.1016/j.vaccine.2012.12.016
   Bhatt S, 2013, NATURE, V496, P504, DOI 10.1038/nature12060
   Bhattacharya D, 2009, J VIROL, V83, P9195, DOI 10.1128/JVI.00271-09
   BLOK J, 1985, J GEN VIROL, V66, P1323, DOI 10.1099/0022-1317-66-6-1323
   BRAY M, 1991, P NATL ACAD SCI USA, V88, P10342, DOI 10.1073/pnas.88.22.10342
   Bui HH, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-361
   Chan Y C, 1965, Singapore Med J, V5, P127
   Chen HC, 2007, J VIROL, V81, P5518, DOI 10.1128/JVI.02575-06
   Costa SM, 2007, VIROLOGY, V358, P413, DOI 10.1016/j.virol.2006.08.052
   Costa SM, 2006, VACCINE, V24, P4562, DOI 10.1016/j.vaccine.2005.08.022
   DIERCKS FH, 1959, AM J TROP MED HYG, V8, P488, DOI 10.4269/ajtmh.1959.8.488
   DINTZIS HM, 1976, P NATL ACAD SCI USA, V73, P3671, DOI 10.1073/pnas.73.10.3671
   Durbin AP, 2001, AM J TROP MED HYG, V65, P405, DOI 10.4269/ajtmh.2001.65.405
   Elgert K.D., 2009, IMMUNOLOGY UNDERSTAN
   Fraser JE, 2014, METHODS MOL BIOL, V1138, P301, DOI 10.1007/978-1-4939-0348-1_19
   Guirakhoo F, 2001, J VIROL, V75, P7290, DOI 10.1128/JVI.75.16.7290-7304.2001
   Guy B, 2010, HUM VACCINES, V6, P696, DOI 10.4161/hv.6.9.12739
   Guzman MG, 2015, LANCET, V385, P453, DOI 10.1016/S0140-6736(14)60572-9
   Guzman MG, 2010, NAT REV MICROBIOL, pS7, DOI 10.1038/nrmicro2460
   HALSTEAD SB, 1977, J EXP MED, V146, P218, DOI 10.1084/jem.146.1.218
   HALSTEAD SB, 1979, J INFECT DIS, V140, P527, DOI 10.1093/infdis/140.4.527
   HALSTEAD SB, 1977, J EXP MED, V146, P201, DOI 10.1084/jem.146.1.201
   HALSTEAD SB, 1980, AM J TROP MED HYG, V29, P638, DOI 10.4269/ajtmh.1980.29.638
   Henriques HR, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002330
   Kelley JF, 2011, VIROLOGY, V418, P27, DOI 10.1016/j.virol.2011.07.006
   Khan AM, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000272
   Kloetzel PM, 2001, NAT REV MOL CELL BIO, V2, P179, DOI 10.1038/35056572
   Larsen Jens Erik Pontoppidan, 2006, Immunome Res, V2, P2, DOI 10.1186/1745-7580-2-2
   Liu T, 2001, J VIROL, V75, P11178, DOI 10.1128/JVI.75.22.11178-11184.2001
   Loureiro J, 2006, ADV IMMUNOL, V92, P225, DOI 10.1016/S0065-2776(06)92006-9
   Lundegaard C, 2008, NUCLEIC ACIDS RES, V36, pW509, DOI 10.1093/nar/gkn202
   Malyala P, 2008, J PHARM SCI-US, V97, P2041, DOI 10.1002/jps.21152
   Mladinich KM, 2012, IMMUNOGENETICS, V64, P111, DOI 10.1007/s00251-011-0566-0
   Moutaftsi M, 2006, NAT BIOTECHNOL, V24, P817, DOI 10.1038/nbt1215
   MYERS RM, 1964, INDIAN J MED RES, V52, P559
   Perera R, 2008, CURR OPIN MICROBIOL, V11, P369, DOI 10.1016/j.mib.2008.06.004
   Pongsumpun P, 2008, TROP MED INT HEALTH, V13, P1180, DOI 10.1111/j.1365-3156.2008.02124.x
   Putnak R, 1996, J INFECT DIS, V174, P1176, DOI 10.1093/infdis/174.6.1176
   Raviprakash K, 2006, VIROLOGY, V353, P166, DOI 10.1016/j.virol.2006.05.005
   Rivino L, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa0526
   Rivino L, 2013, J VIROL, V87, P2693, DOI 10.1128/JVI.02675-12
   Sabchareon A, 2012, LANCET, V380, P1559, DOI 10.1016/S0140-6736(12)61428-7
   Sambrook J., 2001, MOL CLONING LAB MANU
   Schwarz H, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113840
   SMITH C E G, 1956, J Hyg (Lond), V54, P569
   Tan BH, 1996, VIROLOGY, V216, P317, DOI 10.1006/viro.1996.0067
   Tay MYF, 2013, ANTIVIR RES, V99, P301, DOI 10.1016/j.antiviral.2013.06.002
   Valdes K, 2000, CLIN DIAGN LAB IMMUN, V7, P856, DOI 10.1128/CDLI.7.5.856-857.2000
   Vaughn DW, 1996, VACCINE, V14, P329, DOI 10.1016/0264-410X(95)00167-Y
   Villar L, 2015, NEW ENGL J MED, V372, P113, DOI 10.1056/NEJMoa1411037
   Voulgaridou GP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056582
   Wakelin SJ, 2006, IMMUNOL LETT, V106, P1, DOI 10.1016/j.imlet.2006.04.007
   Wang P, 2008, PLOS COMPUT BIOL, V4, DOI 10.1371/journal.pcbi.1000048
   Watanabe H, 2004, SHOCK, V22, P460, DOI 10.1097/01.shk.0000142249.08135.e9
   Weiskopf D, 2015, P NATL ACAD SCI USA, V112, pE4256, DOI 10.1073/pnas.1505956112
   Weiskopf D, 2015, J VIROL, V89, P120, DOI 10.1128/JVI.02129-14
   White LJ, 2007, J VIROL, V81, P10329, DOI 10.1128/JVI.00512-07
   Whitehead SS, 2007, NAT REV MICROBIOL, V5, P518, DOI 10.1038/nrmicro1690
   World Health Organization, 2009, DENG GUID DIAGN TREA
   Yap TL, 2007, J VIROL, V81, P4753, DOI 10.1128/JVI.02283-06
   ZHANG YM, 1988, J VIROL, V62, P3027, DOI 10.1128/JVI.62.8.3027-3031.1988
NR 65
TC 10
Z9 10
U1 0
U2 10
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 1556-6811
EI 1556-679X
J9 CLIN VACCINE IMMUNOL
JI Clin. Vaccine Immunol.
PD JUN
PY 2016
VL 23
IS 6
BP 460
EP 469
DI 10.1128/CVI.00081-16
PG 10
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA DO0GO
UT WOS:000377457600004
PM 27030586
OA Bronze, Green Published
DA 2020-12-01
ER

PT J
AU Amorim, JH
   Alves, RPD
   Bizerra, R
   Pereira, SA
   Pereira, LR
   Fabris, DLN
   Santos, RA
   Romano, CM
   Ferreira, LCD
AF Amorim, Jaime Henrique
   dos Santos Alves, Rubens Prince
   Bizerra, Raiza
   Pereira, Sara Araujo
   Pereira, Lennon Ramos
   Nascimento Fabris, Denicar Lina
   Santos, Robert Andreata
   Romano, Camila Malta
   de Souza Ferreira, Luis Carlos
TI Antibodies are not required to a protective immune response against
   dengue virus elicited in a mouse encephalitis model
SO VIROLOGY
LA English
DT Article
DE Dengue; Nonstructural proteins; Immune response; T lymphocytes;
   Antibodies
ID CD8(+) T-CELL; WEST-NILE-VIRUS; NEUTRALIZING ANTIBODY; VACCINE
   FORMULATIONS; GAMMA-INTERFERON; DOMAIN-III; LYMPHOCYTES; RECOMBINANT;
   CD4(+); MICE
AB Generating neutralizing antibodies have been considered a prerequisite to control dengue virus (DENV) infection. However, T lymphocytes have also been shown to be important in a protective immune state. In order to investigate the contribution of both humoral and cellular immune responses in DENV immunity, we used an experimental model in which a non-lethal DENV2 strain (ACS46) is used to intracranially prime Balb/C mice which develop protective immunity against a lethal DENV2 strain (JHA1). Primed mice generated envelope-specific antibodies and CD8(+) T cell responses targeting mainly non-structural proteins. Immune sera from protected mice did not confer passive protection to naive mice challenged with the JHA1 strain. In contrast, depletion of CD4(+) and CD8(+) T lymphocytes significantly reduced survival of ACS46-primed mice challenged with the JHA1 strain. Collectively, results presented in this study show that a cellular immune response targeting non-structural proteins are a promising way in vaccine development against dengue. (C) 2015 Elsevier Inc. All rights reserved.
C1 [Amorim, Jaime Henrique; dos Santos Alves, Rubens Prince; Bizerra, Raiza; Pereira, Sara Araujo; Pereira, Lennon Ramos; Nascimento Fabris, Denicar Lina; Santos, Robert Andreata; de Souza Ferreira, Luis Carlos] Univ Sao Paulo, Dept Microbiol, Lab Desenvolvimento Vacinas, BR-05508000 Sao Paulo, SP, Brazil.
   [Romano, Camila Malta] Univ Sao Paulo, Dept Mol Infecciosas & Parasitarias LIMHC, Inst Med Trop Sao Paulo, BR-05508000 Sao Paulo, SP, Brazil.
   [Romano, Camila Malta] Univ Sao Paulo, Fac Med, BR-05508000 Sao Paulo, SP, Brazil.
RP Amorim, JH (corresponding author), Univ Sao Paulo, ICB 2, Dept Microbiol, Lab Desenvolvimento Vacinas, Av Prof Lineu Prestes 1374,Cidade Univ, BR-05508000 Sao Paulo, SP, Brazil.
EM jhamorim@usp.br; lcsf@usp.br
RI Romano, Camila/ABC-2883-2020; Romano, Camila M/C-8185-2013; Amorim,
   Jaime Henrique/O-9222-2017; Ferreira, Luis/M-3954-2014
OI Romano, Camila/0000-0003-4550-1987; Amorim, Jaime
   Henrique/0000-0002-0623-2879; Araujo Pereira, Sara/0000-0001-8218-9465;
   Ferreira, Luis/0000-0002-4883-1693
FU FAPESP GrantFundacao de Amparo a Pesquisa do Estado de Sao Paulo
   (FAPESP) [2012/51204-2]
FX are grateful for the technical assistance of E.G. Martins. This work was
   supported by FAPESP Grant 2012/51204-2.
CR Amorim JH, 2015, FUTURE VIROL, V10, P835, DOI 10.2217/FVL.15.48
   Amorim JH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044984
   Back Anne Tuiskunen, 2013, Infect Ecol Epidemiol, V3, DOI 10.3402/iee.v3i0.19839
   Bashyam HS, 2006, J IMMUNOL, V176, P2817, DOI 10.4049/jimmunol.176.5.2817
   Bhatt S, 2013, NATURE, V496, P504, DOI 10.1038/nature12060
   Blaney JE, 2005, J VIROL, V79, P5516, DOI 10.1128/JVI.79.9.5516-5528.2005
   Brien JD, 2008, J IMMUNOL, V181, P8568, DOI 10.4049/jimmunol.181.12.8568
   Chevalier G, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002393
   Chiang CY, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001645
   Cockburn JJB, 2012, EMBO J, V31, P767, DOI 10.1038/emboj.2011.439
   Gao GP, 2008, HUM GENE THER, V19, P927, DOI 10.1089/hum.2008.011
   GEHRMANN J, 1995, BRAIN RES REV, V20, P269, DOI 10.1016/0165-0173(94)00015-H
   Gil L, 2009, VIRAL IMMUNOL, V22, P23, DOI 10.1089/vim.2008.0063
   Guirakhoo F, 2000, J VIROL, V74, P5477, DOI 10.1128/JVI.74.12.5477-5485.2000
   Guirakhoo F, 2004, J VIROL, V78, P4761, DOI 10.1128/JVI.78.9.4761-4775.2004
   Guirakhoo F, 2001, J VIROL, V75, P7290, DOI 10.1128/JVI.75.16.7290-7304.2001
   Guy B, 2010, HUM VACCIN, V6
   Guzman MG, 2015, LANCET, V385, P453, DOI 10.1016/S0140-6736(14)60572-9
   Guzman MG, 2010, NAT REV MICROBIOL, pS7, DOI 10.1038/nrmicro2460
   Han Young Woo, 2012, Immune Netw, V12, P48, DOI 10.4110/in.2012.12.2.48
   Horstick O, 2015, PATHOG GLOB HEALTH, V109, P19, DOI 10.1179/2047773215Y.0000000003
   Knickelbein JE, 2008, SCIENCE, V322, P268, DOI 10.1126/science.1164164
   KURANE I, 1991, J CLIN INVEST, V88, P1473, DOI 10.1172/JCI115457
   Liu T, 2001, J VIROL, V75, P11178, DOI 10.1128/JVI.75.22.11178-11184.2001
   Liu T, 2001, J VIROL, V75, P2107, DOI 10.1128/JVI.75.5.2107-2118.2001
   Lok SM, 2008, NAT STRUCT MOL BIOL, V15, P312, DOI 10.1038/nsmb.1382
   Lundegaard C, 2008, NUCLEIC ACIDS RES, V36, pW509, DOI 10.1093/nar/gkn202
   Luria-Perez R, 2007, VACCINE, V25, P5071, DOI 10.1016/j.vaccine.2007.03.047
   Moutaftsi M, 2006, NAT BIOTECHNOL, V24, P817, DOI 10.1038/nbt1215
   MuraliKrishna K, 1996, J GEN VIROL, V77, P705, DOI 10.1099/0022-1317-77-4-705
   Murgue B, 2000, J MED VIROL, V60, P432, DOI 10.1002/(SICI)1096-9071(200004)60:4&lt;432::AID-JMV11&gt;3.0.CO;2-7
   Pierson TC, 2012, STRUCTURE, V20, P200, DOI 10.1016/j.str.2012.01.014
   Rivino L, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa0526
   Rivino L, 2013, J VIROL, V87, P2693, DOI 10.1128/JVI.02675-12
   Roehrig JT, 2008, VIRAL IMMUNOL, V21, P123, DOI 10.1089/vim.2008.0007
   Romano CM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070318
   Sabchareon A, 2012, LANCET, V380, P1559, DOI 10.1016/S0140-6736(12)61428-7
   SABIN ALBERT B., 1952, AMER JOUR TROP MED AND HYG, V1, P30
   Sitati EM, 2006, J VIROL, V80, P12060, DOI 10.1128/JVI.01650-06
   Teoh EP, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003888
   Vaughn DW, 2000, J INFECT DIS, V181, P2, DOI 10.1086/315215
   Villar L, 2014, N ENGL J MED, V372
   Wang P, 2008, PLOS COMPUT BIOL, V4, DOI 10.1371/journal.pcbi.1000048
   Weiskopf D, 2015, P NATL ACAD SCI USA, V112, pE4256, DOI 10.1073/pnas.1505956112
   Weiskopf D, 2015, J VIROL, V89, P120, DOI 10.1128/JVI.02129-14
   Whitehead SS, 2007, NAT REV MICROBIOL, V5, P518, DOI 10.1038/nrmicro1690
   Yauch LE, 2010, J IMMUNOL, V185, P5405, DOI 10.4049/jimmunol.1001709
   Yoshida T, 2013, ARCH VIROL, V158, P1209, DOI 10.1007/s00705-013-1618-6
   Yun NE, 2009, VACCINE, V27, P4064, DOI 10.1016/j.vaccine.2009.04.015
   Zellweger RM, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003723
   Zhang ZS, 2007, J VIROL METHODS, V143, P125, DOI 10.1016/j.jviromet.2007.02.012
NR 51
TC 15
Z9 16
U1 0
U2 11
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0042-6822
J9 VIROLOGY
JI Virology
PD JAN
PY 2016
VL 487
BP 41
EP 49
DI 10.1016/j.virol.2015.10.006
PG 9
WC Virology
SC Virology
GA CY5HK
UT WOS:000366438500005
PM 26496698
OA Bronze
DA 2020-12-01
ER

PT J
AU Salvador, FS
   Amorim, JH
   Alves, RP
   Pereira, SA
   Ferreira, LCS
   Romano, CM
AF Salvador, Felipe Scassi
   Amorim, Jaime Henrique
   Santos Alves, Rubens Prince
   Pereira, Sara A.
   Souza Ferreira, Luis Carlos
   Romano, Camila Malta
TI Complete Genome Sequence of an Atypical Dengue Virus Serotype 2 Lineage
   Isolated in Brazil
SO MICROBIOLOGY RESOURCE ANNOUNCEMENTS
LA English
DT Article
AB Here, we report the complete polyprotein sequence of a dengue virus 2 strain isolated in Brazil. This virus belongs to the American genotype and has the ability to cause neurovirulence in immunocompetent adult mice. The data presented here may help understand the genetic determinants responsible for neurovirulence.
C1 [Salvador, Felipe Scassi; Romano, Camila Malta] Univ Sao Paulo, Sch Med, Sao Paulo Inst Trop Med, Sao Paulo, Brazil.
   [Amorim, Jaime Henrique; Santos Alves, Rubens Prince; Pereira, Sara A.; Souza Ferreira, Luis Carlos] Univ Sao Paulo, Inst Biomed Sci, Sao Paulo, Brazil.
RP Romano, CM (corresponding author), Univ Sao Paulo, Sch Med, Sao Paulo Inst Trop Med, Sao Paulo, Brazil.
EM cmromano@usp.br
RI Amorim, Jaime Henrique/O-9222-2017; Romano, Camila M/C-8185-2013;
   Romano, Camila/ABC-2883-2020; Ferreira, Luis/M-3954-2014
OI Amorim, Jaime Henrique/0000-0002-0623-2879; Romano,
   Camila/0000-0003-4550-1987; Ferreira, Luis/0000-0002-4883-1693; Alves,
   Rubens/0000-0001-5538-6025; Araujo Pereira, Sara/0000-0001-8218-9465
FU FAPESPFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
   [2012/15381-7, 2012/51204-2, 2011/51761-6]
FX This work was funded by FAPESP grants 2012/15381-7, 2012/51204-2, and
   2011/51761-6.
CR Amorim JH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044984
   ANDERSON CR, 1956, SCIENCE, V124, P224, DOI 10.1126/science.124.3214.224
   Bray M, 1998, J VIROL, V72, P1647, DOI 10.1128/JVI.72.2.1647-1651.1998
   Romano CM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070318
NR 4
TC 1
Z9 1
U1 0
U2 0
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 2576-098X
J9 MICROBIOL RESOUR ANN
JI Microbiol. Resour. Ann.
PD JUL-AUG
PY 2015
VL 3
IS 4
AR e00779-15
DI 10.1128/genomeA.00779-15
PG 2
WC Microbiology
SC Microbiology
GA VI1DL
UT WOS:000460635800071
PM 26184939
OA Green Published, Other Gold
DA 2020-12-01
ER

PT J
AU Amorim, JH
   Bizerra, R
   Alves, RPD
   Fabris, DLN
   Ferreira, LCD
AF Amorim, Jaime Henrique
   Bizerra, Raiza
   dos Santos Alves, Rubens Prince
   Nascimento Fabris, Denicar Lina
   de Souza Ferreira, Luis Carlos
TI Dengue virus models based on mice as experimental hosts
SO FUTURE VIROLOGY
LA English
DT Review
DE dengue virus; mouse models; vaccine
ID ANTIBODY-DEPENDENT ENHANCEMENT; NONSTRUCTURAL PROTEIN NS1; HUMANIZED BLT
   MICE; T-CELL RESPONSES; WEST-NILE-VIRUS; MOUSE MODEL; IMMUNE-RESPONSES;
   DOMAIN-III; PROTECTIVE IMMUNITY; VACCINE DEVELOPMENT
AB Dengue virus (DENV) causes dengue fever, a widely distributed endemic disease transmitted by mosquitoes. The complex interaction of DENV with the human immune system has complicated the development of an effective vaccine. This may be attributed, at least in part, to the lack of a suitable animal model capable to reproduce symptoms observed in humans. Mouse models are simple but usually rely on host-adapted virus strains or immunodeficient mouse lineages. Recent evidences indicated that some natural DENV strains are capable to infect immunocompetent mice. In addition, humanized mouse lineages can more faithfully reproduce some of the symptoms observed in humans. Such experimental models are valuable tools for the study of DENV biology.
C1 [Amorim, Jaime Henrique; Bizerra, Raiza; dos Santos Alves, Rubens Prince; Nascimento Fabris, Denicar Lina; de Souza Ferreira, Luis Carlos] Univ Sao Paulo, Dept Microbiol, Vaccine Dev Lab, ICB 2, BR-05508000 Sao Paulo, SP, Brazil.
RP Amorim, JH (corresponding author), Univ Sao Paulo, Dept Microbiol, Vaccine Dev Lab, ICB 2, Av Prof Lineu Prestes,1374,Cidade Univ, BR-05508000 Sao Paulo, SP, Brazil.
EM jhamorim@usp.br
RI Amorim, Jaime Henrique/O-9222-2017; Ferreira, Luis/M-3954-2014
OI Amorim, Jaime Henrique/0000-0002-0623-2879; Ferreira,
   Luis/0000-0002-4883-1693
FU FAPESPFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
   [2011/51.761-6]
FX The authors are grateful for the financial support of FAPESP (process
   number 2011/51.761-6). The authors have no other relevant affiliations
   or financial involvement with any organization or entity with a
   financial interest in or financial conflict with the subject matter or
   materials discussed in the manuscript apart from those disclosed.
CR Aguirre S, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002934
   Akkina R, 2013, VIROLOGY, V435, P14, DOI 10.1016/j.virol.2012.10.007
   Althouse BM, 2014, VIROLOGY, V452, P237, DOI 10.1016/j.virol.2014.01.015
   Amorim JH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044984
   Amorim JH, 2012, VACCINE, V30, P837, DOI 10.1016/j.vaccine.2011.12.034
   An J, 1999, VIROLOGY, V263, P70, DOI 10.1006/viro.1999.9887
   Atrasheuskaya A, 2003, FEMS IMMUNOL MED MIC, V35, P33, DOI 10.1111/j.1574-695X.2003.tb00646.x
   Avirutnan P, 1998, J IMMUNOL, V161, P6338
   Avirutnan P, 2010, J EXP MED, V207, P793, DOI 10.1084/jem.20092545
   Azevedo AS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020528
   Balsitis SJ, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000790
   Bente DA, 2005, J VIROL, V79, P13797, DOI 10.1128/JVI.79.21.13797-13799.2005
   Berges BK, 2011, RETROVIROLOGY, V8, DOI 10.1186/1742-4690-8-65
   Bhatt S, 2013, NATURE, V496, P504, DOI 10.1038/nature12060
   Biswas S, 2011, IMMUNOLOGY, V134, P419, DOI 10.1111/j.1365-2567.2011.03501.x
   Blaney JE, 2005, J VIROL, V79, P5516, DOI 10.1128/JVI.79.9.5516-5528.2005
   Bray M, 1998, J VIROL, V72, P1647, DOI 10.1128/JVI.72.2.1647-1651.1998
   Cabrera-Hernandez A, 2007, J MED VIROL, V79, P386, DOI 10.1002/jmv.20786
   Cassetti MC, 2010, VACCINE, V28, P4229, DOI 10.1016/j.vaccine.2010.04.045
   Chen HC, 2007, J VIROL, V81, P5518, DOI 10.1128/JVI.02575-06
   Chen YP, 1997, NAT MED, V3, P866, DOI 10.1038/nm0897-866
   Chiang CY, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002432
   Chiang CY, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001645
   Christofferson RC, 2013, VIROL J, V10, DOI 10.1186/1743-422X-10-127
   Chu JJH, 2006, VIROLOGY, V349, P463, DOI 10.1016/j.virol.2006.01.022
   Chu JJH, 2004, J BIOL CHEM, V279, P54533, DOI 10.1074/jbc.M410208200
   Costa SM, 2007, VIROLOGY, V358, P413, DOI 10.1016/j.virol.2006.08.052
   Costa SM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025685
   Cox J, 2012, J VIROL, V86, P7637, DOI 10.1128/JVI.00534-12
   Crill WD, 2001, J VIROL, V75, P7769, DOI 10.1128/JVI.75.16.7769-7773.2001
   Edelman R, 2003, AM J TROP MED HYG, V69, P48, DOI 10.4269/ajtmh.2003.69.48
   Edgil D, 2003, VIROLOGY, V317, P275, DOI 10.1016/j.virol.2003.08.012
   Ferreira GP, 2010, MICROBES INFECT, V12, P546, DOI 10.1016/j.micinf.2010.03.007
   Frias-Staheli N, 2014, J VIROL, V88, P2205, DOI 10.1128/JVI.03085-13
   Goncalves D, 2012, THESCIENTIFICWORLDJO, V2012
   Gromowski GD, 2007, VIROLOGY, V366, P349, DOI 10.1016/j.virol.2007.05.042
   Guirakhoo F, 2001, J VIROL, V75, P7290, DOI 10.1128/JVI.75.16.7290-7304.2001
   Guy B, 2011, LANCET, V377, P381, DOI 10.1016/S0140-6736(11)60128-1
   Guzman MG, 2010, NAT REV MICROBIOL, pS7, DOI 10.1038/nrmicro2460
   HALSTEAD SB, 1980, B WORLD HEALTH ORGAN, V58, P1
   HALSTEAD SB, 1973, J INFECT DIS, V128, P7, DOI 10.1093/infdis/128.1.7
   HALSTEAD SB, 1981, INFECT IMMUN, V31, P102, DOI 10.1128/IAI.31.1.102-106.1981
   HAMMON WM, 1960, SCIENCE, V131, P1102, DOI 10.1126/science.131.3407.1102
   HENCHAL EA, 1990, CLIN MICROBIOL REV, V3, P376, DOI 10.1128/CMR.3.4.376-396.1990
   Henriques HR, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002330
   Huang CYH, 2003, J VIROL, V77, P11436, DOI 10.1128/JVI.77.21.11436-11447.2003
   Huang KJ, 2006, J IMMUNOL, V176, P2825, DOI 10.4049/jimmunol.176.5.2825
   Jaiswal S, 2012, IMMUNOLOGY, V136, P334, DOI 10.1111/j.1365-2567.2012.03585.x
   Johnson AJ, 1999, J VIROL, V73, P783, DOI 10.1128/JVI.73.1.783-786.1999
   Kuruvilla JG, 2007, VIROLOGY, V369, P143, DOI 10.1016/j.virol.2007.06.005
   Kyle JL, 2008, VIROLOGY, V380, P296, DOI 10.1016/j.virol.2008.08.008
   Lan P, 2006, BLOOD, V108, P487, DOI 10.1182/blood-2005-11-4388
   Lawson D, 2007, NUCLEIC ACIDS RES, V35, pD503, DOI 10.1093/nar/gkl960
   Legrand N, 2009, CELL HOST MICROBE, V6, P5, DOI 10.1016/j.chom.2009.06.006
   Lin YL, 1998, J VIROL, V72, P9729, DOI 10.1128/JVI.72.12.9729-9737.1998
   LITTAUA R, 1990, J IMMUNOL, V144, P3183
   Lozach PY, 2005, J BIOL CHEM, V280, P23698, DOI 10.1074/jbc.M504337200
   Markoff L, 2003, ADV VIRUS RES, V59, P177, DOI 10.1016/S0065-3527(03)59006-6
   Melkus MW, 2006, NAT MED, V12, P1316, DOI 10.1038/nm1431
   Miller JL, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.0040017
   Morrison J, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003265
   Mota J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020762
   Mota J, 2009, J VIROL, V83, P8638, DOI 10.1128/JVI.00581-09
   Nene V, 2007, SCIENCE, V316, P1718, DOI 10.1126/science.1138878
   Pham TB, 2009, J CLIN VIROL, V45, P276, DOI 10.1016/j.jcv.2009.04.004
   QU XY, 1993, J GEN VIROL, V74, P89, DOI 10.1099/0022-1317-74-1-89
   Rajmane Y, 2013, VIRUS RES, V173, P386, DOI 10.1016/j.virusres.2013.01.002
   Ren JP, 2007, VIROL J, V4, DOI 10.1186/1743-422X-4-83
   Sabchareon A, 2012, LANCET, V380, P1559, DOI 10.1016/S0140-6736(12)61428-7
   SABIN AB, 1945, SCIENCE, V101, P640, DOI 10.1126/science.101.2634.640
   SABIN ALBERT B., 1952, AMER JOUR TROP MED AND HYG, V1, P30
   SCHERER WF, 1978, AM J TROP MED HYG, V27, P590, DOI 10.4269/ajtmh.1978.27.590
   SCHLESINGER JJ, 1987, J GEN VIROL, V68, P853, DOI 10.1099/0022-1317-68-3-853
   Sessions OM, 2009, NATURE, V458, P1047, DOI 10.1038/nature07967
   Shresta S, 2006, J VIROL, V80, P10208, DOI 10.1128/JVI.00062-06
   Shultz LD, 2010, P NATL ACAD SCI USA, V107, P13022, DOI 10.1073/pnas.1000475107
   SRIVASTAVA AK, 1995, VACCINE, V13, P1251, DOI 10.1016/0264-410X(94)00059-V
   Stoddart CA, 2011, VIROLOGY, V417, P154, DOI 10.1016/j.virol.2011.05.013
   Tan GK, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000672
   Tanner L, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000196
   Traggiai E, 2004, SCIENCE, V304, P104, DOI 10.1126/science.1093933
   Tuiskunen A, 2011, VIROL J, V8, DOI 10.1186/1743-422X-8-398
   van der Schaar HM, 2007, J VIROL, V81, P12019, DOI 10.1128/JVI.00300-07
   van der Schaar HM, 2009, IMMUNOBIOLOGY, V214, P613, DOI 10.1016/j.imbio.2008.11.008
   VANDENBROEK MF, 1995, J VIROL, V69, P4792, DOI 10.1128/JVI.69.8.4792-4796.1995
   Villar L, 2014, NEW ENGL J MED, V372
   Weiskopf D, 2011, J IMMUNOL, V187, P4268, DOI 10.4049/jimmunol.1101970
   WENGLER G, 1978, VIROLOGY, V89, P423, DOI 10.1016/0042-6822(78)90185-X
   Whitehead SS, 2007, NAT REV MICROBIOL, V5, P518, DOI 10.1038/nrmicro1690
   World Health Organization (WHO), DENG SEV DENG
   Wu SF, 2003, VACCINE, V21, P3919, DOI 10.1016/S0264-410X(03)00310-4
   WU SJL, 1995, AM J TROP MED HYG, V52, P468, DOI 10.4269/ajtmh.1995.52.468
   Wu-Hsieh BA, 2009, ANN NY ACAD SCI, V1171, pE42, DOI 10.1111/j.1749-6632.2009.05053.x
   Yauch LE, 2014, ADV VIRUS RES, V88, P315, DOI 10.1016/B978-0-12-800098-4.00007-6
   Yu CY, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002780
   Zellweger RM, 2010, CELL HOST MICROBE, V7, P128, DOI 10.1016/j.chom.2010.01.004
   ZHANG YM, 1988, J VIROL, V62, P3027, DOI 10.1128/JVI.62.8.3027-3031.1988
   Zompi S, 2012, VIRUSES-BASEL, V4, P62, DOI 10.3390/v4010062
   Zust R, 2014, J VIROL, V88, P7276, DOI 10.1128/JVI.03827-13
NR 99
TC 1
Z9 1
U1 0
U2 3
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
   1QB, ENGLAND
SN 1746-0794
EI 1746-0808
J9 FUTURE VIROL
JI Future Virol.
PY 2015
VL 10
IS 7
BP 835
EP 844
DI 10.2217/FVL.15.48
PG 10
WC Virology
SC Virology
GA CO6KR
UT WOS:000359266100005
DA 2020-12-01
ER

PT J
AU Amorim, JH
   Alves, RPD
   Boscardin, SB
   Ferreira, LCD
AF Amorim, Jaime Henrique
   dos Santos Alves, Rubens Prince
   Boscardin, Silvia Beatriz
   de Souza Ferreira, Luis Carlos
TI The dengue virus non-structural 1 protein: Risks and benefits
SO VIRUS RESEARCH
LA English
DT Review
DE Dengue virus; NS1 protein; Pathogenesis; Antiviral; Vaccine; Diagnosis
ID CD8(-) DENDRITIC CELLS; NS1 PROTEIN; PROTECTIVE EFFICACY;
   ENDOTHELIAL-CELLS; GLYCOPROTEIN NS1; LETHAL CHALLENGE; DNA VACCINE;
   RAPID TEST; T-CELLS; ANTIGEN
AB The dengue virus (DENV) non-structural 1 (NS1) protein plays a critical role in viral RNA replication and has a central position in DENV pathogenesis. DENV NS1 is a glycoprotein expressed in infected mammalian cells as soluble monomers that dimerize in the lumen of the endoplasmic reticulum; NS1 is subsequently transported to the cell surface, where it remains membrane associated or is secreted into the extracellular milieu as a hexameric complex. During the last three decades, the DENV NS1 protein has also been intensively investigated as a potential target for vaccines antiviral drugs. In addition, NS1 is the major diagnostic marker for dengue infection. This review highlights some important issues regarding the role of NS1 in DENV pathogenesis and its biotechnological applications, both as a target for the development of safe and effective vaccines and antiviral drugs and as a tool for the generation of accurate diagnostic methods. (C) 2014 Elsevier B.V. All rights reserved.
C1 [Amorim, Jaime Henrique; dos Santos Alves, Rubens Prince; de Souza Ferreira, Luis Carlos] Univ Sao Paulo, Dept Microbiol, Vaccine Dev Lab, BR-05508000 Sao Paulo, Brazil.
   [Boscardin, Silvia Beatriz] Univ Sao Paulo, Dept Parasitol, Lab Antigen Targeting Dendrit Cells, BR-05508000 Sao Paulo, Brazil.
RP Amorim, JH (corresponding author), Univ Sao Paulo, ICB 2, Dept Microbiol, Vaccine Dev Lab, Av Prof Lineu Prestes 1374,Cidade Univ, BR-05508000 Sao Paulo, Brazil.
EM jhamorim@usp.br
RI Ferreira, Luis Carlos S/M-3954-2014; Amorim, Jaime Henrique/O-9222-2017;
   Boscardin, Silvia Beatriz/C-3397-2012
OI Ferreira, Luis Carlos S/0000-0002-4883-1693; Amorim, Jaime
   Henrique/0000-0002-0623-2879; Boscardin, Silvia
   Beatriz/0000-0002-7845-7110; Alves, Rubens/0000-0001-5538-6025
FU FAPESPFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
   [2011/51.761-6, 2007/08648-8]; CNPqNational Council for Scientific and
   Technological Development (CNPq) [INCTV 15203*8, 15203*12]
FX We are grateful for the financial support of FAPESP (2011/51.761-6 and
   2007/08648-8) and CNPq grants (INCTV 15203*8 and 15203*12).
CR Alcon S, 2002, J CLIN MICROBIOL, V40, P376, DOI 10.1128/JCM.40.02.376-381.2002
   Amorim JH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044984
   Amorim JH, 2012, VACCINE, V30, P837, DOI 10.1016/j.vaccine.2011.12.034
   Avirutnan P, 2007, PLOS PATHOG, V3, P1798, DOI 10.1371/journal.ppat.0030183
   Avirutnan P, 2011, J IMMUNOL, V187, P424, DOI 10.4049/jimmunol.1100750
   Avirutnan P, 2010, J EXP MED, V207, P793, DOI 10.1084/jem.20092545
   Bhatt S, 2013, NATURE, V496, P504, DOI 10.1038/nature12060
   Blacksell SD, 2012, CLIN VACCINE IMMUNOL, V19, P804, DOI 10.1128/CVI.05717-11
   Chaiyaratana W, 2009, DIAGN MICR INFEC DIS, V64, P83, DOI 10.1016/j.diagmicrobio.2009.01.004
   Chaterji S, 2011, AM J TROP MED HYG, V84, P224, DOI 10.4269/ajtmh.2011.10-0316
   Chen MC, 2009, J IMMUNOL, V183, P1797, DOI 10.4049/jimmunol.0800672
   Cheng HJ, 2009, MOL IMMUNOL, V47, P398, DOI 10.1016/j.molimm.2009.08.033
   Costa SM, 2007, VIROLOGY, V358, P413, DOI 10.1016/j.virol.2006.08.052
   Costa SM, 2006, VACCINE, V24, P195, DOI 10.1016/j.vaccine.2005.07.059
   den Haan JMM, 2002, J EXP MED, V196, P817, DOI 10.1084/jem.20020295
   den Haan JMM, 2000, J EXP MED, V192, P1685, DOI 10.1084/jem.192.12.1685
   Dussart P, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000280
   Falconar AKI, 1997, ARCH VIROL, V142, P897, DOI 10.1007/s007050050127
   Falconar AKI, 2007, CLIN VACCINE IMMUNOL, V14, P493, DOI 10.1128/CVI.00371-06
   Falconar AKI, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021024
   FALGOUT B, 1989, J VIROL, V63, P1852, DOI 10.1128/JVI.63.5.1852-1860.1989
   FALGOUT B, 1995, J VIROL, V69, P7232, DOI 10.1128/JVI.69.11.7232-7243.1995
   FALGOUT B, 1990, J VIROL, V64, P4356, DOI 10.1128/JVI.64.9.4356-4363.1990
   Flamand M, 1999, J VIROL, V73, P6104, DOI 10.1128/JVI.73.7.6104-6110.1999
   Fry SR, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001199
   Groen J, 2000, CLIN DIAGN LAB IMMUN, V7, P867, DOI 10.1128/CDLI.7.6.867-871.2000
   Gubler DJ, 1999, ADV VIRUS RES, V53, P35, DOI 10.1016/S0065-3527(08)60342-5
   Gubler DJ, 1998, CLIN MICROBIOL REV, V11, P480, DOI 10.1128/CMR.11.3.480
   Guzman MG, 2010, NAT REV MICROBIOL, pS7, DOI 10.1038/nrmicro2460
   Halstead SB, 2007, LANCET, V370, P1644, DOI 10.1016/S0140-6736(07)61687-0
   Hang VT, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000360
   HENCHAL EA, 1988, J GEN VIROL, V69, P2101, DOI 10.1099/0022-1317-69-8-2101
   Henriques HR, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002330
   Huang SS, 2013, INT J NANOMED, V8, P3161, DOI 10.2147/IJN.S49972
   Kalluri S, 2007, PLOS PATHOG, V3, P1361, DOI 10.1371/journal.ppat.0030116
   Koraka P, 2002, MICROBES INFECT, V4, P1209, DOI 10.1016/S1286-4579(02)01647-7
   Kurosu T, 2007, BIOCHEM BIOPH RES CO, V362, P1051, DOI 10.1016/j.bbrc.2007.08.137
   LANCIOTTI RS, 1992, J CLIN MICROBIOL, V30, P545, DOI 10.1128/JCM.30.3.545-551.1992
   Lemes EMB, 2005, J CLIN VIROL, V32, P305, DOI 10.1016/j.jcv.2004.08.015
   Lin CF, 2003, J MED VIROL, V69, P82, DOI 10.1002/jmv.10261
   Lin CF, 2002, J IMMUNOL, V169, P657, DOI 10.4049/jimmunol.169.2.657
   Lin CF, 2001, J MED VIROL, V63, P143, DOI 10.1002/1096-9071(20000201)63:2&lt;143::AID-JMV1009&gt;3.0.CO;2-L
   Lin CF, 2006, VIRAL IMMUNOL, V19, P127, DOI 10.1089/vim.2006.19.127
   Lin SW, 2012, J INFECTION, V64, P325, DOI 10.1016/j.jinf.2011.11.023
   Lindenbach BD, 1997, J VIROL, V71, P9608, DOI 10.1128/JVI.71.12.9608-9617.1997
   Lindenbach BD, 2001, FIELDS VIROLOGY, VII, P991, DOI DOI 10.1016/J.JMB.2013.11.024
   Mackenzie JM, 1996, VIROLOGY, V220, P232, DOI 10.1006/viro.1996.0307
   Martina BEE, 2009, CLIN MICROBIOL REV, V22, P564, DOI 10.1128/CMR.00035-09
   Mohan S, 2012, INT J ANTIMICROB AG, V40, P273, DOI 10.1016/j.ijantimicag.2012.05.002
   Muller DA, 2013, ANTIVIR RES, V98, P192, DOI 10.1016/j.antiviral.2013.03.008
   Muller DA, 2012, ANAL CHEM, V84, P3262, DOI 10.1021/ac2034387
   Muylaert IR, 1996, VIROLOGY, V222, P159, DOI 10.1006/viro.1996.0406
   *PAHO, 1994, DENG DENG HEM FEV AM
   Pongsumpun P, 2008, TROP MED INT HEALTH, V13, P1180, DOI 10.1111/j.1365-3156.2008.02124.x
   Pooley JL, 2001, J IMMUNOL, V166, P5327, DOI 10.4049/jimmunol.166.9.5327
   PRYOR MJ, 1994, J GEN VIROL, V75, P1183, DOI 10.1099/0022-1317-75-5-1183
   QU XY, 1993, J GEN VIROL, V74, P89, DOI 10.1099/0022-1317-74-1-89
   Rajapakse Senaka, 2011, J Emerg Trauma Shock, V4, P120, DOI 10.4103/0974-2700.76835
   Ramirez AH, 2009, DIAGN MICR INFEC DIS, V65, P247, DOI 10.1016/j.diagmicrobio.2009.07.022
   Rathore APS, 2011, ANTIVIR RES, V92, P453, DOI 10.1016/j.antiviral.2011.10.002
   Sampath A, 2009, ANTIVIR RES, V81, P6, DOI 10.1016/j.antiviral.2008.08.004
   SCHLESINGER JJ, 1987, J GEN VIROL, V68, P853, DOI 10.1099/0022-1317-68-3-853
   SRIVASTAVA AK, 1995, VACCINE, V13, P1251, DOI 10.1016/0264-410X(94)00059-V
   TDR/WHO, 2009, DENG GUID DIAGN TREA, P23
   Vaughn DW, 2000, J INFECT DIS, V181, P2, DOI 10.1086/315215
   Vaughn DW, 1997, J INFECT DIS, V176, P322, DOI 10.1086/514048
   Vazquez S, 2010, DIAGN MICR INFEC DIS, V68, P46, DOI 10.1016/j.diagmicrobio.2010.04.006
   Watanabe S, 2012, ANTIVIR RES, V96, P32, DOI 10.1016/j.antiviral.2012.07.008
   Whitby K, 2005, J VIROL, V79, P8698, DOI 10.1128/JVI.79.14.8698-8706.2005
   Whitehead SS, 2007, NAT REV MICROBIOL, V5, P518, DOI 10.1038/nrmicro1690
   WINKLER G, 1988, VIROLOGY, V162, P187, DOI 10.1016/0042-6822(88)90408-4
   World Health Organization, 1997, DENG HAEM FEV DIAGN
   Wu SF, 2003, VACCINE, V21, P3919, DOI 10.1016/S0264-410X(03)00310-4
   Young PR, 2000, J CLIN MICROBIOL, V38, P1053, DOI 10.1128/JCM.38.3.1053-1057.2000
   Zainah S, 2009, J VIROL METHODS, V155, P157, DOI 10.1016/j.jviromet.2008.10.016
   ZHANG YM, 1988, J VIROL, V62, P3027, DOI 10.1128/JVI.62.8.3027-3031.1988
   Zhou JM, 2006, VIRUS GENES, V33, P27, DOI 10.1007/s11262-005-0036-6
NR 77
TC 42
Z9 45
U1 0
U2 14
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0168-1702
EI 1872-7492
J9 VIRUS RES
JI Virus Res.
PD MAR 6
PY 2014
VL 181
BP 53
EP 60
DI 10.1016/j.virusres.2014.01.001
PG 8
WC Virology
SC Virology
GA AD1OE
UT WOS:000333002500008
PM 24434336
DA 2020-12-01
ER

PT J
AU de Souza, RD
   Batista, MT
   Luiz, WB
   Cavalcante, RCM
   Amorim, JH
   Bizerra, RSP
   Martins, EG
   Ferreira, LCD
AF de Souza, Renata Damasio
   Batista, Milene Tavares
   Luiz, Wilson Barros
   Marques Cavalcante, Rafael Ciro
   Amorim, Jaime Henrique
   Pereira Bizerra, Raiza Sales
   Martins, Eduardo Gimenes
   de Souza Ferreira, Luis Carlos
TI Bacillus subtilis Spores as Vaccine Adjuvants: Further Insights into the
   Mechanisms of Action
SO PLOS ONE
LA English
DT Article
ID IMMUNE-RESPONSE; ENDOSPORES; DELIVERY
AB Bacillus subtilis spores have received growing attention regarding potential biotechnological applications, including the use as probiotics and in vaccine formulations. B. subtilis spores have also been shown to behave as particulate vaccine adjuvants, promoting the increase of antibody responses after co-administration with antigens either admixed or adsorbed on the spore surface. In this study, we further evaluated the immune modulatory properties of B. subtilis spores using a recombinant HIV gag p24 protein as a model antigen. The adjuvant effects of B. subtilis spores were not affected by the genetic background of the mouse lineage and did not induce significant inflammatory or deleterious effects after parenteral administration. Our results demonstrated that co-administration, but not adsorption to the spore surface, enhanced the immunogenicity of that target antigen after subcutaneous administration to BALB/c and C57BL/6 mice. Spores promoted activation of antigen presenting cells as demonstrated by the upregulation of MHC and CD40 molecules and enhanced secretion of pro-inflammatory cytokines by murine dendritic cells. In addition, in vivo studies indicated a direct role of the innate immunity on the immunomodulatory properties of B. subtilis spores, as demonstrated by the lack of adjuvant effects on MyD88 and TLR2 knockout mouse strains.
C1 [de Souza, Renata Damasio; Batista, Milene Tavares; Luiz, Wilson Barros; Amorim, Jaime Henrique; Pereira Bizerra, Raiza Sales; Martins, Eduardo Gimenes; de Souza Ferreira, Luis Carlos] Univ Sao Paulo, Vaccine Dev Lab, Inst Biomed Sci, Dept Microbiol, Sao Paulo, Brazil.
   [Marques Cavalcante, Rafael Ciro] Univ Sao Paulo, Inst Biomed Sci, Dept Parasitol, Sao Paulo, Brazil.
RP Ferreira, LCD (corresponding author), Univ Sao Paulo, Vaccine Dev Lab, Inst Biomed Sci, Dept Microbiol, Sao Paulo, Brazil.
EM lcsf@usp.br
RI Luiz, Wilson/H-2073-2012; Amorim, Jaime Henrique/O-9222-2017; Luiz,
   Wilson/L-7575-2015; Ferreira, Luis/M-3954-2014
OI Luiz, Wilson/0000-0001-5219-6699; Amorim, Jaime
   Henrique/0000-0002-0623-2879; Luiz, Wilson/0000-0003-3265-8547;
   Ferreira, Luis/0000-0002-4883-1693
FU Foundation of the State of SApoundo Paulo(FAPESP); National Counsel of
   Technological and Scientific Development (CNPq)National Council for
   Scientific and Technological Development (CNPq)
FX This work was supported by grants from the Foundation of the State of SA
   o pound Paulo(FAPESP) and the National Counsel of Technological and
   Scientific Development (CNPq). The funders had no role in study design,
   data collection and analysis, decision to publish, or preparation of the
   manuscript.
CR AIDA Y, 1990, J IMMUNOL METHODS, V132, P191, DOI 10.1016/0022-1759(90)90029-U
   Amorim JH, 2012, VACCINE, V30, P837, DOI 10.1016/j.vaccine.2011.12.034
   Amuguni H, 2012, HUM VACC IMMUNOTHER, V8, DOI 10.4161/hv.20694
   Barnes AGC, 2007, EUR J IMMUNOL, V37, P1538, DOI 10.1002/eji.200636875
   Bozzacco L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041897
   Breyhan H, 2009, ACTA NEUROPATHOL, V117, P677, DOI 10.1007/s00401-009-0539-7
   Christmas P, 2010, NAT ED, V3, P85
   Cutting SM, 2011, FOOD MICROBIOL, V28, P214, DOI 10.1016/j.fm.2010.03.007
   DEUERLING E, 1995, J BACTERIOL, V177, P4105, DOI 10.1128/jb.177.14.4105-4112.1995
   Fierens K, 2012, CURR PHARM DESIGN, V18, P2305, DOI 10.2174/138161212800166004
   Heegaard PMH, 2011, ARCH VIROL, V156, P183, DOI 10.1007/s00705-010-0863-1
   Huang JM, 2008, FEMS IMMUNOL MED MIC, V53, P195, DOI 10.1111/j.1574-695X.2008.00415.x
   Huang JM, 2010, VACCINE, V28, P1021, DOI 10.1016/j.vaccine.2009.10.127
   Lambrecht BN, 2009, CURR OPIN IMMUNOL, V21, P23, DOI 10.1016/j.coi.2009.01.004
   Li XM, 2012, CLIN VACCINE IMMUNOL, V19, P723, DOI 10.1128/CVI.05700-11
   Liard C, 2011, VACCINE, V29, P6379, DOI 10.1016/j.vaccine.2011.04.080
   Marim FM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015263
   Miyaji EN, 2011, BRAZ J MED BIOL RES, V44, P500, DOI 10.1590/S0100-879X2011007500064
   Montomoli E, 2011, EXPERT REV VACCINES, V10, P1053, DOI [10.1586/erv.11.48, 10.1586/ERV.11.48]
   Negri A, 2013, J MED MICROBIOL, V62, P1379, DOI 10.1099/jmm.0.057372-0
   Nicholson WL, 2000, MICROBIOL MOL BIOL R, V64, P548, DOI 10.1128/MMBR.64.3.548-572.2000
   O'Hagan DT, 2003, NAT REV DRUG DISCOV, V2, P727, DOI 10.1038/nrd1176
   Paccez JD, 2007, VACCINE, V25, P4671, DOI 10.1016/j.vaccine.2007.04.021
   Reed SG, 2009, TRENDS IMMUNOL, V30, P23, DOI 10.1016/j.it.2008.09.006
   Rodrigues JF, 2011, J BIOL CHEM, V286, P5222, DOI 10.1074/jbc.M110.173682
   Song M, 2012, VACCINE, V30, P3266, DOI 10.1016/j.vaccine.2012.03.016
   Tagliamonte M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043318
   Tavares MB, 2013, CURR MICROBIOL, V66, P279, DOI 10.1007/s00284-012-0269-2
   Tavares MB, 2010, FEMS IMMUNOL MED MIC, V59, P131, DOI 10.1111/j.1574-695X.2010.00669.x
   Visciano ML, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-4
   Watanabe H, 2004, SHOCK, V22, P460, DOI 10.1097/01.shk.0000142249.08135.e9
   Wehrl W, 2000, J BACTERIOL, V182, P3870, DOI 10.1128/JB.182.13.3870-3873.2000
   Zanoni I, 2009, NATURE, V460, P264, DOI 10.1038/nature08118
NR 33
TC 21
Z9 22
U1 0
U2 10
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 27
PY 2014
VL 9
IS 1
AR e87454
DI 10.1371/journal.pone.0087454
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 301BI
UT WOS:000330507300184
PM 24475289
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Henriques, HR
   Rampazo, EV
   Goncalves, AJS
   Vicentin, ECM
   Amorim, JH
   Panatieri, RH
   Amorim, KNS
   Yamamoto, MM
   Ferreira, LCS
   Alves, AMB
   Boscardin, SB
AF Henriques, Hugo R.
   Rampazo, Eline V.
   Goncalves, Antonio J. S.
   Vicentin, Elaine C. M.
   Amorim, Jaime H.
   Panatieri, Raquel H.
   Amorim, Kelly N. S.
   Yamamoto, Marcio M.
   Ferreira, Luis C. S.
   Alves, Ada M. B.
   Boscardin, Silvia B.
TI Targeting the Non-structural Protein 1 from Dengue Virus to a Dendritic
   Cell Population Confers Protective Immunity to Lethal Virus Challenge
SO PLOS NEGLECTED TROPICAL DISEASES
LA English
DT Article
ID LCRV VIRULENCE PROTEIN; IN-VIVO; HIV GAG; T-CELLS; NS1 PROTEIN; ANTIGEN
   PRESENTATION; ANTIBODY-RESPONSES; ENDOTHELIAL-CELLS; GLYCOPROTEIN NS1;
   RECEPTOR DEC-205
AB Dengue is the most prevalent arboviral infection, affecting millions of people every year. Attempts to control such infection are being made, and the development of a vaccine is a World Health Organization priority. Among the proteins being tested as vaccine candidates in preclinical settings is the non-structural protein 1 (NS1). In the present study, we tested the immune responses generated by targeting the NS1 protein to two different dendritic cell populations. Dendritic cells (DCs) are important antigen presenting cells, and targeting proteins to maturing DCs has proved to be an efficient means of immunization. Antigen targeting is accomplished by the use of a monoclonal antibody (mAb) directed against a DC cell surface receptor fused to the protein of interest. We used two mAbs (alpha DEC205 and alpha DCIR2) to target two distinct DC populations, expressing either DEC205 or DCIR2 endocytic receptors, respectively, in mice. The fusion mAbs were successfully produced, bound to their respective receptors, and were used to immunize BALB/c mice in the presence of polyriboinosinic: polyribocytidylic acid (poly (I:C)), as a DC maturation stimulus. We observed induction of strong anti-NS1 antibody responses and similar antigen binding affinity irrespectively of the DC population targeted. Nevertheless, the IgG1/IgG2a ratios were different between mouse groups immunized with alpha DEC-NS1 and alpha DCIR2-NS1 mAbs. When we tested the induction of cellular immune responses, the number of IFN-gamma producing cells was higher in alpha DEC-NS1 immunized animals. In addition, mice immunized with the alpha DEC-NS1 mAb were significantly protected from a lethal intracranial challenge with the DENV2 NGC strain when compared to mice immunized with alpha DCIR2-NS1 mAb. Protection was partially mediated by CD4(+) and CD8(+) T cells as depletion of these populations reduced both survival and morbidity signs. We conclude that targeting the NS1 protein to the DEC205(+) DC population with poly (I:C) opens perspectives for dengue vaccine development.
C1 [Henriques, Hugo R.; Rampazo, Eline V.; Vicentin, Elaine C. M.; Panatieri, Raquel H.; Amorim, Kelly N. S.; Yamamoto, Marcio M.; Boscardin, Silvia B.] Univ Sao Paulo, Lab Antigen Targeting Dendrit Cells, Dept Parasitol, Sao Paulo, Brazil.
   [Goncalves, Antonio J. S.; Alves, Ada M. B.] Fundacao Oswaldo Cruz, Lab Biotechnol & Physiol Viral Infect, Inst Oswaldo Cruz, Rio De Janeiro, Brazil.
   [Amorim, Jaime H.; Ferreira, Luis C. S.] Univ Sao Paulo, Lab Vaccine Dev, Dept Microbiol, Sao Paulo, Brazil.
   [Ferreira, Luis C. S.; Alves, Ada M. B.; Boscardin, Silvia B.] Natl Inst Sci & Technol Vaccines, Belo Horizonte, MG, Brazil.
RP Henriques, HR (corresponding author), Univ Sao Paulo, Lab Antigen Targeting Dendrit Cells, Dept Parasitol, Sao Paulo, Brazil.
EM sbboscardin@usp.br
RI Ferreira, Luis Carlos S/M-3954-2014; Amorim, Jaime Henrique/O-9222-2017;
   Boscardin, Silvia Beatriz/C-3397-2012
OI Ferreira, Luis Carlos S/0000-0002-4883-1693; Amorim, Jaime
   Henrique/0000-0002-0623-2879; Boscardin, Silvia
   Beatriz/0000-0002-7845-7110
FU Brazilian National Research Council (CNPq)/National Institutes of
   Science and Technology in Vaccines (INCTV) [15203*12]; Sao Paulo State
   Research Funding Agency (FAPESP)Fundacao de Amparo a Pesquisa do Estado
   de Sao Paulo (FAPESP) [2007/08648-9, 2011/51761-6]; BNP-Paribas Bank;
   Rio de Janeiro State Research Funding Agency (FAPERJ); FAPESPFundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2010/03079-9,
   2009/5033-7]; CAPESCAPES
FX This research was supported by the Brazilian National Research Council
   (CNPq)/National Institutes of Science and Technology in Vaccines (INCTV,
   15203*12), Sao Paulo State Research Funding Agency (FAPESP,
   2007/08648-9, 2011/51761-6), BNP-Paribas Bank and Rio de Janeiro State
   Research Funding Agency (FAPERJ). HRH and JHA received fellowships from
   FAPESP (2010/03079-9 and 2009/5033-7) and EVR received a fellowship from
   CAPES. The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR Alcon S, 2002, J CLIN MICROBIOL, V40, P376, DOI 10.1128/JCM.40.02.376-381.2002
   Amorim JH, 2012, VACCINE, V30, P837, DOI 10.1016/j.vaccine.2011.12.034
   Amorim JH, 2010, J VIROL METHODS, V167, P186, DOI 10.1016/j.jviromet.2010.04.003
   Azevedo AS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020528
   Bonifaz L, 2002, J EXP MED, V196, P1627, DOI 10.1084/jem.20021598
   Bonifaz LC, 2004, J EXP MED, V199, P815, DOI 10.1084/jem.20032220
   Boscardin SB, 2006, J EXP MED, V203, P599, DOI 10.1084/jem.20051639
   BOSCARDIN SB, 2009, NEW GENERATION VACCI, P327
   BOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297
   Chappell CP, 2012, J EXP MED, V209, P1825, DOI 10.1084/jem.20120774
   Cheng HJ, 2009, MOL IMMUNOL, V47, P398, DOI 10.1016/j.molimm.2009.08.033
   Cheong C, 2010, BLOOD, V116, P3828, DOI 10.1182/blood-2010-06-288068
   Corbett AJ, 2005, EUR J IMMUNOL, V35, P2815, DOI 10.1002/eji.200526100
   Costa SM, 2007, VIROLOGY, V358, P413, DOI 10.1016/j.virol.2006.08.052
   Costa SM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025685
   Costa SM, 2006, VACCINE, V24, P195, DOI 10.1016/j.vaccine.2005.07.059
   den Haan JMM, 2002, J EXP MED, V196, P817, DOI 10.1084/jem.20020295
   den Haan JMM, 2000, J EXP MED, V192, P1685, DOI 10.1084/jem.192.12.1685
   Do Y, 2008, EUR J IMMUNOL, V38, P20, DOI 10.1002/eji.200737799
   Do Y, 2012, VACCINE, V30, P6359, DOI 10.1016/j.vaccine.2012.08.051
   Do Y, 2010, EUR J IMMUNOL, V40, P2791, DOI 10.1002/eji.201040511
   Dudziak D, 2007, SCIENCE, V315, P107, DOI 10.1126/science.1136080
   Durbin AP, 2010, CURR TOP MICROBIOL, V338, P129, DOI 10.1007/978-3-642-02215-9_10
   Falconar AKI, 1997, ARCH VIROL, V142, P897, DOI 10.1007/s007050050127
   Flamand M, 1999, J VIROL, V73, P6104, DOI 10.1128/JVI.73.7.6104-6110.1999
   Flynn BJ, 2011, P NATL ACAD SCI USA, V108, P7131, DOI 10.1073/pnas.1103869108
   Gurer C, 2008, BLOOD, V112, P1231, DOI 10.1182/blood-2008-03-148072
   Guzman MG, 2010, NAT REV MICROBIOL, pS7, DOI 10.1038/nrmicro2460
   Hawiger D, 2001, J EXP MED, V194, P769, DOI 10.1084/jem.194.6.769
   Hochrein H, 2001, J IMMUNOL, V166, P5448, DOI 10.4049/jimmunol.166.9.5448
   Idoyaga J, 2008, J IMMUNOL, V180, P3647, DOI 10.4049/jimmunol.180.6.3647
   Idoyaga J, 2011, P NATL ACAD SCI USA, V108, P2384, DOI 10.1073/pnas.1019547108
   Iyoda T, 2002, J EXP MED, V195, P1289, DOI 10.1084/jem.20020161
   Jelinek I, 2011, J IMMUNOL, V186, P2422, DOI 10.4049/jimmunol.1002845
   Lin CF, 2003, J MED VIROL, V69, P82, DOI 10.1002/jmv.10261
   Liu K, 2002, J EXP MED, V196, P1091, DOI 10.1084/jem.20021215
   Longhi MP, 2009, J EXP MED, V206, P1589, DOI 10.1084/jem.20090247
   MACDONALD RA, 1988, J IMMUNOL METHODS, V106, P191, DOI 10.1016/0022-1759(88)90196-2
   Mahnke K, 2005, CANCER RES, V65, P7007, DOI 10.1158/0008-5472.CAN-05-0938
   Murphy BR, 2011, ANNU REV IMMUNOL, V29, P587, DOI 10.1146/annurev-immunol-031210-101315
   Nchinda G, 2010, P NATL ACAD SCI USA, V107, P4281, DOI 10.1073/pnas.1000621107
   Pooley JL, 2001, J IMMUNOL, V166, P5327, DOI 10.4049/jimmunol.166.9.5327
   PRYOR MJ, 1993, VIROLOGY, V194, P769, DOI 10.1006/viro.1993.1318
   Pulendran B, 1999, P NATL ACAD SCI USA, V96, P1036, DOI 10.1073/pnas.96.3.1036
   ROBINSON RA, 1976, JNCI-J NATL CANCER I, V57, P599, DOI 10.1093/jnci/57.3.599
   Rosa DS, 2004, IMMUNOL LETT, V92, P259, DOI 10.1016/j.imlet.2004.01.006
   SCHLESINGER JJ, 1987, J GEN VIROL, V68, P853, DOI 10.1099/0022-1317-68-3-853
   Schmitz J, 2011, VACCINE, V29, P7276, DOI 10.1016/j.vaccine.2011.07.017
   Shortman K, 2002, NAT REV IMMUNOL, V2, P151, DOI 10.1038/nri746
   Soares H, 2007, J EXP MED, V204, P1095, DOI 10.1084/jem.20070176
   Stahl-Hennig C, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000373
   Steinman RM, 2006, CURR TOP MICROBIOL, V311, P17
   Steinman RM, 2010, EUR J IMMUNOL, V40, P2085, DOI 10.1002/eji.201040733
   STEINMAN RM, 1980, IMMUNOL REV, V53, P127, DOI 10.1111/j.1600-065X.1980.tb01042.x
   Tewari K, 2010, VACCINE, V28, P7256, DOI 10.1016/j.vaccine.2010.08.098
   Trumpfheller C, 2006, J EXP MED, V203, P607, DOI 10.1084/jem.20052005
   Trumpfheller C, 2012, J INTERN MED, V271, P183, DOI 10.1111/j.1365-2796.2011.02496.x
   Trumpfheller C, 2008, P NATL ACAD SCI USA, V105, P2574, DOI 10.1073/pnas.0711976105
   Whitehead SS, 2007, NAT REV MICROBIOL, V5, P518, DOI 10.1038/nrmicro1690
   WINKLER G, 1988, VIROLOGY, V162, P187, DOI 10.1016/0042-6822(88)90408-4
   WINKLER G, 1989, VIROLOGY, V171, P302, DOI 10.1016/0042-6822(89)90544-8
   Wu SF, 2003, VACCINE, V21, P3919, DOI 10.1016/S0264-410X(03)00310-4
   Young PR, 2000, J CLIN MICROBIOL, V38, P1053, DOI 10.1128/JCM.38.3.1053-1057.2000
   ZHANG YM, 1988, J VIROL, V62, P3027, DOI 10.1128/JVI.62.8.3027-3031.1988
NR 64
TC 38
Z9 40
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1935-2735
J9 PLOS NEGLECT TROP D
JI Plos Neglect. Trop. Dis.
PD JUL
PY 2013
VL 7
IS 7
AR e2330
DI 10.1371/journal.pntd.0002330
PG 13
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA 296MG
UT WOS:000330188600001
PM 23875054
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Amorim, JH
   Bizerra, RSP
   Alves, RPD
   Sbrogio-Almeida, ME
   Levi, JE
   Capurro, ML
   Ferreira, LCD
AF Amorim, Jaime Henrique
   Pereira Bizerra, Raiza Sales
   dos Santos Alves, Rubens Prince
   Sbrogio-Almeida, Maria Elisabete
   Levi, Jose Eduardo
   Capurro, Margareth Lara
   de Souza Ferreira, Luis Carlos
TI A Genetic and Pathologic Study of a DENV2 Clinical Isolate Capable of
   Inducing Encephalitis and Hematological Disturbances in Immunocompetent
   Mice
SO PLOS ONE
LA English
DT Article
ID DENGUE VIRUS-INFECTION; DOMAIN-III; HEMORRHAGIC-FEVER; NS1 PROTEIN;
   MOUSE MODEL; PATHOGENESIS; RECOMBINANT; MANIFESTATIONS; DETERMINANTS;
   REPLICATION
AB Dengue virus (DENV) is the causative agent of dengue fever (DF), a mosquito-borne illness endemic to tropical and subtropical regions. There is currently no effective drug or vaccine formulation for the prevention of DF and its more severe forms, i.e., dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS). There are two generally available experimental models for the study of DENV pathogenicity as well as the evaluation of potential vaccine candidates. The first model consists of non-human primates, which do not develop symptoms but rather a transient viremia. Second, mouse-adapted virus strains or immunocompromised mouse lineages are utilized, which display some of the pathological features of the infection observed in humans but may not be relevant to the results with regard to the wild-type original virus strains or mouse lineages. In this study, we describe a genetic and pathological study of a DENV2 clinical isolate, named JHA1, which is naturally capable of infecting and killing Balb/c mice and reproduces some of the symptoms observed in DENV-infected subjects. Sequence analyses demonstrated that the JHA1 isolate belongs to the American genotype group and carries genetic markers previously associated with neurovirulence in mouse-adapted virus strains. The JHA1 strain was lethal to immunocompetent mice following intracranial (i.c.) inoculation with a LD50 of approximately 50 PFU. Mice infected with the JHA1 strain lost weight and exhibited general tissue damage and hematological disturbances, with similarity to those symptoms observed in infected humans. In addition, it was demonstrated that the JHA1 strain shares immunological determinants with the DENV2 NGC reference strain, as evaluated by cross-reactivity of anti-envelope glycoprotein (domain III) antibodies. The present results indicate that the JHA1 isolate may be a useful tool in the study of DENV pathogenicity and will help in the evaluation of anti-DENV vaccine formulations as well as potential therapeutic approaches.
C1 [Amorim, Jaime Henrique; Pereira Bizerra, Raiza Sales; dos Santos Alves, Rubens Prince; de Souza Ferreira, Luis Carlos] Univ Sao Paulo, Dept Microbiol, Vaccine Dev Lab, BR-05508 Sao Paulo, Brazil.
   [dos Santos Alves, Rubens Prince] Univ Estadual Santa Cruz, Ilheus, Brazil.
   [Sbrogio-Almeida, Maria Elisabete] Butantan Inst, Sao Paulo, Brazil.
   [Levi, Jose Eduardo] Univ Sao Paulo, Inst Trop Med, BR-05508 Sao Paulo, Brazil.
   [Capurro, Margareth Lara] Univ Sao Paulo, Dept Parasitol, BR-05508 Sao Paulo, Brazil.
RP Amorim, JH (corresponding author), Univ Sao Paulo, Dept Microbiol, Vaccine Dev Lab, BR-05508 Sao Paulo, Brazil.
EM lcsf@usp.br
RI Ferreira, Luis Carlos S/M-3954-2014; Amorim, Jaime Henrique/O-9222-2017;
   Capurro, Margareth/M-5286-2019; Capurro, Margareth/F-8679-2012
OI Ferreira, Luis Carlos S/0000-0002-4883-1693; Amorim, Jaime
   Henrique/0000-0002-0623-2879; Capurro, Margareth/0000-0002-7480-2116
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
   grantFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
   [2009/50033-7]
FX This work was supported by Fundacao de Amparo a Pesquisa do Estado de
   Sao Paulo (FAPESP) grant process 2009/50033-7. The funders had no role
   in study design, data collection and analysis, decision to publish, or
   preparation of the manuscript
CR Amaral DC, 2011, J NEUROINFLAMM, V9, P8
   Amorim JH, 2012, VACCINE, V30, P837, DOI 10.1016/j.vaccine.2011.12.034
   Amorim JH, 2010, J VIROL METHODS, V167, P186, DOI 10.1016/j.jviromet.2010.04.003
   Atrasheuskaya A, 2003, FEMS IMMUNOL MED MIC, V35, P33, DOI 10.1111/j.1574-695X.2003.tb00646.x
   Azevedo AS, 2011, PLOS ONE, V7
   Bhardwaj S, 2001, J VIROL, V75, P4002, DOI 10.1128/JVI.75.8.4002-4007.2001
   Blaney JE, 2005, J VIROL, V79, P5516, DOI 10.1128/JVI.79.9.5516-5528.2005
   Bray M, 1998, J VIROL, V72, P1647, DOI 10.1128/JVI.72.2.1647-1651.1998
   Chang SF, 2010, J CLIN MICROBIOL, V48, P4586, DOI 10.1128/JCM.01228-10
   Chen MC, 2009, J IMMUNOL, V183, P1797, DOI 10.4049/jimmunol.0800672
   Chin JFL, 2007, MICROBES INFECT, V9, P1, DOI 10.1016/j.micinf.2006.09.009
   Chu JJH, 2005, J GEN VIROL, V86, P405, DOI 10.1099/vir.0.80411-0
   Clements DE, 2010, VACCINE, V28, P2705, DOI 10.1016/j.vaccine.2010.01.022
   Clyde K, 2006, J VIROL, V80, P11418, DOI 10.1128/JVI.01257-06
   COLE GA, 1969, AM J EPIDEMIOL, V89, P669, DOI 10.1093/oxfordjournals.aje.a120981
   Costa SM, 2006, VACCINE, V24, P195, DOI 10.1016/j.vaccine.2005.07.059
   de Miranda AS, 2012, BEHAV BRAIN RES, V230, P237, DOI 10.1016/j.bbr.2012.02.020
   Franca RFD, 2010, EXP MOL PATHOL, V89, P321, DOI 10.1016/j.yexmp.2010.07.007
   ERHARDT W, 1984, RES EXP MED, V184, P159, DOI 10.1007/BF01852390
   Fernandez-Mestre MT, 2004, TISSUE ANTIGENS, V64, P469, DOI 10.1111/j.1399-0039.2004.00304.x
   Ferreira GP, 2010, MICROBES INFECT, V12, P546, DOI 10.1016/j.micinf.2010.03.007
   Figueiredo LB, 2008, EMERG INFECT DIS, V14, P314, DOI 10.3201/eid1402.070278
   Gao GP, 2008, HUM GENE THER, V19, P927, DOI 10.1089/hum.2008.011
   Gualano RC, 1998, J GEN VIROL, V79, P437, DOI 10.1099/0022-1317-79-3-437
   Gubler Duane J., 2002, Trends in Microbiology, V10, P100, DOI 10.1016/S0966-842X(01)02288-0
   Gulati S, 2007, TROP MED INT HEALTH, V12, P1087, DOI 10.1111/j.1365-3156.2007.01891.x
   Guzman MG, 2006, REV PANAM SALUD PUBL, V19
   Guzman MG, 2012, NAT REV MICROBIOL S, V12, pS7
   HALSTEAD SB, 1973, J INFECT DIS, V128, P7, DOI 10.1093/infdis/128.1.7
   Halstead SB, 2007, LANCET, V370, P1644, DOI 10.1016/S0140-6736(07)61687-0
   HENCHAL EA, 1988, J GEN VIROL, V69, P2101, DOI 10.1099/0022-1317-69-8-2101
   IGARASHI A, 1978, J GEN VIROL, V40, P531, DOI 10.1099/0022-1317-40-3-531
   IRIE K, 1989, GENE, V75, P197, DOI 10.1016/0378-1119(89)90266-7
   Jessie K, 2004, J INFECT DIS, V189, P1411, DOI 10.1086/383043
   KHO L K, 1981, Southeast Asian Journal of Tropical Medicine and Public Health, V12, P83
   Kumar SRP, 2010, J GEN VIROL, V91, P707, DOI 10.1099/vir.0.017954-0
   Kurosu T, 2007, BIOCHEM BIOPH RES CO, V362, P1051, DOI 10.1016/j.bbrc.2007.08.137
   Lan NTP, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000304
   Leitmeyer KC, 1999, J VIROL, V73, P4738, DOI 10.1128/JVI.73.6.4738-4747.1999
   Lin CF, 2002, J IMMUNOL, V169, P657, DOI 10.4049/jimmunol.169.2.657
   Lin CF, 2006, VIRAL IMMUNOL, V19, P127, DOI 10.1089/vim.2006.19.127
   Martina BEE, 2009, CLIN MICROBIOL REV, V22, P564, DOI 10.1128/CMR.00035-09
   Pandey Basu Dev, 2000, Southeast Asian Journal of Tropical Medicine and Public Health, V31, P266
   PATEY O, 1993, AM J TROP MED HYG, V48, P793, DOI 10.4269/ajtmh.1993.48.793
   Pham TB, 2009, J CLIN VIROL, V45, P276, DOI 10.1016/j.jcv.2009.04.004
   Rammensee HG, 1999, IMMUNOGENETICS, V50, P213, DOI 10.1007/s002510050595
   Row D, 1996, AM J TROP MED HYG, V54, P253, DOI 10.4269/ajtmh.1996.54.253
   RUSSELL PK, 1967, J IMMUNOL, V99, P285
   SABIN ALBERT B., 1952, AMER JOUR TROP MED AND HYG, V1, P30
   Sambrook J, 1989, MOL CLONING LAB MANU, P1527
   Serufo JC, 2006, REV SOC BRASILEIRA M, V5, P465
   Solomon T, 2000, LANCET, V355, P1053, DOI 10.1016/S0140-6736(00)02036-5
   Sun W, 2006, J INFECT DIS, V193, P1658, DOI 10.1086/503372
   TAMURA K, 2011, MOL BIOL EVOL, V28, P2731, DOI [DOI 10.1093/molbev/msr121, DOI 10.1093/MOLBEV/MSR121]
   Tamura K, 2007, MOL BIOL EVOL, V24, P1596, DOI 10.1093/molbev/msm092
   Tan GK, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000672
   Tan GK, 2009, CURR OPIN INFECT DIS, V22, P302, DOI 10.1097/QCO.0b013e328329ae32
   Tanner L, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000196
   Thomas L, 2010, AM J TROP MED HYG, V83, P696, DOI 10.4269/ajtmh.2010.10-0138
   Velandia-Romero ML, 2012, J NEUROVIROL
   Verrastro T, 1996, HEMATOLOGIA HEMOTERA, P1
   Whitehead SS, 2007, NAT REV MICROBIOL, V5, P518, DOI 10.1038/nrmicro1690
   Williams KL, 2009, ANN NY ACAD SCI, V1171, pE12, DOI 10.1111/j.1749-6632.2009.05057.x
   Yauch LE, 2008, ANTIVIR RES, V80, P87, DOI 10.1016/j.antiviral.2008.06.010
   Zhang GL, 2005, NUCLEIC ACIDS RES, V33, pW180, DOI 10.1093/nar/gki479
   Zhang ZS, 2007, J VIROL METHODS, V143, P125, DOI 10.1016/j.jviromet.2007.02.012
NR 66
TC 14
Z9 16
U1 0
U2 9
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 13
PY 2012
VL 7
IS 9
AR e44984
DI 10.1371/journal.pone.0044984
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 005ZK
UT WOS:000308788700070
PM 23028722
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Amorim, JH
   Diniz, MO
   Cariri, FAMO
   Rodrigues, JF
   Bizerra, RSP
   Goncalves, AJS
   Alves, AMD
   Ferreira, LCD
AF Amorim, Jaime Henrique
   Diniz, Mariana Oliveira
   Cariri, Francisco A. M. O.
   Rodrigues, Juliana Falcao
   Pereira Bizerra, Raiza Sales
   Goncalves, Antonio J. S.
   de Barcelos Alves, Ada Maria
   de Souza Ferreira, Luis Carlos
TI Protective immunity to DENV2 after immunization with a recombinant NS1
   protein using a genetically detoxified heat-labile toxin as an adjuvant
SO VACCINE
LA English
DT Article
DE Dengue virus; NS1 protein; Heat-labile toxin; Adjuvants; Vaccines
ID VIRUS NONSTRUCTURAL PROTEIN-1; DENGUE VIRUS; ESCHERICHIA-COLI;
   MONOCLONAL-ANTIBODIES; DNA VACCINE; MICE; GLYCOPROTEIN; RESPONSES;
   PATHOGENESIS; GENE
AB The dengue virus non-structural 1 (NS1) protein contributes to evasion of host immune defenses and represents a target for immune responses. Evidences generated in experimental models, as well as the immune responses elicited by infected individuals, showed that induction of anti-NS1 immunity correlates with protective immunity but may also result in the generation of cross-reactive antibodies that recognize platelets and proteins involved in the coagulation cascade. In the present work, we evaluated the immune responses, protection to type 2 dengue virus (DENV2) challenges and safety parameters in BALB/c mice vaccinated with a recombinant NS1 protein in combination with three different adjuvants: aluminum hydroxide (alum), Freund's adjuvant (FA) or a genetically detoxified derivative of the heat-labile toxin (LTG33D), originally produced by some enterotoxigenic Escherichia coli (ETEC) strains. Mice were subcutaneously (s.c.) immunized with different vaccine formulations and the induced NS1-specific responses, including serum antibodies and T cell responses, were measured. Mice were also subjected to lethal challenges with the DENV2 NGC strain. The results showed that maximal protective immunity (50%) was achieved in mice vaccinated with NS1 in combination with LIG33D. Analyses of the NS1-specific immune responses showed that the anti-virus protection correlated mainly with the serum anti-NS1 antibody responses including higher avidity to the target antigen. Mice immunized with LTG33D elicited a prevailing IgG2a subclass response and generated antibodies with stronger affinity to the antigen than those generated in mice immunized with the other vaccine formulations. The vaccine formulations were also evaluated regarding induction of deleterious side effects and, in contrast to mice immunized with the FA-adjuvanted vaccine, no significant hepatic damage or enhanced C-reactive protein levels were detected in mice immunized with NS1 and LTG33D. Similarly, no detectable alterations in bleeding time and hematological parameters were detected in mice vaccinated with NS1 and LTG33D. Altogether, these results indicate that the combination of a purified recombinant NS1 and a nontoxic LT derivative is a promising alternative for the generation of safe and effective protein-based anti-dengue vaccine. (C) 2011 Elsevier Ltd. All rights reserved.
C1 [de Souza Ferreira, Luis Carlos] Univ Sao Paulo, Lab Desenvolvimento Vacinas, Dept Microbiol, ICB II, BR-05508900 Sao Paulo, Brazil.
   [Pereira Bizerra, Raiza Sales] Univ Estadual Santa Cruz, Ilheus, Brazil.
   [Goncalves, Antonio J. S.; de Barcelos Alves, Ada Maria] Fundacao Oswaldo Cruz, Lab Biotechnol & Physiol Virus Infect, Inst Oswaldo Cruz, Rio De Janeiro, Brazil.
RP Ferreira, LCD (corresponding author), Univ Sao Paulo, Lab Desenvolvimento Vacinas, Dept Microbiol, ICB II, Av Prof Lineu Prestes 1374, BR-05508900 Sao Paulo, Brazil.
EM lcsf@usp.br
RI Rodrigues, Juliana/AAC-3512-2019; Ferreira, Luis Carlos S/M-3954-2014;
   Amorim, Jaime Henrique/O-9222-2017
OI Ferreira, Luis Carlos S/0000-0002-4883-1693; Amorim, Jaime
   Henrique/0000-0002-0623-2879
FU FAPESPFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP);
   FAPERJCarlos Chagas Filho Foundation for Research Support of the State
   of Rio de Janeiro (FAPERJ); CNPqNational Council for Scientific and
   Technological Development (CNPq)
FX We are grateful for the technical assistance of LC. Silva and E.G.
   Martins. This work was supported by FAPESP, FAPERJ and CNPq grants.
CR Amorim JH, 2010, J VIROL METHODS, V167, P186, DOI 10.1016/j.jviromet.2010.04.003
   Avirutnan P, 2010, J EXP MED, V207, P793, DOI 10.1084/jem.20092545
   Azevedo AS, 2011, PLOS ONE, V6
   Barber DL, 2003, J IMMUNOL, V171, P27, DOI 10.4049/jimmunol.171.1.27
   Bargieri DY, 2007, MEM I OSWALDO CRUZ, V102, P313, DOI 10.1590/S0074-02762007005000039
   Blaney JE, 2006, VIRAL IMMUNOL, V19, P10, DOI 10.1089/vim.2006.19.10
   Chen MC, 2009, J IMMUNOL, V183, P1797, DOI 10.4049/jimmunol.0800672
   Coffman RL, 2010, IMMUNITY, V33, P492, DOI 10.1016/j.immuni.2010.10.002
   Costa SM, 2007, VIROLOGY, V358, P413, DOI 10.1016/j.virol.2006.08.052
   Costa SM, 2006, VACCINE, V24, P195, DOI 10.1016/j.vaccine.2005.07.059
   DICKINSON BL, 1995, INFECT IMMUN, V63, P1617, DOI 10.1128/IAI.63.5.1617-1623.1995
   Edelman R, 2003, AM J TROP MED HYG, V69, P48, DOI 10.4269/ajtmh.2003.69.48
   ERHARDT W, 1984, RES EXP MED, V184, P159, DOI 10.1007/BF01852390
   FALCONAR AKI, 1990, J VIROL METHODS, V30, P323, DOI 10.1016/0166-0934(90)90075-Q
   Falconar AKI, 2008, CLIN VACCINE IMMUNOL, V15, P549, DOI 10.1128/CVI.00351-07
   Falconar AKI, 2007, CLIN VACCINE IMMUNOL, V14, P493, DOI 10.1128/CVI.00371-06
   Flamand M, 1999, J VIROL, V73, P6104, DOI 10.1128/JVI.73.7.6104-6110.1999
   Freytag LC, 2005, VACCINE, V23, P1804, DOI 10.1016/j.vaccine.2004.11.010
   Gao GP, 2008, HUM GENE THER, V19, P927, DOI 10.1089/hum.2008.011
   Gubler DJ, 1999, ADV VIRUS RES, V53, P35, DOI 10.1016/S0065-3527(08)60342-5
   Guidry JJ, 1997, INFECT IMMUN, V65, P4943, DOI 10.1128/IAI.65.12.4943-4950.1997
   Guzman MG, 2010, NAT REV MICROBIOL, pS7, DOI 10.1038/nrmicro2460
   HENCHAL EA, 1988, J GEN VIROL, V69, P2101, DOI 10.1099/0022-1317-69-8-2101
   HOTTA S, 1952, J INFECT DIS, V90, P1, DOI 10.1093/infdis/90.1.1
   IRIE K, 1989, GENE, V75, P197, DOI 10.1016/0378-1119(89)90266-7
   Jang M, 1997, J BIOCHEM MOL BIOL, V30, P346
   Kanesa-thasan N, 2001, VACCINE, V19, P3179, DOI 10.1016/S0264-410X(01)00020-2
   Lima DM, 2011, VACCINE, V29, P831, DOI 10.1016/j.vaccine.2010.10.078
   Lin CF, 2002, J IMMUNOL, V169, P657, DOI 10.4049/jimmunol.169.2.657
   Lin CF, 2008, LAB INVEST, V88, P1079, DOI 10.1038/labinvest.2008.70
   Lin CF, 2006, VIRAL IMMUNOL, V19, P127, DOI 10.1089/vim.2006.19.127
   O'Hagan DT, 2009, DRUG DISCOV TODAY, V14, P541, DOI 10.1016/j.drudis.2009.02.009
   O'Hagan DT, 2003, NAT REV DRUG DISCOV, V2, P727, DOI 10.1038/nrd1176
   Palzer Sarah, 2005, Methods Mol Biol, V302, P273
   Petsch D, 2000, J BIOTECHNOL, V76, P97, DOI 10.1016/S0168-1656(99)00185-6
   Putnak JR, 2005, VACCINE, V23, P4442, DOI 10.1016/j.vaccine.2005.03.042
   Rappuoli R, 1999, IMMUNOL TODAY, V20, P493, DOI 10.1016/S0167-5699(99)01523-6
   Rodrigues JF, 2011, J BIOL CHEM, V286, P5222, DOI 10.1074/jbc.M110.173682
   Rothman AL, 2004, J CLIN INVEST, V113, P946, DOI 10.1172/JCI200421512
   Sambrook J, 1989, MOL CLONING LAB MANU, VIII, P1647
   Sbrogio-Almeida ME, 2004, INFECT IMMUN, V72, P2546, DOI 10.1128/IAI.72.5.2546-2555.2004
   SCHLESINGER JJ, 1987, J GEN VIROL, V68, P853, DOI 10.1099/0022-1317-68-3-853
   Schoenborn JR, 2007, ADV IMMUNOL, V96, P41, DOI 10.1016/S0065-2776(07)96002-2
   Schweizer HP, 2001, CURR OPIN BIOTECH, V12, P439, DOI 10.1016/S0958-1669(00)00242-1
   Simmons M, 2006, J VIROL, V80, P9577, DOI 10.1128/JVI.00284-06
   SRIVASTAVA AK, 1995, VACCINE, V13, P1251, DOI 10.1016/0264-410X(94)00059-V
   Tartoff KD, 1987, IMPROVED MEDIA GROWI, V9, P12
   Verrastro T, 1996, HEMATOLOGIA HEMOTERA, P1
   Warrens AN, 1997, GENE, V186, P29, DOI 10.1016/S0378-1119(96)00674-9
   Whitehead SS, 2007, NAT REV MICROBIOL, V5, P518, DOI 10.1038/nrmicro1690
   Wu SF, 2003, VACCINE, V21, P3919, DOI 10.1016/S0264-410X(03)00310-4
   Young PR, 2000, J CLIN MICROBIOL, V38, P1053, DOI 10.1128/JCM.38.3.1053-1057.2000
   ZHANG YM, 1988, J VIROL, V62, P3027, DOI 10.1128/JVI.62.8.3027-3031.1988
   Zoeteweij JP, 2006, J IMMUNOL, V177, P1197, DOI 10.4049/jimmunol.177.2.1197
NR 54
TC 51
Z9 53
U1 0
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 20
PY 2012
VL 30
IS 5
BP 837
EP 845
DI 10.1016/j.vaccine.2011.12.034
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA 909IK
UT WOS:000301558000005
PM 22178517
OA Green Published
DA 2020-12-01
ER

PT J
AU Porchia, BFMM
   Diniz, MO
   Cariri, FAMO
   Santana, VC
   Amorim, JH
   Balan, A
   Braga, CJM
   Ferreira, LCS
AF Porchia, Brum. F. M. M.
   Diniz, Mariana O.
   Cariri, Francisco A. M. O.
   Santana, Vinicius C.
   Amorim, Jaime H.
   Balan, Andrea
   Braga, Catarina J. M.
   Ferreira, Luis Carlos S.
TI Purified Herpes Simplex Type 1 Glycoprotein D (gD) Genetically Fused
   with the Type 16 Human Papillomavirus E7 Oncoprotein Enhances
   Antigen-Specific CD8(+) T Cell Responses and Confers Protective
   Antitumor Immunity
SO MOLECULAR PHARMACEUTICS
LA English
DT Article
DE HPV-16; papillomavirus vaccines; gD; HSV-1; E7 oncoprotein; anticancer
   vaccines
ID ENTRY MEDIATOR; B-LYMPHOCYTE; CERVICAL-CANCER; BINDING-SITE; DNA
   VACCINES; VIRUS ENTRY; KAPPA-B; ACTIVATION; EXPRESSION; RECEPTOR
AB Type 1 herpes virus (HSV-1) glycoprotein D (gD) enhances antigen-specific immune responses, particularly CDS+ T cell responses, in mice immunized with DNA vaccines encoding hybrid proteins genetically fused with the target antigen at a site near the C-terminal end. These effects are attributed to the interaction of gD with the herpes virus entry mediator (HVEM) and the concomitant blockade of a coin-hibitory mechanism mediated by the B- and T-lymphocyte attenuator (BTLA). However, questions concerning the requirement for endogenous synthesis of the antigen or the adjuvant/antigen fusion itself have not been addressed so far. In the present study, we investigated these points using purified recombinant gDs, genetically fused or not with type 16 papilloma virus (HPV-16) E7 oncoprotein. Soluble recombinant gDs, but not denatured forms, retained the ability to bind surface-exposed cellular receptors of HVEM-expressing U937 cells. In addition, in vivo administration of the recombinant proteins, particularly gD genetically fused with E7 (gDE7), promoted the activation of dendritic cells (DC) and antigen-specific cytotoxic CD8(+) T cells. More relevantly, mice immunized with the gDE7 protein developed complete preventive and partial therapeutic antitumor protection, as measured in mice following the implantation of TC-1 cells expressing HPV-16 oncoproteins. Collectively, these results demonstrate that the T cell adjuvant effects of the HSV-1 gD protein did not require endogenous synthesis and could be demonstrated in mice immunized with purified recombinant proteins.
C1 [Ferreira, Luis Carlos S.] Univ Sao Paulo, ICB II, Dept Microbiol, Inst Biomed Sci, BR-05508000 Sao Paulo, Brazil.
   [Balan, Andrea] Brazilian Natl Lab Biosci LNBio, Ctr Res Energy & Mat, Campinas, SP, Brazil.
RP Ferreira, LCS (corresponding author), Univ Sao Paulo, ICB II, Dept Microbiol, Inst Biomed Sci, Av Prof Lineu Prestes,1374,Cidade Univ, BR-05508000 Sao Paulo, Brazil.
EM lcsf@usp.br
RI Amorim, Jaime Henrique/O-9222-2017; Ferreira, Luis Carlos S/M-3954-2014;
   Balan, Andrea/D-1891-2014
OI Amorim, Jaime Henrique/0000-0002-0623-2879; Ferreira, Luis Carlos
   S/0000-0002-4883-1693; Balan, Andrea/0000-0001-6199-3198
FU Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
   (CNPq)National Council for Scientific and Technological Development
   (CNPq); Fundacao de Amparo a Pesquisa do Estado de Sao Paulo
   (FAPESP)Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
FX We gratefully acknowledge the helpful technical assistance of L. C.
   Silva, J. A. Pereira and E. Gimenez. This work was supported by grants
   from the Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
   (CNPq). B.F.M.M.P., MOD., F.A.M.O.C., J.H.A. and CJ.M.B. had fellowships
   granted by Fundacao de Amparo a Pesquisa do Estado de Sao Paulo
   (FAPESP).
CR Appay V, 2008, NAT MED, V14, P623, DOI 10.1038/nm.f.1774
   ARMSTRONG DJ, 1993, BIOCHEM BIOPH RES CO, V192, P1380, DOI 10.1006/bbrc.1993.1569
   Braga CJM, 2010, VACCINE, V28, P1373, DOI 10.1016/j.vaccine.2009.11.003
   Cai GF, 2008, NAT IMMUNOL, V9, P176, DOI 10.1038/ni1554
   Cai GF, 2009, IMMUNOL REV, V229, P244, DOI 10.1111/j.1600-065X.2009.00783.x
   Carfi A, 2001, MOL CELL, V8, P169, DOI 10.1016/S1097-2765(01)00298-2
   Cheung TC, 2009, P NATL ACAD SCI USA, V106, P6244, DOI 10.1073/pnas.0902115106
   Connolly SA, 2005, J VIROL, V79, P1282, DOI 10.1128/JVI.79.2.1282-1295.2005
   Connolly SA, 2002, J VIROL, V76, P10894, DOI 10.1128/JVI.76.21.10894-10904.2002
   de Alencar BCG, 2009, INFECT IMMUN, V77, P4383, DOI 10.1128/IAI.01459-08
   del Rio ML, 2010, J LEUKOCYTE BIOL, V87, P223, DOI 10.1189/jlb.0809590
   Diniz MO, 2010, CLIN VACCINE IMMUNOL, V17, P1576, DOI 10.1128/CVI.00264-10
   Han P, 2004, J IMMUNOL, V172, P5931, DOI 10.4049/jimmunol.172.10.5931
   Heldwein EE, 2008, CELL MOL LIFE SCI, V65, P1653, DOI 10.1007/s00018-008-7570-z
   Hung CF, 2007, EXP MOL MED, V39, P679, DOI 10.1038/emm.2007.74
   Ji HX, 1998, INT J CANCER, V78, P41, DOI 10.1002/(SICI)1097-0215(19980925)78:1<41::AID-IJC8>3.3.CO;2-K
   Kanodia S, 2008, INT J CANCER, V122, P247, DOI 10.1002/ijc.23252
   Krieg C, 2005, J IMMUNOL, V175, P6420, DOI 10.4049/jimmunol.175.10.6420
   Krieg C, 2007, NAT IMMUNOL, V8, P162, DOI 10.1038/ni1418
   Krummenacher C, 2005, EMBO J, V24, P4144, DOI 10.1038/sj.emboj.7600875
   Kutzler M. A., 2008, NATREV, V9, P77
   Lasaro MO, 2008, NAT MED, V14, P205, DOI 10.1038/nm1704
   Lasaro MO, 2005, MICROBES INFECT, V7, P1541, DOI 10.1016/j.micinf.2005.05.024
   Lin KY, 1996, CANCER RES, V56, P21
   Masters S. A., 1997, J BIOL CHEM, V272, P14029
   Morel Y, 2000, J IMMUNOL, V165, P4397, DOI 10.4049/jimmunol.165.8.4397
   Morel Y, 2001, J IMMUNOL, V167, P2479, DOI 10.4049/jimmunol.167.5.2479
   Murphy TL, 2010, ANNU REV IMMUNOL, V28, P389, DOI 10.1146/annurev-immunol-030409-101202
   Rux AH, 1998, J VIROL, V72, P7091, DOI 10.1128/JVI.72.9.7091-7098.1998
   Sciortino MT, 2008, CELL MICROBIOL, V10, P2297, DOI 10.1111/j.1462-5822.2008.01212.x
   Sciortino MT, 2008, BIOCHEM PHARMACOL, V76, P1522, DOI 10.1016/j.bcp.2008.07.030
   Sedy JR, 2005, NAT IMMUNOL, V6, P90, DOI 10.1038/ni1144
   Stiles KM, 2010, J VIROL, V84, P11646, DOI 10.1128/JVI.01550-10
   Tao R, 2008, J IMMUNOL, V180, P6649, DOI 10.4049/jimmunol.180.10.6649
   Tindle R. W., P NATL ACAD SCI US, V88, P5887
   van der Burg SH, 2011, CURR OPIN IMMUNOL, V23, P252, DOI 10.1016/j.coi.2010.12.010
   WATSON RJ, 1982, SCIENCE, V218, P381, DOI 10.1126/science.6289440
   Yewdell JW, 2010, CURR OPIN IMMUNOL, V22, P402, DOI 10.1016/j.coi.2010.04.002
NR 38
TC 6
Z9 7
U1 0
U2 3
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1543-8384
J9 MOL PHARMACEUT
JI Mol. Pharm.
PD NOV-DEC
PY 2011
VL 8
IS 6
BP 2320
EP 2330
DI 10.1021/mp200194s
PG 11
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA 855BA
UT WOS:000297537300034
PM 21985578
DA 2020-12-01
ER

PT J
AU Rodrigues, JF
   Mathias-Santos, C
   Sbrogio-Almeida, ME
   Amorim, JH
   Cabrera-Crespo, J
   Balan, A
   Ferreira, LCS
AF Rodrigues, Juliana F.
   Mathias-Santos, Camila
   Sbrogio-Almeida, Maria Elisabete
   Amorim, Jaime H.
   Cabrera-Crespo, Joaquim
   Balan, Andrea
   Ferreira, Luis C. S.
TI Functional Diversity of Heat-labile Toxins (LT) Produced by
   Enterotoxigenic Escherichia coli
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID ADP-RIBOSYLTRANSFERASE ACTIVITY; CHOLERA-TOXIN; MUCOSAL ADJUVANTS;
   B-SUBUNIT; A-SUBUNIT; IMMUNOGENICITY; RESPONSES; BINDING; MUTANT; SITE
AB Heat-labile toxins (LTs) have ADP-ribosylation activity and induce the secretory diarrhea caused by enterotoxigenic Escherichia coli (ETEC) strains in different mammalian hosts. LTs also act as adjuvants following delivery via mucosal, parenteral, or transcutaneous routes. Previously we have shown that LT produced by human-derived ETEC strains encompass a group of 16 polymorphic variants, including the reference toxin (LT1 or hLT) produced by the H10407 strain and one variant that is found mainly among bacterial strains isolated from pigs (LT4 or pLT). Herein, we show that LT4 ( with six polymorphic sites in the A (K4R, K213E, and N238D) and B (S4T, A46E, and E102K) subunits) displays differential in vitro toxicity and in vivo adjuvant activities compared with LT1. One in vitro generated LT mutant (LTK4R), in which the lysine at position 4 of the A subunit was replaced by arginine, showed most of the LT4 features with an similar to 10-fold reduction of the cytotonic effects, ADP-ribosylation activity, and accumulation of intracellular cAMP in Y1 cells. Molecular dynamic studies of the A subunit showed that the K4R replacement reduces the N-terminal region flexibility and decreases the catalytic site crevice. Noticeably, LT4 showed a stronger Th1-biased adjuvant activity with regard to LT1, particularly concerning activation of cytotoxic CD8(+) T lymphocytes when delivered via the intranasal route. Our results further emphasize the relevance of LT polymorphism among human-derived ETEC strains that may impact both the pathogenicity of the bacterial strain and the use of these toxins as potential vaccine adjuvants.
C1 [Ferreira, Luis C. S.] Univ Sao Paulo, Dept Microbiol, Inst Biomed Sci, Vaccine Dev Lab, BR-05508000 Sao Paulo, Brazil.
   [Sbrogio-Almeida, Maria Elisabete; Cabrera-Crespo, Joaquim] Butantan Inst, Technol Dev Div, BR-05503900 Sao Paulo, Brazil.
   [Balan, Andrea] Res Ctr Energy & Mat, Natl Lab Biosci, BR-13084971 Sao Paulo, Brazil.
RP Ferreira, LCS (corresponding author), Univ Sao Paulo, Dept Microbiol, Inst Biomed Sci, Vaccine Dev Lab, BR-05508000 Sao Paulo, Brazil.
EM lcsf@usp.br
RI Ferreira, Luis Carlos S/M-3954-2014; Balan, Andrea/D-1891-2014;
   Cabrera-Crespo, Joaquin/D-3183-2015; Amorim, Jaime Henrique/O-9222-2017;
   Rodrigues, Juliana/AAC-3512-2019
OI Ferreira, Luis Carlos S/0000-0002-4883-1693; Balan,
   Andrea/0000-0001-6199-3198; Amorim, Jaime Henrique/0000-0002-0623-2879;
   Cabrera-Crespo, Joaquin/0000-0002-1457-6786
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP); Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico (CNPq)National Council for
   Scientific and Technological Development (CNPq)
FX This work was supported by Fundacao de Amparo a Pesquisa do Estado de
   Sao Paulo (FAPESP) and Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico (CNPq) grants.
CR [Anonymous], 1998, PYM
   Arce S, 2005, INFECT IMMUN, V73, P2718, DOI 10.1128/IAI.73.5.2718-2727.2005
   BACK E, 1979, J CLIN MICROBIOL, V10, P791
   Braga CJM, 2008, BRAZ J MICROBIOL, V39, P44, DOI 10.1590/S1517-838220080001000011
   CHUNG DW, 1977, INFECT IMMUN, V16, P832, DOI 10.1128/IAI.16.3.832-841.1977
   de Haan L, 1998, IMMUNOL CELL BIOL, V76, P270, DOI 10.1046/j.1440-1711.1998.00745.x
   de Haan L, 2004, MOL MEMBR BIOL, V21, P77, DOI 10.1080/09687680410001663267
   De Haan L, 1998, IMMUNOLOGY, V94, P424, DOI 10.1046/j.1365-2567.1998.00535.x
   DICKINSON BL, 1995, INFECT IMMUN, V63, P1617, DOI 10.1128/IAI.63.5.1617-1623.1995
   DOMENIGHINI M, 1994, MOL MICROBIOL, V14, P41, DOI 10.1111/j.1365-2958.1994.tb01265.x
   Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158
   Fraser SA, 2003, INFECT IMMUN, V71, P1527, DOI 10.1128/IAI.71.3.1527-1537.2003
   Freytag LC, 2005, VACCINE, V23, P1804, DOI 10.1016/j.vaccine.2004.11.010
   Giuliani MM, 1998, J EXP MED, V187, P1123, DOI 10.1084/jem.187.7.1123
   Hagiwara Y, 2001, VACCINE, V19, P1652, DOI 10.1016/S0264-410X(00)00412-6
   Hajishengallis G, 2005, J DENT RES, V84, P1104, DOI 10.1177/154405910508401205
   Hess B, 1997, J COMPUT CHEM, V18, P1463, DOI 10.1002/(SICI)1096-987X(199709)18:12<1463::AID-JCC4>3.0.CO;2-H
   HIRST TR, 1999, COMPREHENSIVE SOURCE, P104
   Holmgren J, 2003, VACCINE, V21, pS89, DOI 10.1016/S0264-410X(03)00206-8
   HONDA T, 1981, INFECT IMMUN, V34, P337, DOI 10.1128/IAI.34.2.337-340.1981
   Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5
   KARMALI MA, 1985, J CLIN MICROBIOL, V22, P614, DOI 10.1128/JCM.22.4.614-619.1985
   Krissinel E, 2004, ACTA CRYSTALLOGR D, V60, P2256, DOI 10.1107/S0907444904026460
   Lasaro MA, 2008, J BACTERIOL, V190, P2400, DOI 10.1128/JB.00988-07
   Lasaro MA, 2009, FEMS IMMUNOL MED MIC, V55, P93, DOI 10.1111/j.1574-695X.2008.00506.x
   LASKOWSKI RA, 1993, J MOL BIOL, V231, P1049, DOI 10.1006/jmbi.1993.1351
   LEONG J, 1985, INFECT IMMUN, V48, P73, DOI 10.1128/IAI.48.1.73-77.1985
   Lewis DJM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006999
   Mackler B., 1967, METHOD ENZYMOL, V10, P261
   MEKALANOS JJ, 1978, INFECT IMMUN, V20, P552, DOI 10.1128/IAI.20.2.552-558.1978
   Nashar TO, 1996, P NATL ACAD SCI USA, V93, P226, DOI 10.1073/pnas.93.1.226
   Nataro JP, 1998, CLIN MICROBIOL REV, V11, P403
   Partidos CD, 1999, IMMUNOL LETT, V67, P209, DOI 10.1016/S0165-2478(99)00013-9
   PIZZA M, 1994, J EXP MED, V180, P2147, DOI 10.1084/jem.180.6.2147
   PIZZA M, 1994, MOL MICROBIOL, V14, P51, DOI 10.1111/j.1365-2958.1994.tb01266.x
   Ryan EJ, 2000, J IMMUNOL, V165, P5750, DOI 10.4049/jimmunol.165.10.5750
   SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626
   Schweizer HP, 2001, CURR OPIN BIOTECH, V12, P439, DOI 10.1016/S0958-1669(00)00242-1
   Sears CL, 1996, MICROBIOL REV, V60, P167, DOI 10.1128/MMBR.60.1.167-215.1996
   Simmons CP, 1999, J IMMUNOL, V163, P6502
   Simmons CP, 2001, SCAND J IMMUNOL, V53, P218, DOI 10.1046/j.1365-3083.2001.00884.x
   SIXMA TK, 1991, NATURE, V351, P371, DOI 10.1038/351371a0
   SIXMA TK, 1993, J MOL BIOL, V230, P890, DOI 10.1006/jmbi.1993.1209
   Stabb EV, 2001, J BACTERIOL, V183, P309, DOI 10.1128/JB.183.1.309-317.2001
   TSUJI T, 1982, INFECT IMMUN, V38, P444, DOI 10.1128/IAI.38.2.444-448.1982
   Van der Spoel D, 2005, J COMPUT CHEM, V26, P1701, DOI 10.1002/jcc.20291
   van Ginkel FW, 2005, INFECT IMMUN, V73, P6892, DOI 10.1128/IAI.73.10.6892-6902.2005
   VANDENAKKER F, 1995, BIOCHEMISTRY-US, V34, P10996, DOI 10.1021/bi00035a005
   Warrens AN, 1997, GENE, V186, P29, DOI 10.1016/S0378-1119(96)00674-9
   WHO, 2006, WKLY EPIDEMIOL REC, V81, P97
   YAMAMOTO T, 1984, J BIOL CHEM, V259, P5037
   YOST DA, 1981, J BIOL CHEM, V256, P3647
   Zhang WP, 2008, APPL ENVIRON MICROB, V74, P5832, DOI 10.1128/AEM.00893-08
   Zhang WP, 2006, INFECT IMMUN, V74, P3107, DOI 10.1128/IAI.01338-05
NR 54
TC 16
Z9 17
U1 0
U2 13
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD FEB 18
PY 2011
VL 286
IS 7
BP 5222
EP 5233
DI 10.1074/jbc.M110.173682
PG 12
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 719SY
UT WOS:000287230600031
PM 21135101
OA Green Published, Bronze
DA 2020-12-01
ER

PT J
AU Amorim, JH
   Porchia, BFMM
   Balan, A
   Cavalcante, RCM
   da Costa, SM
   Alves, AMD
   Ferreira, LCD
AF Amorim, Jaime Henrique
   Porchia, Bruna F. M. M.
   Balan, Andrea
   Cavalcante, Rafael C. M.
   da Costa, Simone Morais
   de Barcelos Alves, Ada Maria
   de Souza Ferreira, Luis Carlos
TI Refolded dengue virus type 2 NS1 protein expressed in Escherichia coli
   preserves structural and immunological properties of the native protein
SO JOURNAL OF VIROLOGICAL METHODS
LA English
DT Article
DE Dengue virus; NS1 protein; Protein purification; Vaccines
ID STRUCTURE PREDICTION; IMMUNIZATION; ENCEPHALITIS; PROTECTION; ANTIBODY;
   FEVER; MICE
AB The dengue virus NS1 protein has been shown to be a protective antigen under different experimental conditions but the recombinant protein produced in bacterial expression systems is usually not soluble and loses structural and immunological features of the native viral protein In the present study, experimental conditions leading to purification and refolding of the recombinant dengue virus type 2 (DENV-2) NS1 protein expressed in Escherichia coli are described The refolded recombinant protein was recovered as heat-stable soluble dimers with preserved structural features, as demonstrated by spectroscopic methods In addition, antibodies against epitopes of the NS1 protein expressed in eukaryotic cells recognized the refolded protein expressed in E coli but not the denatured form or the same protein submitted to a different refolding condition Collectively, the results demonstrate that the recombinant NS1 protein preserved important conformation and antigenic determinants of the native virus protein and represents a valuable reagent either for the development of vaccines or for diagnostic methods. (C) 2010 Elsevier B V All rights reserved
C1 [de Souza Ferreira, Luis Carlos] Univ Sao Paulo, Lab Desenvolvimento Vacinas, Dept Microbiol, BR-05508900 Sao Paulo, Brazil.
   [Balan, Andrea] Brazilian Synchrotron Light Lab LNLS, Ctr Struct Mol Biol CeBiME, Campinas, Brazil.
   [da Costa, Simone Morais; de Barcelos Alves, Ada Maria] Fundacao Oswaldo Cruz, Lab Biotechnol & Physiol Virus Infect, Inst Oswaldo Cruz, Rio De Janeiro, Brazil.
RP Ferreira, LCD (corresponding author), Univ Sao Paulo, Lab Desenvolvimento Vacinas, Dept Microbiol, ICB 2,Av Prof Lineu Prestes,1374,Cidade Univ, BR-05508900 Sao Paulo, Brazil.
RI Balan, Andrea/D-1891-2014; Amorim, Jaime Henrique/O-9222-2017; Ferreira,
   Luis Carlos S/M-3954-2014
OI Balan, Andrea/0000-0001-6199-3198; Amorim, Jaime
   Henrique/0000-0002-0623-2879; Ferreira, Luis Carlos
   S/0000-0002-4883-1693
FU FAPESPFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP);
   FAPERJCarlos Chagas Filho Foundation for Research Support of the State
   of Rio de Janeiro (FAPERJ); CNPqNational Council for Scientific and
   Technological Development (CNPq)
FX We are grateful for the technical assistance of L.C. Silva and J.A.
   Pereira. We also thank L.F. Arcieri and W.B. Luiz for helpful
   suggestions in the attempts to improve the refolding method and
   preparation of the figures, respectively. This work was supported by
   FAPESP, FAPERJ and CNPq grants.
CR BRYSON K, 2005, NUCLEIC ACIDS RES, V33, pW636, DOI DOI 10.1093/NAR/GK1410
   Chaiyaratana W, 2009, DIAGN MICR INFEC DIS, V64, P83, DOI 10.1016/j.diagmicrobio.2009.01.004
   Cole C, 2008, NUCLEIC ACIDS RES, V36, pW197, DOI 10.1093/nar/gkn238
   Costa SM, 2007, VIROLOGY, V358, P413, DOI 10.1016/j.virol.2006.08.052
   Das D, 2009, PROTEIN EXPRES PURIF, V66, P66, DOI 10.1016/j.pep.2009.02.003
   Flamand M, 1999, J VIROL, V73, P6104, DOI 10.1128/JVI.73.7.6104-6110.1999
   Georgiou G, 1996, CURR OPIN BIOTECH, V7, P190, DOI 10.1016/S0958-1669(96)80012-7
   Gubler DJ, 1999, ADV VIRUS RES, V53, P35, DOI 10.1016/S0065-3527(08)60342-5
   Hang VT, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000360
   HOCKNEY RC, 1994, TRENDS BIOTECHNOL, V12, P456, DOI 10.1016/0167-7799(94)90021-3
   Huang JL, 2001, J MED VIROL, V65, P553, DOI 10.1002/jmv.2072
   Huang KJ, 2006, J IMMUNOL, V176, P2825, DOI 10.4049/jimmunol.176.5.2825
   Kelley LA, 2009, NAT PROTOC, V4, P363, DOI 10.1038/nprot.2009.2
   Kolaj O, 2009, MICROB CELL FACT, V8, DOI 10.1186/1475-2859-8-9
   Linderbach BD, 2001, FIELDS VIROLOGY, P991
   Pongsumpun P, 2008, TROP MED INT HEALTH, V13, P1180, DOI 10.1111/j.1365-3156.2008.02124.x
   PRYOR MJ, 1994, J GEN VIROL, V75, P1183, DOI 10.1099/0022-1317-75-5-1183
   Rosano GL, 2009, MICROB CELL FACT, V8, DOI 10.1186/1475-2859-8-41
   Sahdev S, 2008, MOL CELL BIOCHEM, V307, P249, DOI 10.1007/s11010-007-9603-6
   Sambrook J., 1989, MOL CLONING LAB MANU
   SAMPATH A, 2008, ANTIVIRAL RES
   SCHLESINGER JJ, 1993, VIROLOGY, V192, P132, DOI 10.1006/viro.1993.1015
   SCHLESINGER JJ, 1987, J GEN VIROL, V68, P853, DOI 10.1099/0022-1317-68-3-853
   TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350
   Whitmore L, 2004, NUCLEIC ACIDS RES, V32, pW668, DOI 10.1093/nar/gkh371
   WINKLER G, 1988, VIROLOGY, V162, P187, DOI 10.1016/0042-6822(88)90408-4
   Wu SF, 2003, VACCINE, V21, P3919, DOI 10.1016/S0264-410X(03)00310-4
   Young PR, 2000, J CLIN MICROBIOL, V38, P1053, DOI 10.1128/JCM.38.3.1053-1057.2000
   ZHANG YM, 1988, J VIROL, V62, P3027, DOI 10.1128/JVI.62.8.3027-3031.1988
   Zhou JM, 2006, VIRUS GENES, V33, P27, DOI 10.1007/s11262-005-0036-6
NR 30
TC 30
Z9 31
U1 0
U2 9
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0166-0934
EI 1879-0984
J9 J VIROL METHODS
JI J. Virol. Methods
PD AUG
PY 2010
VL 167
IS 2
BP 186
EP 192
DI 10.1016/j.jviromet.2010.04.003
PG 7
WC Biochemical Research Methods; Biotechnology & Applied Microbiology;
   Virology
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Virology
GA 621HT
UT WOS:000279567400012
PM 20399232
DA 2020-12-01
ER

EF